Methods and systems for analyzing site-specific monomer composition
Site-specific glycan monomer analysis using monomer weight scores in peptide structures addresses the challenges of current glycoprotein analysis, enabling accurate melanoma diagnosis and treatment decision-making, particularly for immunotherapy.
Patent Information
- Application Number
- PCT/US2023/073170
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2023-08-30
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for analyzing glycoproteins are hindered by challenges such as complex glycan structures and overlapping signals from multiple glycans, making it difficult to identify disease states like melanoma accurately and non-invasively.
A method for site-specific analysis of glycan monomers in peptide structures, involving the calculation of monomer weight scores from biological samples using machine learning models, to predict, diagnose, and inform treatment decisions for melanoma, particularly through the use of immunotherapy.
This approach enables early, accurate, and non-invasive diagnosis of melanoma, predicting disease progression and treatment responsiveness, thereby improving patient outcomes by guiding targeted therapies like immune checkpoint blockade therapy.
Smart Images

Figure US2023073170_28112024_PF_FP_ABST
Abstract
Description
METHODS AND SYSTEMS FOR ANALYZING SITE-SPECIFICMONOMER COMPOSITION[0001 ) This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 503,646, filed May 22, 2023, which is incorporated by reference herein in its entirety.FIELD
[0002] The present disclosure generally relates to methods and systems for analyzing peptide structures for generation of a composite measure that represents the weighted average of each glycan monomer across glycan species. More particularly, the present disclosure relates to analyzing quantification data for a set of peptide structures to calculate monomer weight scores for each site monomer, in some cases where the monomer weight scores are associated with a disease state, treatment sensitivity, or other biological feature.BACKGROUND10003] Protein glycosylation and other post-translational modifications play vital roles in virtually all aspects of human physiology. Unsurprisingly, faulty or altered protein glycosylation often accompanies various disease states. The identification of aberrant glycosylation provides opportunities for early detection, intervention, and treatment of affected subjects. Current biomarker identification methods, such as those developed in the fields of proteomics and genomics, can be used to detect indicators of certain diseases, such as cancer, and to differentiate certain types of cancer from other, non-cancerous diseases. However, the use of glycoproteomic analyses has not previously been used to successfully identify disease processes.10004] Glycoprotein analysis is fraught with challenges on several levels. For example, a single glycan composition in a peptide can contain a large number of isomeric structures due to different glycosidic linkages, branching patterns, and / or multiple monosaccharides having the same mass. In addition, the presence of multiple glycans that share the same peptide backbone can lead to assay signals from various glycoforms, lowering their individual abundances compared to aglycosylated peptides. Accordingly, the development of algorithms that can identify glycan structures on peptide fragments remains elusive.{0005} In light of the above, there is a need for improved analytical methods that involve site-specific analysis of glycoproteins to obtain information about protein glycosylationpatterns, which can in turn provide quantitative information that can be used to identify disease states. For example, there is a need to use such analysis to diagnose and / or treat melanoma.|0006| An approach that is non-invasive, accurate, and reliable and that enables early diagnosis and informs treatment is needed. An approach enabling early diagnosis and informing treatment may help reduce negative health outcomes in patients with melanoma. Such an approach can assist in guiding a patient to an urgency for further testing, for example, or in guiding a medical practitioner in predicting whether a particular treatment (e.g., immunotherapy) may or may not be effective and informing treatment decisions accordingly. Thus, it may be desirable to have methods and systems capable of addressing one or more of the above-identified issues.SUMMARY
[0007] Aspects of the present disclosure are based, at least in part, on the development of methods and systems for analysis of site-specific glycan monomer composition, as well as on the discovery that such analysis can be used to predict, diagnose, prognose, and / or inform treatment of one or more disease states, such as melanoma. Accordingly, aspects of the disclosure are directed to methods for analyzing a set of peptide structures for calculating one or more monomer weight scores. Also disclosed are methods for classifying a biological sample comprising analyzing monomer weight scores to generate a disease indicator and generating a diagnosis or prognosis output based on the disease indicator. Further disclosed are treatment methods comprising treatment of a melanoma subject with immunotherapy (e.g., immune checkpoint blockade therapy such as ipilimumab, nivolumab, and / or pembrolizumab) based on analysis of monomer weight scores from a biological sample from the subject.|0008] Disclosed herein, in some aspects, is a method for analyzing a set of peptide structures comprising a linking site, the method comprising: A) calculating a site occupancy score, for a given peptide structure at the linking site, as a function of an adjusted-raw abundance value for the given peptide structure and a sum of a set of adjusted-raw abundance values of the set of peptide structures; and B) calculating a monomer weight score as a sum of the site occupancy score and a multiplier, wherein the multiplier is the number of a specific monomer in the set of peptide structures at the linking site. In some aspects, the method further comprises, prior to (A), receiving a set of raw abundance values of the set of peptide structures and normalizing the set of raw abundance values to a corresponding reference run to generate the set of adjusted-raw abundance values. In some aspects, the method further comprises, priorto (B), calculating a peptide structure monomer weight score as a function of the site occupancy score and the number of a specific monomer for the given peptide structure. In some aspects, the monomer weight score is a function of the peptide structure monomer weight score and the site occupancy score. In some aspects, the set of peptide structures is from a biological sample from a subject. In some aspects, the biological sample comprises serum or plasma samples. In some aspects, the reference run comprises serum or plasma samples. In some aspects, the method further comprises correlating the monomer weight score with an indication or disease state to determine a hazard ratio for the indication or disease state, wherein the hazard ratio is used to update a risk profile of the subject for the indication or disease state. In some aspects, the method further comprises generating a diagnosis output for the indication or disease state for the subject, using a predictive model, as a function of the monomer weight score, wherein the diagnosis output is one of a predictive probability or a risk score. In some aspects, further comprising calculating a site occupancy score, for a given peptide structure at the linking site, as the quotient of the adjusted-raw abundance value for the given peptide structure over the sum of the set of adjusted-raw abundance values. In some aspects, the method further comprises calculating a peptide structure monomer weight score as a product of the site occupancy score and the number of specific monomers for the given peptide structure. In some aspects, the method further comprises calculating a monomer weight score for the subject as a sum of peptide structure monomer weight scores for each peptide structure at the linking site. In some aspects, the method further comprises generating a diagnosis output, based on the monomer weight score, for an indication or disease state, wherein the diagnosis output classifies the biological sample as evidencing a state associated with a disease state progression and / or responsiveness to a specific therapy. In some aspects, the set of raw abundance values is generated using multiple reaction monitoring mass spectrometry (MRM-MS). In some aspects, the method further comprises generating a diagnosis output based on the monomer weight score for an indication or disease state, and generating a treatment output based on at least one of the diagnosis output. In some aspects, the treatment output comprises at least one of an identification of a treatment to treat the subject or a treatment plan. In some aspects, the treatment comprises at least one of radiation therapy, chemoradiotherapy, surgery, immunotherapy, hormone therapy, or a targeted drug therapy. In some aspects, the treatment comprises immunotherapy, wherein the immunotherapy is immune checkpoint blockade therapy. In some aspects, the immune checkpoint blockade therapy comprises ipilimumab, nivolumab, and / or pembrolizumab. In some aspects, the method further comprises generatinga diagnosis output, wherein generating the diagnosis output comprises: generating a report identifying that the biological sample evidences the indication or disease state. In some aspects, the specific monomer is selected from the group consisting of hexose, HexNac, fucose, and sialic acid. In some aspects, the specific monomer is selected from the group consisting of glucose, mannose, galactose, GlcNAc, GalNAc, fucose, NeuGc, and NeuAc. In some aspects, the method further comprises calculating a second monomer weight score as a sum of the site occupancy score and a second multiplier, wherein the second multiplier is the number of a second monomer in the set of peptide structures at the linking site, wherein the second monomer is different from the specific monomer. In some aspects, the method further comprises calculating a plurality of additional monomer weight scores as functions of the site occupancy score and a plurality of additional multipliers, wherein the plurality of additional multipliers are the number of a plurality of additional monomers in the set of peptide structures at the linking site.
[0009] Disclosed herein, in some aspects, is a method of classifying a biological sample with respect to risk of melanoma progression and / or responsiveness to immune checkpoint inhibitor therapy, the method comprising: A) analyzing one or more monomer weight scores of a set of peptide structures from a biological sample from the subject using a machine learning model to generate a disease indicator; and B) generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing a state associated with melanoma progression and / or responsiveness to immune checkpoint inhibitory therapy. In some aspects, the method further comprises receiving a set of raw abundance values of the set of peptide structures and normalizing the set of raw abundance values to a corresponding reference run to generate the set of adjusted-raw abundance values. In some aspects, the method further comprises calculating a site occupancy score, for a given peptide structure at the linking site, as the function of the adjusted-raw abundance value for the given peptide structure and the sum of the set of adjusted-raw abundance values. In some aspects, the method further comprises calculating a site occupancy score, for a given peptide structure at the linking site, as the quotient of the adjusted-raw abundance value for the given peptide structure over the sum of the set of adjusted-raw abundance values calculating a peptide structure monomer weight score as a function of the site occupancy score and the number of specific monomers for the given peptide structure. In some aspects, the method further comprises calculating a peptide structure monomer weight score as a product of the site occupancy score and the number of specific monomers for the given peptide structure. In some aspects, the method further comprisescalculating a monomer weight score of the one or more monomer weight scores as a sum of peptide structure monomer weight scores for each peptide structure at the linking site. In some aspects, the set of peptide structures comprises post translationally modified (PTM) peptides and / or non-PTM peptides. In some aspects, the monomer is selected from the group consisting of hexose, HexNac, fucose, and sialic acid. In some aspects, the monomer is selected from the group consisting of glucose, mannose, galactose, GlcNAc, GalNAc, fucose, NeuGc, and NeuAc. In some aspects, the set of peptides structures comprises glycosylated peptides and non-glycosylated peptides. In some aspects, the biological sample comprises serum or plasma samples. In some aspects, the reference run comprises serum or plasma samples. In some aspects, the method further comprises treating the biological sample to form a prepared sample comprising the set of peptide structures, the set of peptide structures comprising a set of post translationally modified (PTM) peptides and / or non-PTM peptides; detecting a set of product ions associated with each structure of the set of post translationally modified (PTM) peptides and / or non-PTM peptides, and generating the set of raw abundance values for the set of product ions. In some aspects, the analyzing further comprises: correlating the monomer weight score with a melanoma disease state to determine a hazard ratio for the melanoma disease state, wherein the hazard ratio is used to update a risk profile of the subject for the melanoma disease state. In some aspects, the method further comprises generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing a state associated with melanoma progression and / or responsiveness to immune checkpoint inhibitory therapy, wherein the diagnosis output is one of a predictive probability or a risk score. In some aspects, the set of raw abundance values is generated using multiple reaction monitoring mass spectrometry (MRM-MS). In some aspects, the method further comprises generating a treatment output based on at least one of the diagnosis output. In some aspects, the treatment output comprises at least one of an identification of a treatment to treat the subject or a treatment plan. In some aspects, the treatment comprises at least one of radiation therapy, chemoradiotherapy, surgery, hormone therapy, or a targeted drug therapy. In some aspects, generating the diagnosis output comprises: generating a report identifying that the biological sample evidences the indication or disease state. In some aspects, the one or more monomer weight scores correspond to at least one site monomer identified in Table 1. In some aspects, the one or more monomer weight scores correspond to at least one site monomer identified in Table 2. In some aspects, the one or more monomer weight scores correspond to at least one site monomer identified in Table 3. In some aspects, the method further comprises training theat least one supervised machine learning model using training data, wherein the training data comprises a plurality of peptide structure profiles for a plurality of subjects and a plurality of subject diagnoses for the plurality of subjects. In some aspects, the plurality of subject diagnoses is selected from the group consisting of a positive diagnosis for any subject of the plurality of subjects determined to have a melanoma disease state, a negative diagnosis for any subject of the plurality of subjects determined not to have a melanoma disease state, a positive diagnosis for any subject of the plurality of subjects determined to be likely to benefit from immune checkpoint inhibitory therapy, and a negative diagnosis for any subject of the plurality of subjects determined to be unlikely to benefit from immune checkpoint inhibitory therapy. In some aspects, the plurality of subjects are separated into classes of positive and negative diagnoses using a concordance index as a cutoff between positive and negative diagnoses. In some aspects, the method further comprises performing a differential expression analysis using the training data to compare a first portion of the plurality of subjects with the positive diagnosis for melanoma disease state or subjects unlikely to benefit from immune checkpoint inhibitory therapy, versus a second portion of the plurality of subjects having the negative diagnosis for melanoma disease state or subjects likely to benefit from immune checkpoint inhibitory therapy; and identifying a training group of peptide structures based on the differential expression analysis for use as prognostic markers for the melanoma disease state and / or responsiveness to immune checkpoint inhibitory therapy; and forming the training data based on the training group of peptide structures identified. In some aspects, the at least one supervised machine learning model comprises a logistic regression model, and wherein the at least one supervised learning model compares the negative diagnosis versus the positive diagnosis, wherein the comparison can be at least one non-melanoma state vs at least one melanoma state, or the comparison can be at least one positive response to immune checkpoint inhibitory therapy vs at least one negative response to immune checkpoint inhibitory therapy.
[0010] Disclosed herein, in some aspects, is a method of treating melanoma in a subject, the method comprising: A) analyzing one or more monomer weight scores corresponding to at least one site monomer identified in Table 1 using a machine learning model to generate a diagnosis output that classifies the biological sample as evidencing a state associated with melanoma progression, and B) administering a therapeutically effective amount of a treatment for melanoma. In some aspects, the method further comprises receiving a set of raw abundance values of the set of peptide structures and normalizing the set of raw abundance values to a corresponding reference run to generate the set of adjusted-raw abundance values. In someaspects, the method further comprises calculating a site occupancy score, for a given peptide structure at the linking site, as the function of the adjusted-raw abundance value for the given peptide structure and the sum of the set of adjusted-raw abundance values. In some aspects, the method further comprises calculating a site occupancy score, for a given peptide structure at the linking site, as the quotient of the adjusted-raw abundance value for the given peptide structure over the sum of the set of adjusted-raw abundance values. In some aspects, the method further comprises calculating a peptide structure monomer weight score as a function of the site occupancy score and the number of specific monomers for the given peptide structure. In some aspects, the method further comprises calculating a peptide structure monomer weight score as a product of the site occupancy score and the number of specific monomers for the given peptide structure. In some aspects, the method further comprises calculating the a monomer weight score of the one or more monomer weight scores as a sum of peptide structure monomer weight scores for each peptide structure at the linking site. In some aspects, the set of peptide structures comprises post translationally modified (PTM) peptides and / or non-PTM peptides. In some aspects, the monomer is selected from the group consisting of hexose, HexNac, fucose, and sialic acid. In some aspects, the monomer is selected from the group consisting of glucose, mannose, galactose, GlcNAc, GalNAc, fucose, NeuGc, and NeuAc. In some aspects, the set of peptides structures comprises glycosylated peptides and nonglycosylated peptides. In some aspects, the biological sample comprises serum or plasma samples. In some aspects, the reference run comprises serum or plasma samples. In some aspects, the method further comprises treating the biological sample to form a prepared sample comprising the set of peptide structures, the set of peptide structures comprising a set of post translationally modified (PTM) peptides and / or non-PTM peptides; detecting a set of product ions associated with each structure of the set of post translationally modified (PTM) peptides and / or non-PTM peptides, and generating the set of raw abundance values for the set of product ions. In some aspects, the analyzing further comprises: correlating the one or more monomer weight scores with a melanoma disease state to determine a hazard ratio for the melanoma disease state, wherein the hazard ratio is used to update a risk profile of the subject for the melanoma disease state. In some aspects, the method further comprises generating a diagnosis output based on a disease indicator that classifies the biological sample as evidencing a state associated with melanoma progression, wherein the diagnosis output is one of a predictive probability or a risk score. In some aspects, the set of raw abundance values is generated using multiple reaction monitoring mass spectrometry (MRM-MS). In some aspects, the treatmentcomprises at least one of radiation therapy, chemoradiotherapy, immunotherapy, surgery, hormone therapy, or a targeted drug therapy. In some aspects, the treatment comprises immunotherapy, wherein the immunotherapy is immune checkpoint blockade therapy. In some aspects, the immune checkpoint blockade therapy comprises ipilimumab, nivolumab, and / or pembrolizumab. In some aspects, generating the diagnosis output comprises: generating a report identifying that the biological sample evidences the indication or disease state. In some aspects, the one or more monomer weight scores correspond to at least one site monomer identified in Table 2 In some aspects, the one or more monomer weight scores correspond to at least one site monomer identified in Table 3. In some aspects, the method further comprises training the at least one supervised machine learning model using training data, wherein the training data comprises a plurality of peptide structure profiles for a plurality of subjects and a plurality of subject diagnoses for the plurality of subjects. In some aspects, the plurality of subject diagnoses is selected from the group consisting of a positive diagnosis for any subject of the plurality of subjects determined to have a melanoma disease state, a negative diagnosis for any subject of the plurality of subjects determined not to have a melanoma disease state, a positive diagnosis for any subject of the plurality of subjects determined to be likely to benefit from immune checkpoint inhibitory therapy, and a negative diagnosis for any subject of the plurality of subjects determined to be unlikely to benefit from immune checkpoint inhibitory therapy. In some aspects, the plurality of subjects are separated into classes of positive and negative diagnoses using a concordance index as a cutoff between positive and negative diagnoses. In some aspects, the method further comprises performing a differential expression analysis using the training data to compare a first portion of the plurality of subjects with the positive diagnosis for melanoma disease state or subjects unlikely to benefit from immune checkpoint inhibitory therapy, versus a second portion of the plurality of subjects having the negative diagnosis for melanoma disease state or subjects likely to benefit from immune checkpoint inhibitory therapy; and identifying a training group of peptide structures based on the differential expression analysis for use as prognostic markers for the melanoma disease state and / or responsiveness to immune checkpoint inhibitory therapy; and forming the training data based on the training group of peptide structures identified. In some aspects, the at least one supervised machine learning model comprises a logistic regression model, and wherein the at least one supervised learning model compares the negative diagnosis versus the positive diagnosis, wherein the comparison can be at least one non-melanoma state vs at least one melanoma state, or the comparison can be at least one positive response to immune checkpointinhibitory therapy vs at least one negative response to immune checkpoint inhibitory therapy. Also disclosed is a system comprising one or more data processors; and a non-transitory computer readable storage medium containing instructions which, when executed on the one or more data processors, cause the one or more data processors to perform part or all of a method disclosed herein. Further disclosed is a computer-program product tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to cause one or more data processors to perform part or all of a method disclosed herein.[0011 [ Disclosed herein, in some aspects, is a method of monitoring a subject for a melanoma, the method comprising: receiving first monomer weight score data for a first biological sample obtained from a subject at a first timepoint; analyzing the first monomer weight score data using at least one supervised machine learning model to generate a first disease indicator based on at least one site monomer selected from a group of site monomers identified in Table 1, wherein the group of site monomers in Table 1 comprises a group of site monomers having monomer weight scores associated with melanoma; receiving second monomer weight score data of a second biological sample obtained from the subject at a second timepoint; analyzing the second monomer weight score data using the at least one supervised machine learning model to generate a second disease indicator based on the at least one site monomer selected from the group of site monomers identified in Table 1; and generating a diagnosis output based on the first disease indicator and the second disease indicator. In some aspects, generating the diagnosis output comprises: comparing the second disease indicator to the first disease indicator. In some aspects, the first disease indicator indicates that the first biological sample evidences a negative diagnosis for melanoma and the second biological sample evidences a positive diagnosis for melanoma. In some aspects, the first disease indicator indicates that the first biological sample evidences a melanoma that is not responsive to immunotherapy and the second biological sample evidences a melanoma that is responsive to immunotherapy. In some aspects, the at least one supervised machine learning model comprises a logistic regression model, and wherein the at least one supervised learning model compares negative diagnoses versus positive diagnoses, wherein the comparison can be at least one healthy state versus melanoma generally, healthy state versus immunotherapy responsive melanoma, or immunotherapy nonresponsive melanoma versus immunotherapy responsive melanoma. In some aspects, the at least one site monomer comprises at least one site monomer identified in Table 3. In some aspects, the at least one site monomer comprises at all site monomers identified in Table 3.
[0012] Disclosed herein, in some aspects, is a method of treating melanoma in a subject, the method comprising: determining a monomer weight score for at least one site monomer identified in Table 1 in a biological sample from the subject using a multiple reaction monitoring mass spectrometry (MRM-MS) system; analyzing the monomer weight score using at least one machine learning model to generate a disease indicator; generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing that the patient has melanoma; and administering to the subject a therapeutically effective amount of a melanoma therapy.
[0013] Disclosed herein, in some aspects, is a method of treating melanoma in a subject, the method comprising: determining a monomer weight score for at least one site monomer identified in Table 1 in a biological sample from the subject using a multiple reaction monitoring mass spectrometry (MRM-MS) system; analyzing the monomer weight score using at least one machine learning model to generate a disease indicator; generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing that the melanoma is sensitive to immunotherapy; and administering to the subject a therapeutically effective amount of immunotherapy.
[0014] Disclosed herein, in some aspects, is a method of treating melanoma in a subject, the method comprising: determining a monomer weight score for at least one site monomer identified in Table 1 in a biological sample from the subject using a multiple reaction monitoring mass spectrometry (MRM-MS) system; analyzing the monomer weight score using at least one machine learning model to generate a disease indicator; generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing that the melanoma is sensitive to immunotherapy; and administering to the subject a therapeutically effective amount of immunotherapy.
[0015] Disclosed herein, in some aspects, is a method of predicting a risk for melanoma in a subject, the method comprising: determining a monomer weight score for at least one site monomer identified in Table 1 in a biological sample from the subject using a multiple reaction monitoring mass spectrometry (MRM-MS) system; analyzing the monomer weight score using at least one machine learning model to generate a disease indicator; and generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing that the patient has a risk for melanoma.
[0016] Disclosed herein, in some aspects, is a method of predicting immunotherapy sensitivity, the method comprising: determining a monomer weight score for at least one sitemonomer identified in Table 1 in a biological sample from the subject using a multiple reaction monitoring mass spectrometry (MRM-MS) system; analyzing the monomer weight score using at least one machine learning model to generate a disease indicator; and generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing that the patient has a risk for melanoma.
[0017] In one aspect, a system is described according to various embodiments. In various embodiments, the system comprises one or more data processors and a non-transitory computer readable storage medium containing instructions which, when executed on the one or more data processors, cause the one or more data processors to perform part or all of any one or more of the methods described herein.
[0018] In one aspect, disclosed is a computer-program product tangibly embodied in a non- transitory machine-readable storage medium, including instructions configured to cause one or more data processors to perform part or all of any one or more of the methods described herein.BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The present disclosure is described in conjunction with the appended figures:
[0020] Figure 1 is a schematic diagram of an exemplary workflow 100 for the detection of peptide structures associated with a disease state for use in diagnosis and / or treatment in accordance with one or more embodiments.
[0021] Figure 2A is a schematic diagram of a sample preparation workflow in accordance with one or more embodiments.
[0022] Figure 2B is a schematic diagram of data acquisition in accordance with one or more embodiments.
[0023] Figure 3 is a block diagram of an analysis system in accordance with one or more embodiments.
[0024] Figure 4 is a block diagram of a computer system in accordance with various embodiments.
[0025] Figure 5 is a flowchart of a process for analyzing a set of peptide structures in a biological sample in accordance with one or more embodiments.
[0026] Figure 6 is a flowchart of a process for classifying a biological sample with respect to risk of melanoma progression and / or responsiveness to immune checkpoint inhibitor therapy in accordance with one or more embodiments.[0027) Figure 7 is a flowchart of a process for treating melanoma in a subj ect in accordance with one or more embodiments.
[0028] Figure 8 is a flowchart of a process for monitoring a subject for melanoma in accordance with one or more embodiments.
[0029] Figure 9 is a schematic example of a process for determining a monomer weight score.
[0030] Figure 10 is a hazard ratio plot showing hazard ratios for each shown site monomer with regards to progression free survival (PFS) in melanoma patients. Filled in diamonds indicate site monomers corresponding to hazard ratios having FDR < 0.05.
[0031] Figure 11 is a Kaplan-Meier curve showing PFS of patients in the training cohort characterized as more likely to benefit from immunotherapy or less likely to benefits from immunotherapy, determined based on monomer weight features CFAH_882_fuco and HPT_184_fuco.
[0032] Figure 12 is a Kaplan-Meier curve showing progression-free survival of patients in the validation cohort characterized as more likely to benefit from immunotherapy or less likely to benefits from immunotherapy, determined based on site monomers CFAH_882_fuco and HPT_184_fuco.
[0033] Figure 13 is a Kaplan-Meier curve showing progression-free survival of patients in the test cohort characterized as more likely to benefit from immunotherapy or less likely to benefits from immunotherapy, determined based on site monomers CFAH_882_fuco and HPT_184_fuco.
[0034] Figure 14 is a hazard ratio plot showing hazard ratios for each shown site monomer with regards to PFS in melanoma patients. Filled in diamonds indicate site monomers corresponding to hazard ratios having FDR < 0.05.
[0035] Figure 15A shows Kaplan-Meier curves of various event occurrences in the discovery cohort.
[0036] Figure 15B shows Kaplan-Meier curves of OS and censoring distributions in the discovery and external validation cohorts.
[0037] Figures 16A to 16E show Kaplan-Meier curves stratified by classifier prediction where Figures 16A-D are for the discovery cohort and Figure 16E are for the external validation cohort.
[0038] Figures 17A1 to 17E show that fucosylation signatures in peripheral blood N- glycoproteins are associated with reduced clinical benefit. Figures 17A1 and 17A2 are chartsof glycopeptides with differential expression, based on relative abundance measurements, in responders compared to non-responders (p<0.05) were classified based on the glycan structure (Figure 17A1 for fucose and Figure 17A2 for sialic acid). N-linked glycopeptides separated in two groups based on the presence or absence of fucose that strongly associated with response to treatment (p<0.0001), whereas the number of sialic acid residues did not associate with benefit of treatment. HR, hazard ratio. Figures 17A1 also shows a schematic indicating the tumor immune phenotype and underlying mechanism as it relates to fucosylated glycopeptides and afucosylated glycopeptides. Figure 17B shows a chart indicating that di-sialylated O- glycopeptides are enriched in samples with reduced survival (p=0.14). Figure 17C is a chart showing the effect of site occupancy on protein function in relation to treatment. Lack of a glycan on site N70 of alphal -antitrypsin (A1AT_N7O NG) is associated with favorable response, whereas absence of glycosylation at the site N1424 of alpha2-microglobulin is associated with poorer responses. The 4-digit number describes glycans composition (number of hexoses, HexNAc, fucose and sialic acid, respectively). Figure 17D is a chart of hazard ratios of 51 fucose-specific monomer weight features derived from N-gly copeptides sorted by age- and sex-adjusted Cox regression FDR. Hazard ratios of features that achieved FDR<0.05 are filled-in diamonds. Figures 17E1 to 17E4 show four Kaplan-Meier curves showing performance of repeated five-fold cross-validated LASSO-regularized Cox regression-based classifier using 11 fucose-specific features derived from N-glycopeptides that achieved FDR<0.05 in age- and sex-adjusted Cox regression analysis.
[0039] Figures 18A to 18D show Kaplan-Meier curves of OS in the discovery cohort stratified by melanoma subtype (Figure 18A), LDH category (Figure 18B), ECOG performance status (Figure 18C), and BRAF status (Figure 18D), respectively.
[0040] Figures 19A and 19B show Kaplan-Meier curves stratified by early failure (EF, progression and death within 6 months of treatment start, n=40) and sustained controls (SC, progression and death-free beyond 3 years of treatment; n=56) in the discovery cohort. “Other” defines intermediate phenotypes (n=106). Figure 19A has PFS on the y-axis and Figure 19B has OS on the y-axis.
[0041] Figures 20 A to 20C show Kaplan-Meier curves in the full discovery cohort stratified by classifier prediction and one of LDH category (Figure 20A), ECOG performance status (Figure 20B), and BRAF status (Figure 20C).
[0042] Figure 21 provides an example of a workflow overview.[0043) Figure 22 overlap of unique glycopeptides (Figure 22A) and Glycoproteins (Figure 22B) identified with each enrichment approach.10044] Figures 23A-23D provides an overview of glycosylation features and validation of search results. Figure 23A) Comparison of glycan types detected across all the enrichment approaches. Figure 23B) Comparison of SOLA enriched glycan types from plasma and crude membrane fractions against whole cell lysate enrichment. Figure 23C) Fucosylated glycopeptide search results from samples treated with 2-FF or sialidase and enriched by SOLA or RAX plotted as proportion against all complex N-glycan modified glycopeptides. Figure 23D) Sialylated glycopeptide search results from samples treated with 2-FF or sialidase and enriched by SOLA or RAX plotted as proportion against all complex N-glycan modified glycopeptides.
[0045] Figures 24A-24D show identification of polyLacNAc-modified glycopeptides and pathway analysis. Figure 24A) and Figure 24B) Exemplary spectra of polyLacNAc elongated glycopeptide from HLA-DRA (P01903). The glycan in the inset is used to visualize the compositional assignment and highlights the 731.27 m / z fragment (HexNAcHex) 2 indicative of polyLacNAc elongation. Figure 24C) KEGG pathway analysis of all the glycoproteins detected in this study and Figure 245D) KEGG pathway analysis of the subset of detected glycoproteins modified with polyLacNAc elongation.
[0046] Figure 25A-25B shows Tetraspanin- 13 is a carrier of polyLacNAc elongated N- glycans. Figure 25A) Alpha fold model of Tetraspanin- 13 modeled with polyLacNAc elongated N-glycans through GLYCAM. Figure 25B) MS / MS Spectrum of glycopeptide used to model N-glycan.
[0047] Figure 26 shows 2-Fluoro-Fucose Treatment of SOLA enriched Plasma and Crude membrane fractions.
[0048] Figures 27A-27C provides HLA DRA polyLacNAc spectra. Figure 27A)-Figure 27C) are exemplary spectra of desialylated N-glycopeptides modified with polyLacNAc.
[0049] Figure 28 illustrates KEGG pathway of ECM-Receptor interactions. Highlighted are all the glycoproteins detected carrying polyLacNAc in the study.
[0050] Figure 29 provides an exemplary spectra of Tetraspanin-13.
[0051] Figure 30 provides alignment of all 33 members of Tetraspanin family. ECI andEC2 denote extracellular loops 1 and 2, respectively. Black dashes indicate sites containing N- glycosylation sequon N- Xxx - S / T (Xxx- any amino acid besides Proline).
[0052] Figure 31 is a representative figure of a mass spectra with m / z represented on the X-axis and intensity represented on the Y-axis.
[0053] Figure 32 shows cell surface fucosylation in HEPG2 cells, detected by AAL (top graph) and LCA (bottom) lectins.
[0054] Figure 33 shows cell surface fucosylation in HEP3B cells, detected by AAL (top graph) and LCA (bottom) lectins.
[0055] Figure 34 shows cell surface fucosylation in HepG2 cells detected by staining with AAL lectin.
[0056] Figure 35 demonstrates expression analysis of glycosylation-related genes induced by cytokines in HepG2 cells.DETAILED DESCRIPTIONI. Overview
[0057] The embodiments described herein recognize that glycoproteomics is an emerging field that can be used in the overall diagnosis and / or treatment of subjects with various types of diseases. Glycoproteomics aims to determine the positions, identities, and quantities of glycans and glycosylated proteins in a given sample (e.g., blood sample, serum sample, cell, tissue, etc.). Protein glycosylation is one of the most common and most complex forms of post-translational protein modification, and can affect protein structure, conformation, and function. For example, glycoproteins may play crucial roles in important biological processes such as cell signaling, host-pathogen interactions, and immune response and disease. Glycoproteins may therefore be important to diagnosing different types of diseases.
[0058] Although protein glycosylation provides useful information about cancer and other diseases, analysis of protein glycosylation may be difficult as the glycan typically cannot be traced back to the protein site of origin with currently available methodologies. Glycoprotein analysis can be challenging in general due to several reasons. For example, a single glycan composition in a peptide may contain a large number of isomeric structures because of different glycosidic linkages, branching, and many monosaccharides having the same mass. Further, the presence of multiple glycans that share the same peptide sequence may cause the mass spectrometry (MS) signal to split into various glycoforms, lowering their individual abundances compared to the peptides that are not glycosylated (aglycosylated peptides).
[0059] However, to understand various disease conditions and to diagnose and prognose certain diseases, such as melanoma, more accurately, it may be important to perform analysisof glycoproteins and to identify not only the glycan but also the linking site (e.g., the amino acid residue of attachment) within the protein. Thus, there is a need to provide a method for site-specific glycoprotein analysis to obtain detailed information about protein glycosylation patterns that may be able to provide information about a disease state (e.g., a melanoma disease state). This information can be used to distinguish the disease state from other states, diagnose a subject as having or not having the disease state, determine a likelihood that a subject has the disease state, determine the responsiveness of a disease to a particular treatment, or a combination thereof. For example, such analysis may be useful in diagnosing a melanoma disease state for a subject (e.g., a negative diagnosis for the melanoma disease state, a positive diagnosis for the melanoma disease state). Sample collection and analysis can be collected at different time points for comparing melanoma disease states over time for a subject. For example, the negative diagnosis may include a healthy state. An example of the positive diagnosis includes the subject suffering from melanoma. A diagnosis can also assess a malignancy status of a previously identified melanoma. Further, a prognosis can assess whether a melanoma is or is not responsive to (or likely to be responsive to) a particular therapy such as immunotherapy (e.g., immune checkpoint inhibitors such as ipilimumab, nivolumab, and / or pembrolizumab).
[0060] Accordingly, the embodiments described herein provide various methods and systems for analyzing proteins in subjects and, in particular, glycoproteins. In one or more embodiments, one or more machine learning models are trained to analyze peptide structure data, monomer weight data, or a combination thereof and generate a disease indicator that provides information relating to one or more diseases. For example, in various embodiments, the peptide structure data comprises quantification metrics (e.g., abundance or concentration data) for peptide structures. A peptide structure may be defined by an aglycosylated peptide sequence (e.g., a peptide or peptide fragment of a larger parent protein) or a glycosylated peptide sequence. A glycosylated peptide sequence (also referred to as a glycopeptide structure) may be a peptide sequence having a glycan structure that is attached to a linking site (e.g., an amino acid residue) of the peptide sequence, which may occur via, for example, a particular atom of the amino acid residue). Non-limiting examples of glycosylated peptides include N-linked glycopeptides and O-linked glycopeptides. In some aspects, the monomer weight data comprises one or more monomer weight scores for one or more linker sites. One or more monomer weight scores may be used to generate a disease indicator.
[0061] The embodiments described herein recognize that the abundance of one or more monomer type at one or more particular linker sites may be used to determine the likelihood of that subject evidencing a melanoma disease state. Certain peptide structures and monomer weights that are associated with a melanoma disease state may be more relevant to that disease state than other peptide structures that are also associated with that disease state.
[0062] Analyzing the abundance of peptide structures and glycosylated peptide structures in a biological sample, along with the monomer weights obtained from analysis of such peptide structures, may provide a more accurate way in which to distinguish a positive melanoma disease state (e.g., a state including the presence of melanoma) from a negative melanoma disease state (e.g., healthy state, an absence of melanoma, etc.). Additionally or alternatively, the disclosed methods may provide a more accurate way in which to predict the responsiveness of a melanoma to immunotherapy (or other) treatment. This type of analysis may be more conducive to generating accurate diagnoses and / or prognoses as compared to glycoprotein analysis that focuses on analyzing glycoproteins that are too large to be resolved via mass spectrometry. Further, with glycoproteins, there may be too many potential proteoforms to consider. Still further, analysis of peptide structure data in the manner described by the various embodiments herein may be more conducive to generating accurate diagnoses as compared to glycomic analysis that provides little to no information about what proteins and to which amino acid residue sites various glycan structures attach.
[0063] Further, the methods, systems, and compositions provided by the embodiments described herein may enable an earlier, more accurate and / or less invasive diagnosis of melanoma in a subject as compared to currently available diagnostic modalities (e.g., biopsies, imaging, biochemical tests) used for determining whether immunotherapy (e.g., immune checkpoint inhibitors such as ipilimumab, nivolumab, and / or pembrolizumab) is indicated.
[0064] The description below provides exemplary implementations of the methods and systems described herein for analysis of peptide structures and for research, diagnosis, and / or treatment of melanoma. Various examples implement the methods and systems described herein as a screening tool. Descriptions and examples of various terms, as used herein, are provided in Section II below.IL Exemplary Descriptions of Terms
[0065] As used herein the specification, “a” or “an” may mean one or more. As used herein in the claim(s), when used in conjunction with the word “comprising,” the words “a” or “an”may mean one or more than one. Some embodiments of the disclosure may consist of or consist essentially of one or more elements, method steps, and / or methods of the disclosure. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein and that different embodiments may be combined.
[0066] The use of the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.” For example, “x, y, and / or z” can refer to “x” alone, “y” alone, “z” alone, “x, y, and z,” “(x and y) or z,” “x or (y and z),” or “x or y or z.” It is specifically contemplated that x, y, or z may be specifically excluded from an embodiment. As used herein “another” may mean at least a second or more.
[0067] The term “ones” means more than one.
[0068] As used herein, the term “plurality” may be 2, 3, 4, 5, 6, 7, 8, 9, 10, or more.
[0069] As used herein, the term “set of’ means one or more. For example, a set of items includes one or more items.
[0070] As used herein, the phrase “at least one of,” when used with a list of items, means different combinations of one or more of the listed items may be used and only one of the items in the list may be needed. The item may be a particular object, thing, step, operation, process, or category. In other words, “at least one of’ means any combination of items or number of items may be used from the list, but not all of the items in the list may be required. For example, without limitation, “at least one of item A, item B, or item C” means item A; item A and item B; item B; item A, item B, and item C; item B and item C; or item A and C. In some cases, “at least one of item A, item B, or item C” means, but is not limited to, two of item A, one of item B, and ten of item C; four of item B and seven of item C; or some other suitable combination.
[0071] As used herein, “substantially” means sufficient to work for the intended purpose. The term “substantially” thus allows for minor, insignificant variations from an absolute or perfect state, dimension, measurement, result, or the like such as would be expected by a person of ordinary skill in the field but that do not appreciably affect overall performance. When used with respect to numerical values or parameters or characteristics that can be expressed as numerical values, “substantially” means within ten percent.
[0072] Throughout this specification, unless the context requires otherwise, the words “comprise”, “comprises” and “comprising” will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or elementor group of steps or elements. By “consisting of’ is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of’ indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of’ is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of’ indicates that the listed elements are required or mandatory, but that no other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.
[0073] Reference throughout this specification to “one embodiment,” “an embodiment,” “a particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional embodiment,” or “a further embodiment” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in various embodiments.
[0074] “Treating” or treatment of a disease or condition refers to executing a protocol, which may include administering one or more drugs to an individual, such as a patient, in an effort to alleviate signs or symptoms of the disease. Desirable effects of treatment include decreasing the rate of disease progression, ameliorating or palliating the disease state, and remission or improved prognosis. Alleviation can occur prior to signs or symptoms of the disease or condition appearing, as well as after their appearance. Thus, “treating” or “treatment” may include “preventing” or “prevention” of disease or undesirable condition. In addition, “treating” or “treatment” does not require complete alleviation of signs or symptoms, does not require a cure, and specifically includes protocols that have only a marginal effect on the patient.
[0075] The term “therapeutically effective” as used throughout this application refers to anything that promotes or enhances the well-being of the subject with respect to the medical treatment of this condition. This includes, but is not limited to, a reduction in the frequency or severity of one or more signs or symptoms of a disease, including melanoma.
[0076] The term “melanoma disease state” as used herein refers to the presence in an individual of melanoma of any type and of any stage.[0077) The term “early stage” as used herein refers to stage 0, stage 1, or stage 2 cancer, such as defined by the American Joint Committee on Cancer (AJCC) TNM system and based on the size of the tumor, whether or not it has spread to nearby lymph nodes, and whether or not it has spread to distant sites.
[0078] The term “late stage” as used herein refers to stage 3 or stage 4 cancer, such as defined by the American Joint Committee on Cancer (AJCC) TNM system and based on the size of the tumor, whether or not it has spread to nearby lymph nodes, and whether or not it has spread to distant sites.
[0079] The term “amino acid,” as used herein, generally refers to any organic compound that includes an amino group (e.g., -NH2), a carboxyl group (-COOH), and a side chain group (R) which varies based on a specific amino acid. Amino acids can be linked using peptide bonds.
[0080] The term “alkylation,” as used herein, generally refers to the transfer of an alkyl group from one molecule to another. In various embodiments, alkylation is used to react with reduced cysteines to prevent the re-formation of disulfide bonds after reduction has been performed.
[0081] The term “linking site” or “glycosylation site” (or, in some cases, simply “site”) as used herein generally refers to the location where a sugar molecule of a glycan or glycan structure is directly bound (e.g., covalently bound) to an amino acid of a peptide, a polypeptide, or a protein. For example, the linking site may be an amino acid residue and a glycan structure may be linked via an atom of the amino acid residue. Non-limiting examples of types of glycosylation can include N-linked glycosylation, O-linked glycosylation, C-linked glycosylation, S-linked glycosylation, and glycation.
[0082] The terms “biological sample,” “biological specimen,” or “biospecimen” as used herein, generally refers to a specimen taken by sampling so as to be representative of the source of the specimen, typically, from a subject. A biological sample can be representative of an organism as a whole, specific tissue, cell type, or category or sub-category of interest. Biological samples may include, but are not limited to stool, synovial fluid, whole blood, blood serum, blood plasma, urine, sputum, tissue, saliva, tears, spinal fluid, tissue section(s) obtained by biopsy; cell(s) that are placed in or adapted to tissue culture; sweat, mucous, gastric fluid, abdominal fluid, amniotic fluid, cyst fluid, peritoneal fluid, pancreatic juice, breast milk, lung lavage, marrow, gastric acid, bile, semen, pus, aqueous humor, transudate, and the like including derivatives, portions and combinations of the foregoing. In some examples,biological samples include, but are not limited, to stool, biopsy, blood and / or plasma. In some examples, biological samples include, but are not limited, to urine or stool. Biological samples include, but are not limited, to biopsy. Biological samples include, but are not limited, to tissue dissections and tissue biopsies. Biological samples include, but are not limited, any derivative or fraction of the aforementioned biological samples. The biological sample can include a macromolecule. The biological sample can include a small molecule. The biological sample can include a virus. The biological sample can include a cell or derivative of a cell. The biological sample can include an organelle. The biological sample can include a cell nucleus. The biological sample can include a rare cell from a population of cells. The biological sample can include any type of cell, including without limitation prokaryotic cells, eukaryotic cells, bacterial, fungal, plant, mammalian, or other animal cell type, mycoplasmas, normal tissue cells, tumor cells, or any other cell type, whether derived from single cell or multicellular organisms. The biological sample can include a constituent of a cell. The biological sample can include nucleotides (e.g., ssDNA, dsDNA, RNA), organelles, amino acids, peptides, proteins, carbohydrates, glycoproteins, or any combination thereof. The biological sample can include a matrix (e.g., a gel or polymer matrix) comprising a cell or one or more constituents from a cell (e.g., cell bead), such as DNA, RNA, organelles, proteins, or any combination thereof, from the cell. The biological sample may be obtained from a tissue of a subject. The biological sample can include a hardened cell. Such hardened cells may or may not include a cell wall or cell membrane. The biological sample can include one or more constituents of a cell but may not include other constituents of the cell. An example of such constituents may include a nucleus or an organelle. The biological sample may include a live cell. The live cell can be capable of being cultured. 0083) The term “biomarker,” as used herein, generally refers to any measurable substance taken as a sample from a subject whose presence is indicative of some phenomenon. Nonlimiting examples of such phenomenon can include a disease state, a condition, or exposure to a compound or environmental condition. In various embodiments described herein, biomarkers may be used for diagnostic purposes (e.g., to diagnose a health state, a disease state). The term “biomarker” can be used interchangeably with the term “marker.”
[0084] The term “denaturation,” as used herein, generally refers to any molecule that loses quaternary structure, tertiary structure, and secondary structure which is present in their native state. Non-limiting examples include proteins or nucleic acids being exposed to an external compound or environmental condition such as acid, base, temperature, pressure, radiation, etc.
[0085] The term “denatured protein,” as used herein, generally refers to a protein that loses quaternary structure, tertiary structure, and secondary structure which is present in their native state.
[0086] The terms “digestion” or “enzymatic digestion,” as used herein, generally refers to a biological process that employs enzymes to break specific amino acid peptide bonds. For example, digesting a peptide includes contacting the peptide with an digesting enzyme, e.g., trypsin to produce fragments of the glycopeptide. In some examples, a protease enzyme is used to digest a glycopeptide. The term “protease” refers to an enzyme that performs proteolysis or breakdown of large peptides into smaller polypeptides or individual amino acids. Examples of a protease include, but are not limited to, one or more of a serine protease, threonine protease, cysteine protease, aspartate protease, glutamic acid protease, metalloprotease, asparagine peptide lyase, and any combinations of the foregoing. Enzymatic digestion may be used in preparation for mass spectrometry using trypsin digestion protocols. Proteins may be digested using other proteases in preparation for mass spectrometry if access is limited to cleavage sites.
[0087] The term “disease state” as used herein, generally refers to a condition that affects the structure or function of an organism. Non-limiting examples of causes of disease states may include pathogens, immune system dysfunctions, cell damage caused by aging, cell damage caused by other factors (e.g., trauma and cancer). Disease states can include any state of a disease whether symptomatic or asymptomatic. Disease states can include disease stages of a disease progression. Disease states can cause minor, moderate, or severe disruptions in structure or function of an organism (e.g., a subject).
[0088] The term “fragment,” as used herein, generally refers to an ion fragmentation process which occurs in a MRM-MS instrument. Fragmenting may produce various fragments having the same mass but varying with respect to their charge, e.g. , some biomarkers described herein produce more than one product m / z.
[0089] The terms “glycan” or “polysaccharide” as used herein, both generally refer to a carbohydrate residue of a glycoconjugate, such as the carbohydrate portion of a glycopeptide, glycoprotein, glycolipid, or proteoglycan. Glycans can include monosaccharides.
[0090] The term “glycopeptide” or “glycopolypeptide” as used herein, generally refers to a peptide or polypeptide comprising at least one glycan residue. In various embodiments, glycopeptides comprise carbohydrate moi eties (e.g, one or more glycans) covalently attached to a side chain (i.e. R group) of an amino acid residue. 1
[0091] The term “glycopeptide fragment” or “glycosylated peptide fragment” or“glycopeptide” as used herein, generally refers to a glycosylated peptide (or glycopeptide) having an amino acid sequence that is the same as part (but not all) of the amino acid sequence of the glycosylated protein from which the glycosylated peptide is obtained, e.g., ion fragmentation within a MRM-MS instrument. MRM refers to multiple-reaction-monitoring. Unless specified otherwise, within the specification, “glycopeptide fragments” or “fragments of a glycopeptide” refer to the fragments produced directly by using a mass spectrometer optionally after the glycoprotein has been digested enzymatically to produce the glycopeptides. [00921 The term “glycoprotein,” as used herein, generally refers to a protein having at least one glycan residue bonded thereto. In some examples, a glycoprotein is a protein with at least one oligosaccharide chain covalently bonded thereto. Examples of glycoproteins include but are not limited to the peptide structures including glycan molecules shown in the various Tables presented herein. A glycopeptide, as used herein, refers to a fragment of a glycoprotein, unless specified otherwise to the contrary.
[0093] The term “liquid chromatography,” as used herein, generally refers to a technique used to separate a sample into parts. Liquid chromatography can be used to separate, identify, and quantify components.
[0094] The term “mass spectrometry,” as used herein, generally refers to an analytical technique used to identify molecules. In various embodiments described herein, mass spectrometry can be involved in characterization and sequencing of proteins.
[0095] The term “glycopeptide structure monomer weight score,” (also “peptide structure monomer weight score,” used interchangeably) as used herein, generally refers to a value calculated as a function of a site occupancy score of a given peptide structure at a given site and the number of a specific monomer (e.g., specific monosaccharide) for the given glycopeptide structure. In some cases, a glycopeptide structure monomer weight score is a product of the site occupancy score and the number of a specific monomer for the given glycopeptide structure. Thus, as one example, a glycopeptide structure monomer weight score for glycan 5402 at site 33 of the AGP1 protein is the product of the number of a particular type of monomer (e.g., hexose) on that structure and the site occupancy of the 5402 structure at that site. A “glycopeptide structure monomer weight score” may, in some embodiments, be described in terms of a particular type of monomer and / or a particular type of peptide structure. For example a specific glycopeptide structure monomer weight score may be a glycan 5402 hexose weight score, i.e., a glycopeptide structure monomer weight score calculated as aproduct of the number of hexose molecules on glycan 5402 (i.e., 5) and the site occupancy of glycan 5402 at a particular site.
[0096] The term “monomer weight score,” as used herein, generally refers to a value calculated as a sum of individual glycopeptide structure monomer weight scores for all peptide structures at a particular site. In some embodiments, the monomer weight score is a sum of the individual glycopeptide structure monomer weight scores for all peptide structures at a particular site. Thus, as one example, a monomer weight score for hexose at site 33 of the protein AGP1 is a sum of the individual hexose weight scores for each glycan at site 33.[00971 The term “monomer,” as used herein, generally refers to a single or type of unit of a glycan structure. In some aspects, the term “monomer” describes a monosaccharide. Examples of monomers include hexose (e.g., mannose or galactose), HexNac (e.g., GlcNAc or GalNAc), fucose, sialic acid (e.g., NeuAc), mannose, galactose, GlcNAc, and GalNAc.[0098 | The term “m / z” or “mass-to-charge ratio,” as used herein, generally refers to an output value from a mass spectrometry instrument. In various embodiments, m / z can represent a relationship between the mass of a given ion and the number of elementary charges that it carries. The “m” in m / z stands for mass and the “z” stands for charge. In some embodiments, m / z can be displayed on an x-axis of a mass spectrum.[00991 The term “patient,” as used herein, generally refers to a mammalian subject. The mammal can be a human, or an animal including, but not limited to an equine, porcine, canine, feline, ungulate, and primate animal. In one embodiment, the individual is a human. The methods and uses described herein are useful for both medical and veterinary uses. A “patient” is a human subject unless specified to the contrary.
[0100] The term “peptide,” as used herein, generally refers to amino acids linked by peptide bonds. Peptides can include amino acid chains between 10 and 50 residues. Peptides can include amino acid chains shorter than 10 residues, including, oligopeptides, dipeptides, tripeptides, and tetrapeptides. Peptides can include chains longer than 50 residues and may be referred to as “polypeptides” or “proteins.” As used herein, the phrase “peptide,” is meant to include glycopeptides unless stated otherwise.[0101[ The terms “protein” or “polypeptide” or “peptide” may be used interchangeably herein and generally refer to a molecule including at least three amino acid residues. Proteins can include polymer chains made of amino acid sequences linked together by peptide bonds. Proteins may be digested in preparation for mass spectrometry using trypsin digestionprotocols. Proteins may be digested using other proteases in preparation for mass spectrometry if access is limited to cleavage sites.
[0102] The term “peptide structure,” as used herein, generally refers to peptides or a portion thereof or glycopeptides or a portion thereof. In various embodiments described herein, a peptide structure can include any molecule comprising at least two amino acids in sequence.
[0103] The term “reduction,” as used herein, generally refers to the gain of an electron by a substance. In various embodiments described herein, a sugar can directly bind to a protein, thereby, reducing the amino acid to which it binds. Such reducing reactions can occur in glycosylation. In various embodiments, reduction may be used to break disulfide bonds between two cysteines.
[0104] The term “sample,” as used herein, generally refers to a sample from a subject of interest and may include a biological sample of a subject. The sample may include a cell sample. The sample may include a cell line or cell culture sample. The sample can include one or more cells. The sample can include one or more microbes. The sample may include a nucleic acid sample or protein sample. The sample may also include a carbohydrate sample or a lipid sample. The sample may be derived from another sample. The sample may include a tissue sample, such as a biopsy, core biopsy, needle aspirate, or fine needle aspirate. The sample may include a fluid sample, such as a blood sample, urine sample, or saliva sample. The sample may include a skin sample. The sample may include a cheek swab. The sample may include a plasma or serum sample. The sample may include a cell-free or cell free sample. A cell-free sample may include extracellular polynucleotides. The sample may originate from blood, plasma, serum, urine, saliva, mucosal excretions, sputum, stool, or tears. The sample may originate from red blood cells or white blood cells. The sample may originate from feces, spinal fluid, CNS fluid, gastric fluid, amniotic fluid, cyst fluid, peritoneal fluid, marrow, bile, other body fluids, tissue obtained from a biopsy, skin, or hair.
[0105] The term “sequence,” as used herein, generally refers to a biological sequence including one-dimensional monomers that can be assembled to generate a polymer. Nonlimiting examples of sequences include nucleotide sequences (e.g., ssDNA, dsDNA, and RNA), amino acid sequences (e.g., proteins, peptides, and polypeptides), and carbohydrates (e.g., compounds including Cm ( bOjn).
[0106] The term “site monomer,” (also “monomer weight feature”), as used herein, generally refers to a single type of glycan monomer at a particular glycopeptide structure site. Types of glycan monomers include, for example, hexose (i.e., mannose and galactose; referredto herein in some aspect as “hex”), HexNAc (i.e., GlcNAc and GalNAc; referred to herein in some aspect as “hexnac”), fucose (i.e., deoxyhexose; referred to herein in some aspect as “fuco”), and sialic acid (i.e., NeuAc; referred to herein in some aspect as “sial”). Thus, as one example, site monomers for site 33 of protein AGP1 include AGPl_33_hex (i.e., a hexose monomer at site 33 of AGP1), AGP 1 33 hexnac (i.e., a GlcNAc or GalNAc monomer at site 33 of AGP1), AGPl_33_fuco (i.e., a focuse monomer at site 33 of AGP1), and AGPl_33_sial (i.e., a sialic acid monomer at site 33 of AGP1).
[0107] The term “subject,” as used herein, generally refers to an animal, such as a mammal (e.g., human) or avian (e.g., bird), or other organism, such as a plant. For example, the subject can include a vertebrate, a mammal, a rodent (e.g., a mouse), a primate, a simian or a human. Animals may include, but are not limited to, farm animals, sport animals, and pets. A subject can include a healthy or asymptomatic individual, an individual that has or is suspected of having a disease (e.g., cancer) or a pre-disposition to the disease, and / or an individual that is in need of therapy or suspected of needing therapy. A subject can be a patient. A subject can include a microorganism or microbe (e.g., bacteria, fungi, archaea, viruses). A subject may be one who has been previously identified as having a disease or a condition, and optionally has already undergone, or is undergoing, a therapeutic intervention for the disease or condition. Alternatively, a subject can also be one who has not been previously diagnosed as having a disease or a condition. For example, a subject can be one who exhibits one or more risk factors for a disease or a condition, or a subject who does not exhibit disease risk factors, or a subject who is asymptomatic for a disease or a condition. A subject can also be one who is suffering from or at risk of developing a disease or a condition. A subject may also be referred to as an individual or patient.(0108] The term “training data,” as used herein generally refers to data that can be input into models, statistical models, algorithms and any system or process able to use existing data to make predictions.
[0109] As used herein, a “model” may include one or more algorithms, one or more mathematical techniques, one or more machine learning algorithms, or a combination thereof.
[0110] As used herein, “machine learning” may be the practice of using algorithms to parse data, learn from it, and then make a determination or prediction about something in the world. Machine learning uses algorithms that can learn from data without relying on rules-based programming. A machine learning algorithm may include a parametric model, a nonparametric model, a deep learning model, a neural network, a linear discriminant analysis model, aquadratic discriminant analysis model, a support vector machine, a random forest algorithm, a nearest neighbor algorithm, a combined discriminant analysis model, a k-means clustering algorithm, a supervised model, an unsupervised model, logistic regression model, a multivariable regression model, a penalized multivariable regression model, or another type of model.
[0111] As used herein, an “artificial neural network” or “neural network” (NN) may refer to mathematical algorithms or computational models that mimic an interconnected group of artificial nodes or neurons that processes information based on a connectionistic approach to computation. Neural networks, which may also be referred to as neural nets, can employ one or more layers of nonlinear units to predict an output for a received input. Some neural networks include one or more hidden layers in addition to an output layer. The output of each hidden layer is used as input to the next layer in the network, z.e., the next hidden layer or the output layer. Each layer of the network generates an output from a received input in accordance with current values of a respective set of parameters. In the various embodiments, a reference to a “neural network” may be a reference to one or more neural networks.
[0112] A neural network may process information in two ways: when it is being trained it is in training mode and when it puts what it has learned into practice it is in inference (or prediction) mode. Neural networks learn through a feedback process (e.g., backpropagation) which allows the network to adjust the weight factors (modifying its behavior) of the individual nodes in the intermediate hidden layers so that the output matches the outputs of the training data. In other words, a neural network learns by being fed training data (learning examples) and eventually learns how to reach the correct output, even when it is presented with a new range or set of inputs. A neural network may include, for example, without limitation, at least one of a Feedforward Neural Network (FNN), a Recurrent Neural Network (RNN), a Modular Neural Network (MNN), a Convolutional Neural Network (CNN), a Residual Neural Network (ResNet), an Ordinary Differential Equations Neural Networks (neural-ODE), or another type of neural network.
[0113] As used herein, a “target glycopeptide analyte,” may refer to a peptide structure (e.g., glycosylated or aglycosylated / non-glycosylated), a fraction of a peptide structure, a substructure (e.g., a glycan or a glycosylation site) of a peptide structure, a product of one or more of the above listed structures and sub-structures, associated detection molecules (e.g., signal molecule, label, or tag), or an amino acid sequence that can be measured by mass spectrometry.
[0114] As used herein, a “peptide data set,” may be used interchangeably with “peptide structure data” and can refer to any data of or relating to a peptide from a resulting mass spectrometry run. A peptide data set can comprise data obtained from a sample or biological sample using mass spectrometry. A peptide dataset can comprise data relating to an external standard, data relating to an internal standard, and data relating to a target glycopeptide analyte of a sample. A peptide data set can result from analysis originating from a single run. In some embodiments, the peptide data set can include raw abundance and mass to charge ratios for one or more peptides.
[0115] As used herein, a “a transition,” may refer to or identify a peptide structure. In some embodiments, a transition can refer to the specific pair of m / z values associated with a precursor ion and a product or fragment ion.
[0116] As used herein, a “non-glycosylated endogenous peptide” (“NGEP”) may refer to a peptide structure that does not comprise a glycan molecule. In various embodiments, an NGEP and a target glycopeptide analyte can originate from the same subject. In various embodiments, an NGEP and a target glycopeptide analyte may be derived from the same protein sequence. In some embodiments, the NGEP and the target glycopeptide analyte may be derived from or include the same peptide sequence. In various embodiments, an NGEP can be labeled with an isotope in preparation for mass spectrometry analysis.[Oil 7] As used herein, “abundance,” may refer to a quantitative value generated using mass spectrometry. In various embodiments, the quantitative value may relate to the amount of a particular peptide structure. In some embodiments, the quantitative value may comprise an amount of an ion produced using mass spectrometry. In some embodiments, the quantitative value may be expressed as an m / z value. In other embodiments, the quantitative value may be expressed in atomic mass units.
[0118] As used herein, “relative abundance,” may refer to a comparison of two or more abundances. In various embodiments, the comparison may comprise comparing one peptide structure to a total number of peptide structures. In some embodiments, the comparison may comprise comparing one peptide glycoform (e.g., two identical peptides differing by one or more glycans) to a set of peptide glycoforms. In some embodiments, the comparison may comprise comparing a number of ions having a particular m / z ratio by a total number of ions detected. In various embodiments, a relative abundance can be expressed as a ratio. In other embodiments, a relative abundance can be expressed as a percentage. Relative abundance can be presented on a y-axis of a mass spectrum plot.
[0119] As used herein, an “internal standard,” may refer to something that can be contained (e.g., spiked-in) in the same sample as a target glycopeptide analyte undergoing mass spectrometry analysis. Internal standards can be used for calibration purposes. Additionally, internal standards can be used in the systems and method described herein. In some aspects, an internal standard can be selected based on similarity m / z and or retention times and can be a “surrogate” if a specific standard is too costly or unavailable. Internal standards can be heavy labeled or non-heavy labeled.III. Overview of Exemplary Workflow
[0120] Figure 1 is a schematic diagram of an exemplary workflow 100 for the detection of peptide structures associated with a disease state for use in diagnosis and / or treatment in accordance with one or more embodiments. Workflow 100 may include various operations including, for example, sample collection 102, sample intake 104, sample preparation and processing 106, data analysis 108, and output generation 110.
[0121] Sample collection 102 may include, for example, obtaining a biological sample 112 of one or more subjects, such as subject 114. Biological sample 112 may take the form of a specimen obtained via one or more sampling methods. Biological sample 112 may be representative of subject 114 as a whole or of a specific tissue, cell type, or other category or sub-category of interest. Biological sample 112 may be obtained in any of a number of different ways. In various embodiments, biological sample 112 includes whole blood sample 116 obtained via a blood draw. In other embodiments, biological sample 112 includes set of aliquoted samples 118 that includes, for example, a serum sample, a plasma sample, a blood cell (e.g., white blood cell (WBC), red blood cell (RBC) sample, another type of sample, or a combination thereof. Biological samples 112 may include nucleotides (e.g., ssDNA, dsDNA, RNA), organelles, amino acids, peptides, proteins, carbohydrates, glycoproteins, or any combination thereof.
[0122] In various embodiments, a single run can analyze a sample (e.g., the sample including a peptide analyte), an external standard (e.g., an NGEP of a serum sample), and an internal standard. As such, abundance or raw abundance for the external standard, the internal standard, and target glycopeptide analyte can be determined by mass spectrometry in the same run.
[0123] In various embodiments, external standards may be analyzed prior to analyzing samples. In various embodiments, the external standards can be run independently between thesamples. In some embodiments, external standards can be analyzed after every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more experiments. In various embodiments, external standard data can be used in some or all of the normalization systems and methods described herein. In additional embodiments, blank samples may be processed to prevent column fouling.(0124] Sample intake 104 may include one or more various operations such as, for example, aliquoting, registering, processing, storing, thawing, and / or other types of operations. In one or more embodiments, when biological sample 112 includes whole blood sample 116, sample intake 104 includes aliquoting whole blood sample 116 to form a set of aliquoted samples that can then be sub-aliquoted to form set of samples 120.(0125] Sample preparation and processing 106 may include, for example, one or more operations to form set of peptide structures 122. In various embodiments, set of peptide structures 122 may include various fragments of unfolded proteins that have undergone digestion and may be ready for analysis.(0126] Further, sample preparation and processing 106 may include, for example, data acquisition 124 based on set of peptide structures 122. For example, data acquisition 124 may include use of, for example, but is not limited to, a liquid chromatography / mass spectrometry (LC / MS) system.(012*7] Data analysis 108 may include, for example, peptide structure analysis 126. In some embodiments, data analysis 108 also includes output generation 110. In other embodiments, output generation 110 may be considered a separate operation from data analysis 108. Output generation 110 may include, for example, generating final output 128 based on the results of peptide structure analysis 126. Final output 128 may be used for determining research, diagnosis, and / or treatment.
[0128] In various embodiments, final output 128 is comprised of one or more outputs. Final output 128 may take various forms. For example, final output 128 may be a report that includes, for example, a diagnosis output, a treatment output (e.g., a treatment design output, a treatment plan output, or combination thereof), analyzed data (e.g., relativized and normalized) or combination thereof. In some embodiments, report can comprise a target glycopeptide analyte concentration as a function of the NGEP concentration value and the normalized abundance. In some embodiments, final output 128 may be an alert (e.g., a visual alert, an audible alert, etc.), a notification (e.g., a visual notification, an audible notification, an email notification, etc.), an email output, or a combination thereof. In some embodiments, finaloutput 128 may be sent to remote system 130 for processing. Remote system 130 may include, for example, a computer system, a server, a processor, a cloud computing platform, cloud storage, a laptop, a tablet, a smartphone, some other type of mobile computing device, or a combination thereof.
[0129] In other embodiments, workflow 100 may optionally exclude one or more of the operations described herein and / or may optionally include one or more other steps or operations other than those described herein (e.g., in addition to and / or instead of those described herein). Accordingly, workflow 100 may be implemented in any of a number of different ways for use in the research, diagnosis, and / or treatment of a disease state.IV. Detection and Quantification of Peptide Structures|0130| Figures 2A and 2B are schematic diagrams of a workflow for sample preparation and processing 106 in accordance with one or more embodiments. Figures 2A and 2B are described with continuing reference to Figure 1. Sample preparation and processing 106 may include, for example, preparation workflow 200 shown in Figure 2A and data acquisition 124 shown in Figure 2B.IV. A. Sample Preparation and Processing
[0131] Figure 2A is a schematic diagram of preparation workflow 200 in accordance with one or more embodiments. Preparation workflow 200 may be used to prepare a sample, such as a sample of set of samples 120 in Figure 1, for analysis via data acquisition 124. For example, this analysis may be performed via mass spectrometry (e.g., LC-MS). In various embodiments, preparation workflow 200 may include denaturation and reduction 202, alkylation 204, and digestion 206. Areas of the preparation workflow can cause inconsistency between different samples and different experiments, necessitating, the improved normalization systems and methods described herein and throughout.
[0132] In general, polymers, such as proteins, in their native form, can fold to include secondary, tertiary, and / or other higher order structures. Such higher order structures may functionalize proteins to complete tasks (e.g., enable enzymatic activity) in a subject. Further, such higher order structures of polymers may be maintained via various interactions between side chains of amino acids within the polymers. Such interactions can include ionic bonding, hydrophobic interactions, hydrogen bonding, and disulfide linkages between cysteine residues. However, when using analytic systems and methods, including mass spectrometry, unfoldingsuch polymers (e.g., peptide / protein molecules) may be desired to obtain sequence information. In some embodiments, unfolding a polymer may include denaturing the polymer, which may include, for example, linearizing the polymer.
[0133] In one or more embodiments, denaturation and reduction 202 can be used to disrupt higher order structures (e.g., secondary, tertiary, quaternary, etc.) of one or more proteins (e.g., polypeptides and peptides) in a sample (e.g., one of set of samples 120 in Figure 1). Denaturation and reduction 202 includes, for example, a denaturation procedure and a reduction procedure. In some embodiments, the denaturation procedure may be performed using, for example, thermal denaturation, where heat is used as a denaturing agent. The thermal denaturation can disrupt ionic bonding, hydrophobic interactions, and / or hydrogen bonding. (0134] In various embodiments, the denaturation procedure may include using one or more denaturing agents. In one or more embodiments, the denaturation procedure may include using temperature. In one or more embodiments, the denaturation procedure may include using one or more denaturing agents in combination with heat. These one or more denaturing agents may include, for example, but are not limited to, any number of chaotropic salts (e.g., urea, guanidine), surfactants (e.g., sodium dodecyl sulfate (SDS), beta octyl glucoside, Triton X- 100), or combination thereof. In some cases, such denaturing agents may be used in combination with heat when sample preparation workflow further includes a cleanup procedure.(0135] The resulting one or more denatured (e.g., unfolded, linearized) proteins may then undergo further processing in preparation of analysis. For example, a reduction procedure may be performed in which one or more reducing agents are applied. In various embodiments, a reducing agent can produce an alkaline pH. A reducing agent may take the form of, for example, without limitation, dithiothreitol (DTT), tris(2-carboxyethyl)phosphine (TCEP), or some other reducing agent. The reducing agent may reduce (e.g., cleave) the disulfide linkages between cysteine residues of the one or more denatured proteins to form one or more reduced proteins.
[0136] In various embodiments, the one or more reduced proteins resulting from denaturation and reduction 202 may undergo a process to prevent the reformation of disulfide linkages between, for example, the cysteine residues of the one or more reduced proteins. This process may be implemented using alkylation 204 to form one or more alkylated proteins. For example, alkylation 204 may be used to add an acetamide group to a sulfur on each cysteine residue to prevent disulfide linkages from reforming. In various embodiments, an acetamidegroup can be added by reacting one or more alkylating agents with a reduced protein. The one or more alkylating agents may include, for example, one or more acetamide salts. An alkylating agent may take the form of, for example, iodoacetamide (IAA), 2-chloroacetamide, some other type of acetamide salt, or some other type of alkylating agent.
[0137] In some embodiments, alkylation 204 may include a quenching procedure. The quenching procedure may be performed using one or more reducing agents (e.g., one or more of the reducing agents described above).
[0138] In various embodiments, the one or more alkylated proteins formed via alkylation 204 can then undergo digestion 206 in preparation for analysis (e.g., mass spectrometry analysis). Digestion 206 of a protein may include cleaving the protein at or around one or more cleavage sites (e.g., site 205 which may be one or more amino acid residues). For example, without limitation, an alkylated protein may be cleaved at the carboxyl side of the lysine or arginine residues. This type of cleavage may break the protein into various segments, which include one or more peptide structures (e.g., glycosylated or aglycosylated).
[0139] In various embodiments, digestion 206 is performed using one or more proteolysis catalysts. For example, an enzyme can be used in digestion 206. In some embodiments, the enzyme takes the form of trypsin. In other embodiments, one or more other types of enzymes (e.g., proteases) may be used in addition to or in place of trypsin. These one or more other enzymes include, but are not limited to, LysC, LysN, AspN, GluC, and ArgC. In some embodiments, digestion 206 may be performed using tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin, one or more engineered forms of trypsin, one or more other formulations of trypsin, or a combination thereof. In some embodiments, digestion 206 may be performed in multiple steps, with each involving the use of one or more digestion agents. For example, a secondary digestion, tertiary digestion, etc. may be performed. In one or more embodiments, trypsin is used to digest serum samples. In one or more embodiments, trypsin / LysC cocktails are used to digest plasma samples.
[0140] In some embodiments, digestion 206 further includes a quenching procedure. The quenching procedure may be performed by acidifying the sample (e.g., to a pH <3). In some embodiments, formic acid may be used to perform this acidification.
[0141] In various embodiments, preparation workflow 200 further includes post-digestion procedure 207. Post-digestion procedure 207 may include, for example, a cleanup procedure. The cleanup procedure may include, for example, the removal of unwanted components in the sample that results from digestion 206. For example, unwanted components may include, butare not limited to, inorganic ions, surfactants, etc. In some embodiments, post-digestion procedure 207 further includes a procedure for the addition of heavy-labeled peptide internal standards.
[0142] Although preparation workflow 200 has been described with respect to a sample created or taken from biological sample 112 that is blood-based (e.g., a whole blood sample, a plasma sample, a serum sample, etc.), sample preparation workflow 200 may be similarly implemented for other types of samples (e.g., tears, urine, tissue, interstitial fluids, sputum, etc. to produce set of peptides structures 122.IV.B. Peptide Structure Identification and Quantitation(0143] Figure 2B is a schematic diagram of data acquisition 124 in accordance with one or more embodiments. In various embodiments, data acquisition 124 can commence following sample preparation 200 described in Figure 2A. In various embodiments, data acquisition 124 can comprise quantification 208, quality control 210, and peak integration and normalization 212.
[0144] In various embodiments, targeted quantification 208 of peptides and glycopeptides can incorporate use of liquid chromatography -mass spectrometry LC / MS instrumentation. For example, LC-MS / MS, or tandem MS may be used. In general, LC / MS (e.g., LC-MS / MS) can combine the physical separation capabilities of liquid chromatograph (LC) with the mass analysis capabilities of mass spectrometry (MS). According to some embodiments described herein, this technique allows for the separation of digested peptides to be fed from the LC column into the MS ion source through an interface.
[0145] In various embodiments, any LC / MS device can be incorporated into the workflow described herein. In various embodiments, an instrument or instrument system suited for identification and targeted quantification 208 may include, for example, a Triple Quadrupole LC / MS™. In various embodiments, targeted quantification 208 is performed using multiple reaction monitoring mass spectrometry (MRM-MS).
[0146] In various embodiments described herein, identification of a particular protein or peptide and an associated quantity can be assessed. In various embodiments described herein, identification of a particular glycan and an associated quantity can be assessed. In various embodiments described herein, particular glycans can be matched to a glycosylation site on a protein or peptide and the abundances measured.[0147) In some cases, targeted quantification 208 includes using a specific collision energy associated for the appropriate fragmentation to consistently see an abundant product ion. Glycopeptide structures may have a lower collision energy than aglycosylated peptide structures. When analyzing a sample that includes glycopeptide structures, the source voltage and gas temperature may be lowered as compared to generic proteomic analysis.
[0148] In various embodiments, quality control 210 procedures can be put in place to optimize data quality. In various embodiments, measures can be put in place allowing only errors within acceptable ranges outside of an expected value. In various embodiments, employing statistical models (e.g., using Westgard rules) can assist in quality control 210. For example, quality control 210 may include, for example, assessing the retention time and abundance of representative peptide structures (e.g., glycosylated and / or aglycosylated) and spiked-in internal standards, in either every sample, or in each quality control sample (e.g., pooled serum digest).
[0149] Peak integration and normalization 212 may be performed to process the data that has been generated and transform the data into a format for analysis. For example, peak integration and normalization 212 may include converting abundance data for various product ions that were detected for a selected peptide structure into a single quantification metric (e.g., a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, a normalized concentration, etc.) for that peptide structure. In some embodiments, peak integration and normalization 212 may be performed using one or more of the techniques described in U.S. Patent Publication No. 2020 / 0372973 Al and / or US Patent Publication No. 2020 / 0240996A1, the disclosures of which are incorporated by reference herein in their entireties.V. Peptide Structure Data AnalysisV. A. Exemplary System for Peptide Structure Data AnalysisV.A.l. Analysis System for Peptide Structure Data Analysis
[0150] Figure 3 is a block diagram of an analysis system 300 in accordance with one or more embodiments. Analysis system 300 can be used to both detect and analyze various peptide structures that have been associated with various disease states. Analysis system 300 is one example of an implementation for a system that may be used to perform data analysis 108 in Figure 1. Thus, analysis system 300 is described with continuing reference to workflow 100 as described in Figures 1, 2A, and / or 2B.
[0151] Analysis system 300 may include computing platform 302 and data store 304. In some embodiments, analysis system 300 also includes display system 306. Computing platform 302 may take various forms. In one or more embodiments, computing platform 302 includes a single computer (or computer system) or multiple computers in communication with each other. In other examples, computing platform 302 takes the form of a cloud computing platform.
[0152] Data store 304 and display system 306 may each be in communication with computing platform 302. In some examples, data store 304, display system 306, or both may be considered part of or otherwise integrated with computing platform 302. Thus, in some examples, computing platform 302, data store 304, and display system 306 may be separate components in communication with each other, but in other examples, some combination of these components may be integrated together. Communication between these different components may be implemented using any number of wired communications links, wireless communications links, optical communications links, or a combination thereof.
[0153] Analysis system 300 includes, for example, peptide structure analyzer 308, which may be implemented using hardware, software, firmware, or a combination thereof. In one or more embodiments, peptide structure analyzer 308 is implemented using computing platform 302.
[0154] Peptide structure analyzer 308 receives peptide structure data 310 for processing. Peptide structure data 310 may be, for example, the peptide structure data that is output from sample preparation and processing 106 in Figures 1, 2 A, and 2B. Accordingly, peptide structure data 310 may correspond to set of peptide structures 122 identified for biological sample 112 and may thereby correspond to biological sample 112.
[0155] Peptide structure data 310 can be sent as input into peptide structure analyzer 308, retrieved from data store 304 or some other type of storage (e.g., cloud storage), accessed from cloud storage, or obtained in some other manner. In some cases, peptide structure data 310 may be retrieved from data store 304 in response to (e.g., directly or indirectly based on) receiving user input entered by a user via an input device.
[0156] Peptide structure analyzer 308 includes model 312 that is configured to receive peptide structure data 310 for processing. Model 312 may be implemented in any of a number of different ways. Model 312 may be implemented using any number of models, functions, equations, algorithms, and / or other mathematical techniques.[0157) In one or more embodiments, model 312 includes machine learning system 314, which may itself be comprised of any number of machine learning models and / or algorithms. For example, machine learning system 314 may include, but is not limited to, at least one of a deep learning model, a neural network, a linear discriminant analysis model, a quadratic discriminant analysis model, a support vector machine, a random forest algorithm, a nearest neighbor algorithm (e.g., a k-Nearest Neighbors algorithm), a combined discriminant analysis model, a k-means clustering algorithm, an unsupervised model, a multivariable regression model, a penalized multivariable regression model, or another type of model. In various embodiments, model 312 includes a machine learning system 314 that comprises any number of or combination of the models or algorithms described above.
[0158] In various embodiments, model 312 analyzes peptide structure data 310 to generate disease indicator 316 that indicates whether the biological sample is positive for a colorectal cancer disease state based on set of peptide structures 318 identified as being associated with the colorectal cancer disease state. Peptide structure data 310 may include quantification data for the plurality of peptide structures. Quantification data for a peptide structures can include at least one of an abundance, a relative abundance, a normalized abundance, a relative quantity, an adjusted quantity, a normalized quantity, a relative concentration, an adjusted concentration, or a normalized concentration. For example, peptide structure data 310 may include a set of quantification metrics for each peptide structure of a plurality of peptide structures. A quantification metric for a peptide structure may be selected as one of a relative quantity, an adjusted quantity, a normalized quantity, a relative abundance, an adjusted abundance, and a normalized abundance. In some cases, a quantification metric for a peptide structure is selected from one of a relative concentration, an adjusted concentration, and a normalized concentration. In one or more embodiments, the quantification metrics used are normalized abundances. In this manner, peptide structure data 310 may provide abundance information about the plurality of peptide structures with respect to biological sample 112.
[0159] Disease indicator 316 may take various forms. In some examples, disease indicator 316 includes a classification that indicates whether or not the subject is positive for the melanoma disease state. In various embodiments, disease indicator 316 can include a score 320. In some aspects, score 320 indicates whether the melanoma disease state is present or not. For example, score 320 may be, a probability score that indicates how likely it is that the biological sample 112 evidences the presence of the melanoma disease state. Alternatively or in addition, disease indicator 316 includes a classification hat indicates whether or not thesubject has immunotherapy responsive melanoma (i.e., will respond to immunotherapy treatment, for example immune checkpoint inhibitors such as ipilimumab, nivolumab, and / or pembrolizumab) or immunotherapy nonresponsive melanoma (i.e., will not respond to immunotherapy treatment, for example immune checkpoint inhibitors such as ipilimumab, nivolumab, and / or pembrolizumab). In such cases, score 320 may be, for example, a probability score that indicates how likely it is that the biological sample 112 evidences the presence of an immunotherapy responsive melanoma.
[0160] In one or more embodiments, a peptide structure of set of peptide structures 318 comprises a glycosylated peptide structure, or glycopeptide structure, that is defined by a peptide sequence and a glycan structure attached to a linking site of the peptide sequence quantity. For example, the peptide structure may be a glycopeptide or a portion of a glycopeptide. In some embodiments, a peptide structure of set of peptide structures 318 comprises an aglycosylated peptide structure that is defined by a peptide sequence. For example, the peptide structure may be a peptide or a portion of a peptide and may be referred to as a quantification peptide.
[0161] Set of peptide structures 318, and / or monomer weight scores derived therefrom, may be identified as being those most predictive or relevant to the melanoma disease state based on training of model 312.[ 162J Invarious embodiments, machine learning system 314 takes the form of binary classification model 322. Binary classification model 322 may include, for example, but is not limited to, a regression model. Binary classification model 322 may include, for example, a penalized multivariable regression model that is trained to identify set of peptide structures 318 from a plurality of (or panel of) peptide structures identified in various subjects. Binary classification model 322 may be trained to identify weight coefficients for peptide structures and those peptide structures having non-zero weights or weight coefficients above a selected threshold (e.g., absolute weight coefficient above 0.0, 0.01, 0.05, 0.1, 0.015, 0.2, etc.) may be selected for inclusion in set of peptide structures 318.
[0163] Peptide structure analyzer 308 may generate final output 128 based on disease indicator 316 output by model 312. In other embodiments, final output 128 may be an output generated by model 312.
[0164] In some embodiments, final output 128 includes disease indicator 316. In one or more embodiments, final output 128 includes diagnosis output 324, treatment output 326, or both. Diagnosis output 324 may include, for example, a diagnosis for the melanoma state. Thediagnosis can include a positive diagnosis or a negative diagnosis for the melanoma disease state. Alternatively or in addition, the diagnosis can include a determination that the subject has immunotherapy responsive melanoma or immunotherapy nonresponsive melanoma. In some aspects, immunotherapy responsive melanoma describes melanoma responsive to treatment with immune checkpoint inhibitors. In some aspects, immunotherapy responsive melanoma describes melanoma responsive to combination treatment with ipilimumab and nivolumab. In some aspects, immunotherapy responsive melanoma describes melanoma responsive to combination treatment with pembrolizumab.
[0165] In one or more embodiments, when disease indicator 316 and / or diagnosis output 324 indicate a positive diagnosis for the melanoma disease state, a biopsy may be recommended. For example, a biopsy of the subject may be performed in response to disease indicator 316 and / or diagnosis output 324 indicating a positive diagnosis for the melanoma disease state. In some embodiments, peptide structure analyzer 308 (or another system implemented on computing platform 302) may generate a report recommending that a biopsy is to be performed for the subject in response to disease indicator 316 and / or diagnosis output 324 indicating a positive diagnosis for the melanoma disease state. In other embodiments, peptide structure analyzer 308 may send diagnosis final output 128 to remote system 130 over one or more wireless, wired, and / or optical communications links and remote system 130 may generate a report recommending that a biopsy is to be performed for the subject in response to disease indicator 316 and / or diagnosis output 324 indicating a positive diagnosis for the adenoma or colorectal cancer disease state. The biopsy may be used to confirm the diagnosis to determine whether or not to administer treatment, which treatment to administer, and / or how quickly to administer treatment. When disease indicator 316 and / or diagnosis output 324 indicate a negative diagnosis for the melanoma disease state, the report that is generated by peptide structure analyzer 308, remote system 130, or some other system implemented on computing platform 142 may recommend a period of monitoring for the subject. For example, a negative diagnosis indication by disease indicator 316 and / or diagnosis output 324 may thus help prevent unnecessary treatment or overtreatment of the subject.
[0166] Treatment output 326 may include, for example, at least one of an identification of a treatment for the subj ect, a treatment plan for administering the treatment, or both. Treatment for melanoma may include, for example, but is not limited to, at least one of surgery, radiation therapy, a targeted drug therapy (e.g., one or more targeted therapeutic agents), chemotherapy (e.g., one or more chemotherapeutic agents), immunotherapy (e.g., one or moreimmunotherapeutic agents such as immune checkpoint inhibitors ipilimumab, nivolumab, and / or pembrolizumab), hormone therapy, neoadjuvant therapy, or some other form of treatment. The treatment plan may include, for example, but is not limited to, a timeline or schedule for administering the treatment, dosing information, other treatment-related information, or a combination thereof.(0167] Final output 128 may be sent to remote system 130 for processing in some examples. In other embodiments, final output 128 may be displayed on graphical user interface 330 in display system 306 for viewing by a human operator.V.A.2. Computer Implemented System(0168] Figure 4 is a block diagram of a computer system in accordance with various embodiments. Computer system 400 may be an example of one implementation for computing platform 302 described above in Figure 3.(0169] In one or more examples, computer system 400 can include a bus 402 or other communication mechanism for communicating information, and a processor 404 coupled with bus 402 for processing information. In various embodiments, computer system 400 can also include a memory, which can be a random-access memory (RAM) 406 or other dynamic storage device, coupled to bus 402 for determining instructions to be executed by processor 404. Memory also can be used for storing temporary variables or other intermediate information during execution of instructions to be executed by processor 404. In various embodiments, computer system 400 can further include a read only memory (ROM) 408 or other static storage device coupled to bus 402 for storing static information and instructions for processor 404. A storage device 410, such as a magnetic disk or optical disk, can be provided and coupled to bus 402 for storing information and instructions.
[0170] In various embodiments, computer system 400 can be coupled via bus 402 to a display 412, such as a cathode ray tube (CRT), liquid crystal display (LCD), or light emitting diode (LED) for displaying information to a computer user. An input device 414, including alphanumeric and other keys, can be coupled to bus 402 for communicating information and command selections to processor 404. Another type of user input device is a cursor control 416, such as a mouse, a joystick, a trackball, a gesture input device, a gaze-based input device, or cursor direction keys for communicating direction information and command selections to processor 404 and for controlling cursor movement on display 412. This input device 414 typically has two degrees of freedom in two axes, a first axis (e.g., x) and a second axis (e.g.,y), that allows the device to specify positions in a plane. However, it should be understood that input devices 414 allowing for three-dimensional (e.g., x, y, and z) cursor movement are also contemplated herein.
[0171] Consistent with certain implementations of the present teachings, results can be provided by computer system 400 in response to processor 404 executing one or more sequences of one or more instructions contained in RAM 406. Such instructions can be read into RAM 406 from another computer-readable medium or computer-readable storage medium, such as storage device 410. Execution of the sequences of instructions contained in RAM 406 can cause processor 404 to perform the processes described herein. Alternatively, hard-wired circuitry can be used in place of or in combination with software instructions to implement the present teachings. Thus, implementations of the present teachings are not limited to any specific combination of hardware circuitry and software.
[0172] The term “computer-readable medium” (e.g., data store, data storage, storage device, data storage device, etc.) or “computer-readable storage medium” as used herein refers to any media that participates in providing instructions to processor 404 for execution. Such a medium can take many forms, including but not limited to, non-volatile media, volatile media, and transmission media. Examples of non-volatile media can include, but are not limited to, optical, solid state, magnetic disks, such as storage device 410. Examples of volatile media can include, but are not limited to, dynamic memory, such as RAM 406. Examples of transmission media can include, but are not limited to, coaxial cables, copper wire, and fiber optics, including the wires that comprise bus 402.
[0173] Common forms of computer-readable media include, for example, a floppy disk, a flexible disk, hard disk, magnetic tape, or any other magnetic medium, a CD-ROM, any other optical medium, punch cards, paper tape, any other physical medium with patterns of holes, a RAM, PROM, and EPROM, a FLASH-EPROM, any other memory chip or cartridge, or any other tangible medium from which a computer can read.
[0174] In addition to computer readable medium, instructions or data can be provided as signals on transmission media included in a communications apparatus or system to provide sequences of one or more instructions to processor 404 of computer system 400 for execution. For example, a communication apparatus may include a transceiver having signals indicative of instructions and data. The instructions and data are configured to cause one or more processors to implement the functions outlined in the disclosure herein. Representative examples of data communications transmission connections can include, but are not limited to,telephone modem connections, wide area networks (WAN), local area networks (LAN), infrared data connections, NFC connections, optical communications connections, etc.
[0175] It should be appreciated that the methodologies described herein, flow charts, diagrams, and accompanying disclosure can be implemented using computer system 400 as a standalone device or on a distributed network of shared computer processing resources such as a cloud computing network.
[0176] The methodologies described herein may be implemented by various means depending upon the application. For example, these methodologies may be implemented in hardware, firmware, software, or any combination thereof. For a hardware implementation, the processing unit may be implemented within one or more application specific integrated circuits (ASICs), digital signal processors (DSPs), digital signal processing devices (DSPDs), programmable logic devices (PLDs), field programmable gate arrays (FPGAs), processors, controllers, micro-controllers, microprocessors, electronic devices, other electronic units designed to perform the functions described herein, or a combination thereof.[0177) In various embodiments, the methods of the present teachings may be implemented as firmware and / or a software program and applications written in conventional programming languages such as C, C++, Python, etc. If implemented as firmware and / or software, the embodiments described herein can be implemented on a non-transitory computer-readable medium in which a program is stored for causing a computer to perform the methods described above. It should be understood that the various engines described herein can be provided on a computer system, such as computer system 400, whereby processor 404 would execute the analyses and determinations provided by these engines, subject to instructions provided by any one of, or a combination of, the memory components RAM 406, ROM, 408, or storage device 410 and user input provided via input device 414.VI. Exemplary Methodologies Relating to Peptide Structure Data Analysis, Monomer Weight Score Calculations, and Diagnosis and Prognosis of Disease StatesVI. A. Analyzing a Set of Peptide Structures
[0178] Figure 5 is a flowchart of a process for analyzing a set of peptide structures in accordance with one or more embodiments. Process 500 may be implemented using, for example, at least a portion of workflow 100 as described in Figures 1, 2, and / or analysis system 300 as described in Figure 3.
[0179] Step 502 includes calculating a site occupancy score, for a given peptide structure at the linking site, as a function of an adjusted-raw abundance value for the given peptide structure and a sum of a set of adjusted-raw abundance values of the set of peptide structures. The adjusted-raw abundance values may be generated by normalizing a set of raw abundance values of the set of peptide structures to a corresponding reference run. The set of peptide structures can be a set of peptide structures comprising the same linking site and may be from a biological sample from a subject.
[0180] Step 504 includes calculating a monomer weight score as a sum of the site occupancy score and a multiplier, where the multiplier is the number of a specific monomer in the set of peptide structures at the linking site. Step 504 can additionally include calculating a peptide structure monomer weight score as a function of the site occupancy score and the number of a specific monomer for the given peptide structure. One or more peptide structure monomer weight scores may be used to calculate the monomer weight score.[01811 Steps 502 and 504 can, in some cases, be repeated at least 1, 2, 3, 4, 5, 6, or more times, calculating site occupancy scores for a plurality of peptide structures and a plurality of monomer weight scores for a plurality of specific monomers at the linking site. In some cases, steps 502 and 504 are not repeated.
[0182] An additional step in process 500 can include correlating the monomer weight score (or, in some cases, plurality of monomer weight scores) with an indication or disease state to determine a hazard ratio for the indication or disease state. An additional step in process 500 can include generating a diagnosis output for the indication or disease state for the subject, using a predictive model, as a function of the monomer weight score, wherein the diagnosis output is one of a predictive probability or a risk score. An additional step in process 500 can include generating a treatment output (e.g., an identification of a treatment to treat the subject such as identification of immunotherapy). An additional step in process 500 can include generating a report identifying that a biological sample evidences the indication or disease state.VI.B . Classifying a Biological Sample10183] Figure 6 is a flowchart of a process for classifying a biological sample in accordance with one or more embodiments. Process 600 may be implemented using, for example, at least a portion of workflow 100 as described in Figures 1, 2, and / or analysis system 300 as described in Figure 3.
[0184] Step 602 includes analyzing one or more monomer weight scores of a set of peptide structures from a biological sample from a subject (e.g., a subject having or suspected of having a malignancy such as melanoma) using a machine learning model to generate a disease indicator. The set of peptide structures can be a set of peptide structures comprising the same linking site and may include glycosylated peptides and non-glycosylated peptides. The set of peptide structures may include peptides structures comprising one or more site monomers of Tables 1, 2, or 3, such that the one or more monomer weight scores are monomer weight scores of the one or more site monomers of Tables 1, 2, or 3. In step 602, in accordance with various embodiments, the one or more monomer weight scores can be associated with the melanoma disease state.
[0185] In one or more embodiments, step 602 may be implemented using a binary classification model (e.g., a regression model). In some examples, the regression model may be, for example, penalized multivariable regression model. In various embodiments, the disease indicator may be computed using a weight coefficient associated with each peptide structure, the weight coefficient of a corresponding peptide structure of the peptide structures may indicate the relative significance of the corresponding peptide structure to the disease indicator.
[0186] In some embodiments, step 602 may include computing a peptide structure profile for the biological sample that identifies a weighted value for each peptide structure. The weighted value for a peptide structure of the peptide structures may be a product of a quantification metric for the peptide structure identified from the peptide structure data and a weight coefficient for the peptide structure. The disease indicator may be computed using the peptide structure profile. For example, the disease indicator may be a logit equal to the sum of the weighted values for the peptide structures plus an intercept value. The intercept value may be determined during the training of the model.|0.187] The peptide structure profile for a given peptide structure may include a corresponding feature — relative abundance, concentration, site occupancy, peptide structure monomer weight — for that peptide structure. The relative abundance may be a normalized relative abundance; the concentration may be normalized concentration. In some cases, two peptide structure profiles may be computed for the same peptide structure, each profile corresponding to a different feature. For example, a first peptide structure profile may include a relative abundance for a corresponding peptide structure and a second peptide structure profile may include a concentration for the same corresponding peptide structure.
[0188] In various embodiments, the disease indicator comprises a probability that the biological sample is positive for the melanoma disease state and the supervised machine learning model is configured to generate an output that identifies the biological sample as either evidencing (“positive for”) the melanoma disease state when the disease indicator is greater than a selected threshold or not evidencing (“negative for”) the melanoma disease state when the disease indicator is not greater than the selected threshold. The selected threshold may be, for example, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, or some other threshold between 0.30 and 0.65. In one or more embodiments, the selected threshold is 0.5.
[0189] Step 604 includes generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing a state associated with melanoma progression and / or responsiveness to immune checkpoint inhibitory therapy. In step 604, in accordance with various embodiments, the diagnosis output can be, for example, diagnosis of a disease or malignancy (e.g., melanoma), identification of a treatment responsive malignancy (e.g., of immunotherapy responsive melanoma), and / or prognosis of disease severity.
[0190] The diagnosis output may include the disease indicator, or a diagnosis made based on the disease indicator. The diagnosis may be, for example, “positive” for the melanoma disease state if the biological sample evidences the melanoma disease state based on the disease indicator. The diagnosis may be, for example, “negative” if the biological sample does not evidence the melanoma disease state based on the disease indicator. A negative diagnosis may mean that the biological sample has a non-melanoma state. The negative diagnosis for the melanoma disease state can include at least one of a healthy state, or some other non-malignant state.[01911 Generating the diagnosis output in step 604 may include determining that the score falls above (or at or above) a selected threshold and generating a positive diagnosis for the melanoma disease state. Alternatively, step 604 can include determining that the score falls below (or at or below) a selected threshold and generating a negative diagnosis for the adenoma or melanoma disease state. In some scoring systems, the score can include a probability score and the selected threshold can be 0.5. In other scoring systems, the selected threshold can fall within a range between 0.30 and 0.65.
[0192] In one or more embodiments, the final output in step 604 may include a treatment output if the diagnosis output indicates a positive diagnosis for the melanoma disease state or a positive identification of immunotherapy responsive melanoma. The treatment output may include, for example, at least one of an identification of a treatment for the subject, a treatmentplan for administering the treatment, or both. Treatment for melanoma may include, for example, but is not limited to, at least one of surgery, radiation therapy, a targeted drug therapy (e.g., one or more targeted therapeutic agents), chemotherapy (e.g., one or more chemotherapeutic agents), immunotherapy (e.g., one or more immunotherapeutic agents, e.g., immune checkpoint inhibitors such as ipilimumab, nivolumab, and / or pembrolizumab)), or some other form of treatment. The treatment plan may include, for example, but is not limited to, a timeline or schedule for administering the treatment, dosing information, other treatment- related information, or a combination thereof.
[0193] Figure 7 is a flowchart of a process for treating a subject with melanoma. Step 702 includes analyzing one or more monomer weight scores corresponding to at least one site monomer identified in Table 1 using a machine learning model to generate a diagnosis output that classifies the biological sample as evidencing a state associated with melanoma progression. Such analysis may be performed in line with the methods described above. Step 704 includes administering a therapeutically effective amount of a treatment for melanoma. In some cases, for example where step 702 identifies the subject as having immunotherapy sensitive melanoma, the treatment administered in step 704 is an immunotherapy (e.g., immune checkpoint inhibitors such as ipilimumab, nivolumab, and / or pembrolizumab).
[0194] The group of site monomers in Tables 1, 2, or 3 include site monomers that have been determined relevant to distinguishing at least between melanoma and a healthy state and between immunotherapy-responsive melanoma and immunotherapy-nonresponsive melanoma. For example, the group of site monomers may be used to predict the probability of melanoma for use in clinically screening patients. In another example, the group of site monomers may be used to predict the probability of having immunotherapy-responsive melanoma for use in informing treatment decisions.
[0195] In one or more embodiments, the at least 1 site monomer includes at least 1, at least 2, at least 3, at least 4, at least 5, or more of the site monomers listed in Table 1. In some embodiments, the at least 1 site monomer includes 1 or both of the site monomers listed in Table 3.Table 1: Markers (Site Monomers) Associated with MelanomaTable 2: Fucose Markers Associated with MelanomaTable 3: Fucose Markers Strongly Associated with MelanomaVI. C. Monitoring a Subject for a Melanoma Disease State(0196] Figure 8 is a flowchart of a process for monitoring a subject for a melanoma disease state in accordance with one or more embodiments. Process 800 may be implemented using, for example, at least a portion of workflow 800 as described in Figures 1, 2, and / or analysis system 300 as described in Figure 3.(0197] Step 802 includes receiving first monomer weight score data for a first biological sample obtained from a subject at a first timepoint. 01981 Step 804 includes analyzing the first monomer weight score data using a supervised machine learning model to generate a first disease indicator based on at least 1 site monomer from a group of site monomers identified in Table 1, 2, or 3. The group of site monomers in Tables 1, 2, or 3 includes a group of site monomers associated with a melanoma disease state in accordance with various embodiments. The supervised machine can be a binary classification model. In some embodiments, the binary classification model can be a logistical regression model.
[0199] Step 806 includes receiving second monomer weight score data of a second biological sample obtained from the subject at a second timepoint.|O20O[ Step 808 includes analyzing the second monomer weight score data using the supervised machine learning model to generate a second disease indicator based on the at least 1 site monomer selected from the group of site monomers identified in Tables 1, 2, or 3.
[0201] Step 810 includes generating a diagnosis output based on the first disease indicator and the second disease indicator. Generating the diagnostic output can include comparing the second disease indicator to the first disease indicator.
[0202] In some embodiments, the first disease indicator indicates that the first biological sample evidences the negative diagnosis for the melanoma disease state and the second biological sample evidences the positive diagnosis for the melanoma disease. In other embodiments, the diagnosis output identifies whether a non-melanoma disease state has progressed to the melanoma disease state wherein the non-melanoma disease state includes either a healthy state, or a control state. In some embodiments, the first disease indicator indicates that the first biological sample evidences immunotherapy-sensitive melanoma and the second biological sample evidences immunotherapy-resistant melanoma.VII. Peptide Structure and Product Compositions, Kits and Reagents
[0203] Table 4 identifies the proteins corresponding to the site monomers or peptide structures of Tables 1, 2, 3, 14, and 15A-D. Table 4 identifies a corresponding protein abbreviation and protein name for each of protein SEQ ID NOS: 1-12, 25, and 37-44. Further, Table 4 identifies a corresponding Uniprot ID for each of protein SEQ ID NOS: 1-12, 25, and 37-44.Table 4: Protein SEQ ID NOS
[0204] Aspects of the disclosure include kits comprising one or more compositions, each comprising one or more peptide structures of the disclosure that can be used as assay standards, and instructions for use. Kits in accordance with one or more embodiments described herein may include a label indicating the intended use of the contents of the kit. The term “label” as used herein with respect to a kit includes any writing, or recorded material supplied on or with a kit, or that otherwise accompanies a kit.[0205) The peptide structures and the transitions produced therefrom, as well as monomer weight scores calculated therefrom as described herein, may be useful for diagnosing andtreating a melanoma disease state. A transition includes a precursor ion and at least one product ion grouping. As reviewed herein, the peptide structures, as well as their corresponding precursor ion and product ion groupings (these ions having defined m / z ratios or m / z ratios that fall within the m / z ranges identified herein), can be used in mass spectrometry-based analyses to diagnose and facilitate treatment of diseases, such as, for example, melanoma.(0206] Aspects of the disclosure include methods for analyzing one or more peptide structures, as described herein. In some embodiments, the methods involve processing a sample from a patient to generate a prepared sample that can be inputted into a mass spectrometry system (e.g., a reaction monitoring mass spectrometry system). In certain embodiments, processing the sample can comprise performing one or more of a denaturation procedure, a reduction procedure, an alkylation procedure, and a digestion procedure. The denaturation and reduction procedures may be implemented in a manner similar to, for example, denaturation and reduction 202 in Figure 2. The alkylation procedure may be implemented in a manner similar to, for example, alkylation procedure 204 in Figure 2. The digestion procedure may be implemented in a manner similar to, for example, digestion procedure 206 in Figure 2.
[0207] In some embodiments, the methods for analyzing one or more peptide structures involve detecting a set of product ions generated by a reaction monitoring mass spectrometry system in which one or more product ions may correspond to each of the one or more peptide structures that have been inputted into the mass spectrometry system. As described herein, each peptide structure can be converted into a set of product ions having a defined m / z ratio. In some embodiments, the methods involve generating quantification (e.g., abundance) data for the one or more product ions detected using the reaction monitoring mass spectrometry system.
[0208] In some embodiments, the methods further comprise generating a diagnosis output using the quantification data and a model that has been trained using supervised or unsupervised machine learning. In certain embodiments, the reaction monitoring mass spectrometry system may include multiple / selected reaction monitoring mass spectrometry (MRM / SRM-MS) to detect the one or more product ions and generate the quantification data.VII. A. Representative Experimental Results
[0209] To assess the association of individual peptide structures (biomarkers) with metastatic advanced melanoma, univariate age- and sex-adjusted Cox regression analysis wasperformed on a cohort of 205 samples sourced from Massachusetts General Hospital. Results of the analysis are summarized below with reference to Tables 5-6 and Figures 10-14.Table 5 - Fucose MarkersTable 6 - Fucose markersVIII. Exemplary Embodiments for Melanoma Diagnosis, Prognosis, and Treatment 0210| The present disclosure concerns embodiments for systems, methods, and compositions related to identification of melanoma, risk thereof, or responsiveness thereof to a particular treatment (e.g., immunotherapy) in an individual. The embodiments concern classifying biological samples, measuring for one or more certain markers from a biological sample, assaying for one or more certain markers from a biological sample, determining the presence of one or more certain markers from a biological sample, and so forth. Embodiments of the disclosure utilize models that accurately either identify, for example, that an individual has melanoma, has a higher risk for melanoma over the general population, has melanoma that is responsive to immunotherapy, or has melanoma that is not responsive to immunotherapy, based on the presence of one or more markers in sample(s) from the individual. The individual may or may not be at a higher risk for melanoma based on one or more risk factors. An individual may be at risk for melanoma based on family or personal history; age; having oneor more genetic markers associated with melanoma; and / or other risk factor for melanoma recognized in the art.|0211 [ In various embodiments of the disclosure, an individual is in need of identifying whether or not they have melanoma, or a risk thereof. The individual may be subjected to measuring or testing for one or more markers encompassed herein as a matter of routine health maintenance or because of a specific concern, for example, such as the presence of one or more risk factors and / or one or more symptoms of melanoma. The individual may be in need of such identification based on any one of the risk factors noted above, or the individual may be in need of such identification based on having one or more symptoms of melanoma.
[0212] In some cases, the analysis of the sample of the individual as described herein is the sole test utilized for identifying melanoma, whereas in other cases a medical provider may utilize one or more other tests, such as biopsy, ultrasound; magnetic resonance imaging; CT scan; and so forth. In particular embodiments, calculating a monomer weight score for one or more site monomers markers of Table 1, 2, or 3 is utilized alone or in conjunction with one or more of these tests.
[0213] In some embodiments, the systems, methods, and compositions encompassed herein are sufficiently specific to utilize markers that distinguish between control and melanoma. In some embodiments, the systems, methods, and compositions encompassed herein are sufficiently specific to utilize markers that distinguish between melanoma that is responsive to immunotherapy and melanoma that is not responsive to immunotherapy. In some embodiments, the markers are accurate regardless of the status of one or more characteristics of the individual: biological sex, sample source, sample collection, or age, as examples.
[0214] In some embodiments, the individual is suspected of having melanoma or is at risk for melanoma and is in need of diagnosis thereof in addition to identification whether it is a particular stage of melanoma. In various embodiments, the individual is known to have melanoma and is in need of determining whether it is early stage melanoma or late stage melanoma, such as to determine a treatment regimen for the cancer. In specific embodiments, the same test that identifies whether an individual has melanoma determines whether the melanoma is early stage or late stage or a particular stage.
[0215] In various embodiments, the sample for analysis for melanoma identification may be a solid or fluid from the individual, such as skin, peripheral blood, serum, and / or plasma from the individual. The present disclosure provides for measuring for one or more circulating glycoproteins, glycopeptides, or non-glycosylated peptides in blood, serum, or plasma todiagnose or identify the presence of melanoma and / or to identify early stage or late stage melanoma in an individual. In various embodiments, the sample is measured for monomer weight scores for 1, 2, 3, 4, 5, or more of the site monomers of Table 1, 2, or 3.
[0216] Embodiments of the disclosure include methods of classifying samples, including skin, peripheral blood, serum, or plasma samples, from an individual suspected of having, known to have, or at risk for having melanoma by measuring from the sample for one or more glycopeptides and / or non-glycosylated peptides encompassed herein. The methods encompass whether or not melanoma is identified in the individual. In some cases, the measuring identifies the individual as not having melanoma or as having melanoma. In some cases, the measuring identifies the individual as having melanoma that is responsive to immunotherapy or as having melanoma that is not responsive to immunotherapy. The measuring may identify the individual as having a particular stage of melanoma, including at least early stage or late stage. In specific cases, the measuring comprises successive or concomitant steps of identifying that the individual has melanoma and whether the individual has early stage or late stage melanoma.
[0217] In various embodiments, an individual at risk for having melanoma is subjected to methods of the disclosure to identify, or not, the presence of melanoma. Such methods also measure for one or more glycopeptides and / or non-glycosylated peptides encompassed herein, as well as calculate monomer weight scores for one or more site monomers encompassed herein. The individual may be of any kind, although in specific cases individual at risk for having melanoma has a family history or one or more other risk factors.
[0218] Embodiments of the disclosure include methods of predicting that an individual will have melanoma, including early stage or late stage melanoma, or identifying early stage or late stage melanoma in an individual, or predicting that an individual has a melanoma that is responsive to immunotherapy by determining a monomer weight score for one or more site monomers from Table 1 in one or more samples from the individual. The individual may be known to have melanoma or may be suspected of having melanoma In various embodiments, the sample is measured for monomer weight scores for 1, 2, or more of the site monomers of Table 1, 2, or 3.
[0219] In embodiments wherein the measuring identifies the individual as having melanoma, the individual may be recommended to take action to treat the melanoma, such as with at least one of radiation therapy, chemotherapy or drug therapy (Bevacizumab, evacizumab, Irinotecan Hydrochloride, Capecitabine, Cetuximab, Ramucirumab, Oxaliplatin, Cetuximab, 5-FU, Ipilimumab, Irinotecan Hydrochloride, Pembrolizumab, LeucovorinCalcium, Trifluridine and Tipiracil Hydrochloride, Nivolumab, Nivolumab, Oxaliplatin. Panitumumab, Pembrolizumab, Ramucirumab, Regorafenib, Regorafenib, Panitumumab, Ziv- Aflibercept), immunotherapy (e.g., immune checkpoint inhibitors such as ipilimumab, nivolumab, ipilimumab plus nivolumab, and / or pembrolizumab), chemoradiotherapy, surgery, hormone therapy and / or a targeted drug therapy, as examples.IX. Cancer Therapy
[0220] In some aspects, the disclosed methods comprise administering a cancer therapy to a subject or patient. The cancer therapy may be chosen based on an analysis or method described herein. In some aspects, the cancer therapy comprises a local cancer therapy. In some aspects, the cancer therapy excludes a systemic cancer therapy. In some aspects, the cancer therapy excludes a local therapy. In some aspects, the cancer therapy comprises a local cancer therapy without the administration of a systemic cancer therapy. In some aspects, the cancer therapy comprises an immunotherapy, which may be an immune blockade or immune checkpoint inhibitor therapy. In some aspects, the cancer therapy comprises radiotherapy. Any of these cancer therapies may also be excluded. Combinations of these therapies may also be administered.
[0221] The term “cancer,” as used herein, may be used to describe a solid tumor, metastatic cancer, or non-metastatic cancer. In certain aspects, the cancer may originate in the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, duodenum, small intestine, large intestine, colon, rectum, anus, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, pancreas, prostate, skin, stomach, testis, tongue, or uterus.IX.A. Radiotherapy(0222] In some aspects, the disclosed methods comprise administering radiotherapy, such as ionizing radiation, as a cancer therapy to a subject or patient. As used herein, “ionizing radiation” means radiation comprising particles or photons that have sufficient energy or can produce sufficient energy via nuclear interactions to produce ionization (gain or loss of electrons). A certain non-limiting example of ionizing radiation is an x-radiation. Means for delivering x-radiation to a target tissue or cell are known in the art.
[0223] In some aspects, the radiotherapy can comprise external radiotherapy, internal radiotherapy, radioimmunotherapy, or intraoperative radiation therapy (IORT). In some aspects, the external radiotherapy comprises three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT), proton beam therapy, image-guidedradiation therapy (IGRT), or stereotactic radiation therapy. In some aspects, the internal radiotherapy comprises interstitial brachytherapy, intracavitary brachytherapy, or intraluminal radiation therapy. In some aspects, the radiotherapy is administered to a primary tumor. In some aspects, the radiotherapy is administered to a metastatic tumor.IX.B. Cancer Immunotherapy(0224] In some aspects, the disclosed methods comprise administering a cancer immunotherapy as a cancer therapy to a subject or patient. Cancer immunotherapy is the use of the immune system to treat cancer. Immunotherapies can be categorized as active, passive or hybrid (active and passive). These approaches exploit the fact that cancer cells often have molecules on their surface that can be detected by the immune system, known as tumor- associated antigens (TAAs); they are often proteins or other macromolecules (e.g. carbohydrates). Active immunotherapy directs the immune system to attack tumor cells by targeting TAAs. Passive immunotherapies enhance existing anti-tumor responses and include the use of monoclonal antibodies, lymphocytes and cytokines. Various immunotherapies are known in the art, and examples are described below.IX.B.l. Checkpoint Inhibitors and Combination Treatment
[0225] Aspects of the disclosure may include administration of immune checkpoint inhibitors or immune blockade therapies, examples of which are further described below. As disclosed herein, “checkpoint inhibitor therapy” (also “immune checkpoint blockade therapy”, “immune checkpoint therapy”, “ICT,” “checkpoint blockade immunotherapy,” or “CBI”), refers to cancer therapy comprising providing one or more immune checkpoint inhibitors to a subject suffering from or suspected of having cancer.IX.B .1. a. PD- 1 , PDL 1 , and PDL2 inhibitors(0226] PD-1 can act in the tumor microenvironment where T cells encounter an infection or tumor. Activated T cells upregulate PD-1 and continue to express it in the peripheral tissues. Cytokines such as IFN-gamma induce the expression of PDL 1 on epithelial cells and tumor cells. PDL2 is expressed on macrophages and dendritic cells. The main role of PD-1 is to limit the activity of effector T cells in the periphery and prevent excessive damage to the tissues during an immune response. Inhibitors of the disclosure may block one or more functions of PD-1 and / or PDL 1 activity.
[0227] Alternative names for “PD-1” include CD279 and SLEB2. Alternative names for “PDL1” include B7-H1, B7-4, CD274, and B7-H. Alternative names for “PDL2” include B7-DC, Btdc, and CD273. In some aspects, PD-1, PDL1, and PDL2 are human PD-1, PDL1 and PDL2.|0228| In some aspects, the PD-1 inhibitor is a molecule that inhibits the binding of PD-1 to its ligand binding partners. In a specific aspect, the PD-1 ligand binding partners are PDL1 and / or PDL2. In another aspect, a PDL1 inhibitor is a molecule that inhibits the binding of PDL1 to its binding partners. In a specific aspect, PDL1 binding partners are PD-1 and / or B7- 1. In another aspect, the PDL2 inhibitor is a molecule that inhibits the binding of PDL2 to its binding partners. In a specific aspect, a PDL2 binding partner is PD-1. The inhibitor may be an antibody, an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide. Exemplary antibodies are described in U.S. Patent Nos. 8,735,553, 8,354,509, and 8,008,449, all incorporated herein by reference. Other PD-1 inhibitors for use in the methods and compositions provided herein are known in the art such as described in U. S. Patent Application Nos. US2014 / 0294898, US2014 / 022021, and US2011 / 0008369, all incorporated herein by reference. 0229) In some aspects, the PD-1 inhibitor is an anti-PD-1 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody). In some aspects, the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab. In some aspects, the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some aspects, the PDL1 inhibitor comprises AMP- 224. Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS- 936558, and OPDIVO®, is an anti-PD-1 antibody described in W02006 / 121168. Pembrolizumab, also known as MK-3475, Merck 3475, lambrolizumab, KEYTRUDA®, and SCH-900475, is an anti-PD-1 antibody described in W02009 / 114335. Pidilizumab, also known as CT-011, hBAT, or hBAT-1, is an anti-PD-1 antibody described in W02009 / 101611. AMP-224, also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor described in W02010 / 027827 and WO2011 / 066342. Additional PD-1 inhibitors include MEDI0680, also known as AMP-514, and REGN2810.
[0230] In some aspects, the immune checkpoint inhibitor is a PDL1 inhibitor such as Durvalumab, also known as MEDI4736, atezolizumab, also known as MPDL3280A, avelumab, also known as MSB00010118C, MDX-1105, BMS-936559, or combinations thereof. In certain aspects, the immune checkpoint inhibitor is a PDL2 inhibitor such as rHIgM12B7.
[0231] In some aspects, the inhibitor comprises the heavy and light chain CDRs or VRs of nivolumab, pembrolizumab, or pidilizumab. Accordingly, in one aspect, the inhibitor comprises the CDR1, CDR2, and CDR3 domains of the VH region of nivolumab, pembrolizumab, or pidilizumab, and the CDR1, CDR2 and CDR3 domains of the VL region of nivolumab, pembrolizumab, or pidilizumab. In another aspect, the antibody competes for binding with and / or binds to the same epitope on PD-1, PDL1, or PDL2 as the above- mentioned antibodies. In another aspect, the antibody has at least about 70, 75, 80, 85, 90, 95, 97, or 99% (or any derivable range therein) variable region amino acid sequence identity with the above-mentioned antibodies.IX.B.l.b. CTLA-4, B7-1, and B7-2
[0232] Another immune checkpoint that can be targeted in the methods provided herein is the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152. The complete cDNA sequence of human CTLA-4 has the Genbank accession number LI 5006. CTLA-4 is found on the surface of T cells and acts as an “off’ switch when bound to B7-1 (CD80) or B7-2 (CD86) on the surface of antigen-presenting cells. CTLA4 is a member of the immunoglobulin superfamily that is expressed on the surface of Helper T cells and transmits an inhibitory signal to T cells. CTLA4 is similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to B7-1 and B7-2 on antigen-presenting cells. CTLA-4 transmits an inhibitory signal to T cells, whereas CD28 transmits a stimulatory signal. Intracellular CTLA- 4 is also found in regulatory T cells and may be important to their function. T cell activation through the T cell receptor and CD28 leads to increased expression of CTLA-4, an inhibitory receptor for B7 molecules. Inhibitors of the disclosure may block one or more functions of CTLA-4, B7-1, and / or B7-2 activity. In some aspects, the inhibitor blocks the CTLA-4 and B7-1 interaction. In some aspects, the inhibitor blocks the CTLA-4 and B7-2 interaction.
[0233] In some aspects, the immune checkpoint inhibitor is an anti-CTLA-4 antibody (e.g. , a human antibody, a humanized antibody, or a chimeric antibody), an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
[0234] Anti-human-CTLA-4 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present methods can be generated using methods well known in the art. Alternatively, art recognized anti-CTLA-4 antibodies can be used. For example, the anti- CTLA-4 antibodies disclosed in: US 8,119,129, WO 01 / 14424, WO 98 / 42752; WO 00 / 37504 (CP675,206, also known as tremelimumab; formerly ticilimumab), U.S. Patent No. 6,207,156; Hurwitz etal., 1998; can be used in the methods disclosed herein. The teachings of each of theaforementioned publications are hereby incorporated by reference. Antibodies that compete with any of these art-recognized antibodies for binding to CTLA-4 also can be used. For example, a humanized CTLA-4 antibody is described in International Patent Application No. W02001 / 014424, W02000 / 037504, and U.S. PatentNo. 8,017,114; all incorporated herein by reference.( 0235] A further anti-CTLA-4 antibody useful as a checkpoint inhibitor in the methods and compositions of the disclosure is ipilimumab (also known as 10D1, MDX- 010, MDX- 101, and Yervoy®) or antigen binding fragments and variants thereof (see, e.g., WO 01 / 14424).
[0236] In some aspects, the inhibitor comprises the heavy and light chain CDRs or VRs of tremelimumab or ipilimumab. Accordingly, in one aspect, the inhibitor comprises the CDR1, CDR2, and CDR3 domains of the VH region of tremelimumab or ipilimumab, and the CDR1, CDR2 and CDR3 domains of the VL region of tremelimumab or ipilimumab. In another aspect, the antibody competes for binding with and / or binds to the same epitope on PD-1, B7-1, or B7- 2 as the above- mentioned antibodies. In another aspect, the antibody has at least about 70, 75, 80, 85, 90, 95, 97, or 99% (or any derivable range therein) variable region amino acid sequence identity with the above-mentioned antibodies.IX.B.l.c. LAG3
[0237] Another immune checkpoint that can be targeted in the methods provided herein is the lymphocyte-activation gene 3 (LAG3), also known as CD223 and lymphocyte activating 3. The complete mRNA sequence of human LAG3 has the Genbank accession number NM 002286. LAG3 is a member of the immunoglobulin superfamily that is found on the surface of activated T cells, natural killer cells, B cells, and plasmacytoid dendritic cells. LAG3’s main ligand is MHC class II, and it negatively regulates cellular proliferation, activation, and homeostasis of T cells, in a similar fashion to CTLA-4 and PD-1, and has been reported to play a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in a tolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 is also known to be involved in the maturation and activation of dendritic cells. Inhibitors of the disclosure may block one or more functions of LAG3 activity.
[0238] In some aspects, the immune checkpoint inhibitor is an anti-LAG3 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
[0239] Anti-human-LAG3 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present methods can be generated using methods well known in the art.Alternatively, art recognized anti-LAG3 antibodies can be used. For example, the anti-LAG3 antibodies can include: GSK2837781, IMP321, FS-118, Sym022, TSR-033, MGD013, BI754111, AVA-017, or GSK2831781. The anti-LAG3 antibodies disclosed in: US 9,505,839 (BMS-986016, also known as relatlimab); US 10,711,060 (IMP-701, also known as LAG525); US 9,244,059 (IMP731, also known as H5L7BW); US 10,344,089 (25F7, also known as LAG3.1); WO 2016 / 028672 (MK-4280, also known as 28G-10); WO 2017 / 019894 (BAP050); Burova E., et al.. J. ImmunoTherapy Cancer, 2016; 4(Supp. 1):P195 (REGN3767); Yu, X., et al., mAbs, 2019; 11 :6 (LBL-007) can be used in the methods disclosed herein. These and other anti-LAG-3 antibodies useful in the claimed disclosure can be found in, for example: WO 2016 / 028672, WO 2017 / 106129, WO 2017062888, WO 2009 / 044273, WO 2018 / 069500, WO 2016 / 126858, WO 2014 / 179664, WO 2016 / 200782, WO 2015 / 200119, WO 2017 / 019846, WO 2017 / 198741, WO 2017 / 220555, WO 2017 / 220569, WO 2018 / 071500, WO2017 / 015560; WO 2017 / 025498, WO 2017 / 087589 , WO 2017 / 087901, WO 2018 / 083087, WO 2017 / 149143, WO 2017 / 219995, US 2017 / 0260271, WO 2017 / 086367, WO2017 / 086419, WO 2018 / 034227, and WO 2014 / 140180. The teachings of each of the aforementioned publications are hereby incorporated by reference. Antibodies that compete with any of these art-recognized antibodies for binding to LAG3 also can be used.
[0240] In some aspects, the inhibitor comprises the heavy and light chain CDRs or VRs of an anti-LAG3 antibody. Accordingly, in one aspect, the inhibitor comprises the CDR1, CDR2, and CDR3 domains of the VH region of an anti-LAG3 antibody, and the CDR1, CDR2 and CDR3 domains of the VL region of an anti-LAG3 antibody. In another aspect, the antibody has at least about 70, 75, 80, 85, 90, 95, 97, or 99% (or any derivable range therein) variable region amino acid sequence identity with the above-mentioned antibodies.IX.B.l.d. TIM-3
[0241] Another immune checkpoint that can be targeted in the methods provided herein is the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), also known as hepatitis A virus cellular receptor 2 (HAVCR2) and CD366. The complete mRNA sequence of human TIM-3 has the Genbank accession number NM_032782. TIM-3 is found on the surface IFNy- producing CD4+ Thl and CD8+ Tel cells. The extracellular region of TIM-3 consists of a membrane distal single variable immunoglobulin domain (IgV) and a glycosylated mucin domain of variable length located closer to the membrane. TIM-3 is an immune checkpoint and, together with other inhibitory receptors including PD-1 and LAG3, it mediates the T-cell exhaustion. TIM-3 has also been shown as a CD4+ Thl-specific cell surface protein thatregulates macrophage activation. Inhibitors of the disclosure may block one or more functions of TIM-3 activity.[0242 [ In some aspects, the immune checkpoint inhibitor is an anti-TIM-3 antibody (e.g., a human antibody, a humanized antibody, or a chimeric antibody), an antigen binding fragment thereof, an immunoadhesin, a fusion protein, or oligopeptide.
[0243] Anti-human-TIM-3 antibodies (or VH and / or VL domains derived therefrom) suitable for use in the present methods can be generated using methods well known in the art. Alternatively, art recognized anti-TIM-3 antibodies can be used. For example, anti-TIM-3 antibodies including: MBG453, TSR-022 (also known as Cobolimab), and LY3321367 can be used in the methods disclosed herein. These and other anti-TIM-3 antibodies useful in the claimed disclosure can be found in, for example: US 9,605,070, US 8,841,418, US2015 / 0218274, and US 2016 / 0200815. The teachings of each of the aforementioned publications are hereby incorporated by reference. Antibodies that compete with any of these art-recognized antibodies for binding to LAG3 also can be used.[0244) In some aspects, the inhibitor comprises the heavy and light chain CDRs or VRs of an anti-TIM-3 antibody. Accordingly, in one aspect, the inhibitor comprises the CDR1, CDR2, and CDR3 domains of the VH region of an anti-TIM-3 antibody, and the CDR1, CDR2 and CDR3 domains of the VL region of an anti-TIM-3 antibody. In another aspect, the antibody has at least about 70, 75, 80, 85, 90, 95, 97, or 99% (or any derivable range therein) variable region amino acid sequence identity with the above-mentioned antibodies.IX.B.2. Inhibition of co-stimulatory molecules
[0245] In some aspects, the immunotherapy comprises an inhibitor of a co-stimulatory molecule. In some aspects, the inhibitor comprises an inhibitor of B7-1 (CD80), B7-2 (CD86), CD28, ICOS, 0X40 (TNFRSF4), 4-1BB (CD137; TNFRSF9), CD40L (CD40LG), GITR (TNFRSF18), and combinations thereof. Inhibitors include inhibitory antibodies, polypeptides, compounds, and nucleic acids.IX.B.3. Dendritic cell therapy
[0246] Dendritic cell therapy provokes anti-tumor responses by causing dendritic cells to present tumor antigens to lymphocytes, which activates them, priming them to kill other cells that present the antigen. Dendritic cells are antigen presenting cells (APCs) in the mammalian immune system. In cancer treatment they aid cancer antigen targeting. One example of cellular cancer therapy based on dendritic cells is sipuleucel-T.IX.B.4. CAR-T cell therapy
[0247] Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are engineered receptors that combine a new specificity with an immune cell to target cancer cells. Typically, these receptors graft the specificity of a monoclonal antibody onto a T cell. The receptors are called chimeric because they are fused of parts from different sources. CAR-T cell therapy refers to a treatment that uses such transformed cells for cancer therapy.
[0248] The basic principle of CAR-T cell design involves recombinant receptors that combine antigen-binding and T-cell activating functions. The general premise of CAR-T cells is to artificially generate T-cells targeted to markers found on cancer cells. Scientists can remove T-cells from a person, genetically alter them, and put them back into the patient for them to attack the cancer cells. Once the T cell has been engineered to become a CAR-T cell, it acts as a “living drug”. CAR-T cells create a link between an extracellular ligand recognition domain to an intracellular signaling molecule which in turn activates T cells. The extracellular ligand recognition domain is usually a single-chain variable fragment (scFv). An important aspect of the safety of CAR-T cell therapy is how to ensure that only cancerous tumor cells are targeted, and not normal cells. The specificity of CAR-T cells is determined by the choice of molecule that is targeted.IX.B.4.a. Cytokine therapy
[0249] Cytokines are proteins produced by many types of cells present within a tumor. They can modulate immune responses. The tumor often employs them to allow it to grow and reduce the immune response. These immune-modulating effects allow them to be used as drugs to provoke an immune response. Two commonly used cytokines are interferons and interleukins.IX.B.4.b. Adoptive T-cell therapy
[0250] Adoptive T cell therapy is a form of passive immunization by the transfusion of T- cells (adoptive cell transfer). They are found in blood and tissue and usually activate when they find foreign pathogens. Specifically they activate when the T-cell's surface receptors encounter cells that display parts of foreign proteins on their surface antigens. These can be either infected cells, or antigen presenting cells (APCs). They are found in normal tissue and in tumor tissue, where they are known as tumorinfiltrating lymphocytes (TILs). They are activated by the presence of APCs such as dendritic cells that present tumor antigens. Although these cells canattack the tumor, the environment within the tumor is highly immunosuppressive, preventing immune-mediated tumor death.102511 In particular aspects of the present disclosure, a cancer immunotherapy comprises treatment with ipilimumab and nivolumab in combination. In certain aspects of the present disclosure, a cancer immunotherapy comprises treatment with pembrolizumab.IX. C. Chemotherapies
[0252] In some aspects, the cancer therapy to be administered to the subject comprises a chemotherapy. Suitable classes of chemotherapeutic agents include (a) Alkylating Agents, such as nitrogen mustards (e.g., mechlorethamine, cylophosphamide, ifosfamide, melphalan, chlorambucil), ethylenimines and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, chlorozoticin, streptozocin) and triazines (e.g., dicarbazine), (b) Antimetabolites, such as folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., 5-fluorouracil, floxuridine, cytarabine, azauridine) and purine analogs and related materials (e.g., 6-mercaptopurine, 6-thioguanine, pentostatin), (c) Natural Products, such as vinca alkaloids (e.g., vinblastine, vincristine), epipodophylotoxins (e.g., etoposide, teniposide), antibiotics (e.g., dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin and mitoxanthrone), enzymes (e.g., L-asparaginase), and biological response modifiers (e.g., Interferon-a), and (d) Miscellaneous Agents, such as platinum coordination complexes (e.g., cisplatin, carboplatin), substituted ureas (e.g., hydroxyurea), methylhy diazine derivatives (e.g., procarbazine), and adreocortical suppressants (e.g., taxol and mitotane).IX.D. Surgery
[0253] In some aspects, the cancer therapy to be administered to the subject comprises one or more surgeries. Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative, and palliative surgery. Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and / or destroyed and may be used in conjunction with other therapies, such as the treatment of the present aspects, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy, and / or alternative therapies. Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically-controlled surgery (Mohs’ surgery).
[0254] Upon excision of part or all of cancerous cells, tissue, or tumor, a cavity may be formed in the body. Treatment may be accomplished by perfusion, direct injection, or local application of the area with an additional anti-cancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may be of varying dosages as well.X. Exemplary Embodiments for Determining Whether a Patient is Not Likely to Benefit from Checkpoint Inhibitor Therapy
[0255] Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from checkpoint inhibitors therapy. The clinical success of immune- checkpoint inhibitors (ICI) in metastatic melanoma has confirmed the validity of therapeutic strategies that boost the immune system to counteract cancer. However, as only about half of patients derive durable clinical benefit, there is a need for assays that can identify nonresponders with high accuracy, fast turnaround time and minimal invasiveness. A novel platform was utilized that combines mass spectrometry with an artificial intelligence-based data processing engine to interrogate the blood glycoproteome in melanoma patients before receiving ICI therapy. Independent training, validation and testing cohorts were leveraged to generate a model that predicts immunotherapy response (HR=2.7; P=0.026). The classifier was further validated in an independent cohort and achieved a significant separation of responders and non-responders (HR=5.6; P=0.027). To understand how glycosylation of circulating proteins may affect response to treatment, changes in glycosylation structure were analyzed and a fucosylation signature was discovered in non-responders. A fucosylation-based predictor was developed that stratified effectively patients, supporting the hypothesis that this protein modification directly impacts ICI efficacy. The data demonstrates the utility of the prediction of ICI benefit in patients with malignant melanoma.
[0256] Over the last decade, ICI therapeutics have significantly advanced the clinical management and outcome of patients with a range of malignancies, including metastatic melanoma; yet, only 30-40% of patients obtain sustained clinical benefit from single agent ICI therapy such as pembrolizumab or nivolumab. While combination treatment of nivolumab with ipilimumab has resulted in higher response rates of up to 60%, this is also associated with an incidence of 55% of grade 3-to-4 side effects. Therefore, considerable efforts have been expended to identify predictive biomarkers as companion diagnostics for the earlydetermination of patients who are unlikely to benefit from ICI treatment or may experience severe adverse events, to guide alternative therapies. Assessment of PD-L1 expression in the tumor microenvironment and quantification of tumor mutational burden have found limited utility as indicators of durable clinical benefits. Likewise, a number of other genomic and transcriptomic markers have been investigated as predictors of response of metastatic melanoma to ICI therapies, including HLA-I genotype, neoantigen load and T cell repertoire. In addition, gene expression signatures like immune-predictive score (IMPRES) and IFN-y- responsive genes expressed in tumors or tumor immune microenvironment (TiME) have been proposed as predictors of ICI response in metastatic melanoma. While these approaches are fruitful, they have yet not demonstrated broad clinical utility as there is debate around their consistency and reproducibility across cohorts.
[0257] The utility of molecular tumor profiling is also limited by the heterogeneity of tumor samples and the availability of adequate tissue obtained through invasive procedures. Liquid biopsies have emerged as a viable alternative to monitor treatment response as they are minimally invasive, convenient for serial sampling, and informative of functional states of immune cells modulated by ICI. Whereas peripheral immune cells and plasma factors contribute to antitumor responses modulated by ICI, previous studies focused on small groups of proteins. Moreover, the impact of post-translational modifications of circulating proteins on ICI response has not been evaluated in a systematic and scalable way to date.
[0258] The plasma glycoproteome of metastatic melanoma patients was interrogated before receiving ICI treatment and using a novel analytical platform that employed machine learning methods to analyze data generated by targeted mass spectrometry. Glycopeptide markers differentially expressed in patients with a short or durable response were identified and used to build a predictor of response to therapy. It should be noted that a durable response in this context means a relatively prolonged response to immunotherapy that is associated with a decreased progression of the melanoma and an improved overall survivability, whereas a short response means a relatively poor response to immunotherapy that is associated with no decreased progression of the melanoma and no improvement to overall survivability.
[0259] A discovery cohort of 202 patients was recruited as part of studies conducted at the Massachusetts General Hospital (MGH) in which patients with metastatic melanoma (stage IV) were treated with first or second-line anti-PD-1 monotherapy or anti-PD-l / anti-CTLA4 combination therapy. Pre-treatment samples were collected under the Institutional Review Board protocols of the Massachusetts General Hospital (protocols 12-488 and 11-181). In thiscontext, pre-treatment samples refer to samples obtained from subject who have not yet received the immunotherapy for this clinical study. Written informed consent was obtained from each patient. Responses to immunotherapy were assessed for overall survival (OS). A validation cohort of 27 patients was recruited as part of studies conducted at the University of South Australia (Uni SA) in which patients with metastatic melanoma were treated with first or second-line anti-PD-1 monotherapy or anti-PD-l / anti-CTLA4 combination therapy. Hereinafter, the “discovery cohort” will refer to the samples collected at MGH and the “independent validation cohort” or “external validation cohort” will refer to the samples collected at the Uni SA. Written informed consent was obtained from each patient. Plasma was stored at -80 °C and thawed at the time of the glycoproteomic analysis.
[0260] Pooled human plasma (MilliporeSigma, St. Louis, MO) was used for quality control, assay normalization and calibration purposes. Dithiothreitol (DTT) and iodoacetamide (IAA) were purchased from MilliporeSigma (St. Louis, MO). Mass spectrometry grade trypsin / Lys-C protease mix, formic acid, and acetonitrile were purchased from Thermo Fisher Scientific (Waltham, MA).
[0261] Plasma samples were thermally denatured at 100°C for 5 minutes before they were reduced with DTT, alkylated with IAA, quenched with DTT, and followed by digestion with trypsin / Lys-C protease mix in a water bath at 37°C for 18 hours. To quench the digestion, formic acid was added to each sample after incubation to a final concentration of 1% (v / v). Digested plasma samples were injected into an Agilent 6495C triple quadrupole mass spectrometer equipped with an Agilent 1290 Infinity ultra-high-pressure liquid chromatography (UHPLC) system and a Waters (Milford, MA) ACQUITY Peptide HSS T3 Column (2.1 mm internal diameter x 150 mm length, 1.8 pm particle size). Separation of the peptides and glycopeptides was performed using a 49-min binary gradient. The aqueous mobile phase A was 0.1% formic acid in water (v / v), and the organic mobile phase B was 0.1% formic acid in acetonitrile (v / v). The flow rate was set at 0.5 mL / min. Electrospray ionization was used as the ionization source and was operated in positive ion mode. The triple quadrupole MS was operated in dynamic multiple reaction monitoring (dMRM) mode, with modifications and improvements from a previous method. Samples were injected in a randomized fashion with regard to clinical parameters, and reference pooled plasma samples were injected interspersed with test samples to allow for correction of within-run drift of baseline signal.
[0262] PB-NET, a peak integration software that had been developed in-house, was used to integrate peaks and obtain raw abundances for peptides and glycopeptides. Raw abundancefor peptide markers was normalized by using spiked-in heavy isotope-labeled internal standards with known peptide concentrations for each protein. Relative abundance was determined for a glycopeptide by calculating the quotient of a raw abundance signal intensity of the glycopeptide and the raw abundance of a corresponding non-glycosylated peptide from the same protein. For glycopeptides having the same peptide sequence with more than two glycan types identified at a given glycosylation site, site occupancy was determined for a particular glycopeptide by calculating its fractional abundance across all glycan types observed at that site. It should be noted that each glycan type represents a unique combination of saccharide units that is attached to a same glycosylation site of a particular peptide sequence. For each glycopeptide biomarker, the product of its site occupancy or relative abundance and corresponding peptide concentration was used to calculate approximate glycopeptide concentration, also referred to as normalized abundance. Concentration was determined for 521 glycopeptides, 443 of which are based on site occupancy and 78 on relative abundance, and for 75 peptides, totaling 596 unique concentration-normalized biomarkers. Relative abundance was determined for 532 unique glycopeptides. Univariate age- and sex-adjusted Cox regression with respect to overall survival % (OS) was performed using both relative abundance-normalized features and concentration-normalized features to determine a set of glycopeptides and non-glycosylated peptides that are significantly associated with OS.(0263] The sample set was randomly divided and stratified by immunotherapy regimen, melanoma subtype, and early failure (progressed or died within 6 months of treatment start) / sustained control (progression and death-free within 3 years of treatment start) status. 40% of the sample set was used as a training set, 30% was used as a validation set on which to tune model hyperparameters, and the remaining 30% was used as an independent testing set. Allocation of samples into the three sets (training, validation, and test) was sufficiently balanced across all demographic and clinical covariates listed in Table 7A (confirmed by Chi- squared, Fisher’s Exact, Student t, or Wilcoxon rank-based tests as appropriate). A five-fold repeated cross-validated LASSO-regularized Cox regression model was employed on the training set, yielding a set of 14 biomarkers, including 13 glycopeptides and one non- glycosylated peptide (Tables 15A-15D). A risk score threshold by which to divide the cohort into “likely ICI responders” and “non-responders” was chosen via Harrell’ s c-index to optimize sensitivity for non-response in the validation set. The identical threshold was used in the independent test set and in the external validation cohort. All analyses were conducted in R version 4.2.2 (Vienna, Austria).
[0264] Table 7A. Demographic and clinical covariates in the discovery cohort. Counts are followed by the appropriate column-wise percentage, while continuous variables are summarized by medians and either IQRs or, for time to event variables, 95% confidence limits (NR = not reached).Fell cohort Trailing set Validation setTest set
[0265] Table 7B. Demographic and clinical covariates in the discovery cohort stratified by classifier prediction. Counts are followed by the appropriate column-wise percentage, while continuous variables are summarized by medians and either IQRs or, for time to eventsubject diagnosed with melanoma will benefit from immunotherapy comprising detecting one or more biomarkers. In some embodiments, the one or more biomarkers comprise one or more glycopeptides. In some embodiments, the one or more biomarkers comprises one or more peptide structures set forth in Table 8A. In some embodiments, the method comprises detecting one or more peptides comprising a sequence set forth in SEQ ID NOs: 44-57. In some embodiments, the peptides of Table 8A can comprise a glycan with the symbol structure or composition noted in Table 8C.
[0267] Table 8A. Peptide Structures Associated with Likelihood of Benefit ofImmunotherapy in Melanoma Patients
[0268] Table 8B LC-MRM-MS parameters for peptide structures associated with PatientsHaving Melanoma that are Unlikely or Likely to Benefit with Immunotherapy
[0269] Table 8C. Glycan symbol structure and glycan composition that corresponds to the glycan structure GL NO in Table 8 ALegend for Table 4
[0270] Table 8D Coefficients for each marker used in the regression models
[0271] Glycopeptides with differences in relative abundance in relation to OS were analyzed by type of glycans. Asparagine (N)-linked glycans and O-linked glycopeptides were further separated based on the number of hexose, A-acetylhexosamine, fucose, or sialic acid units. A site-specific monomer weight feature for N-glycopeptides was calculated by determining the average number of a specific monosaccharide at a given glycosylation site, weighted by glycan species site occupancy. A five-fold repeated cross-validated LASSO- regularized Cox regression model based only on fucose-dependent engineered features that achieved FDR<0.05 in univariate age- and sex-adjusted Cox regression was developed, and a risk score threshold was chosen using the same method as described above. The same training, validation, and test set were used as in the other cross-validated Cox model described above.
[0272] Responses to immunotherapy were assessed for overall survival (OS). The discovery cohort is composed of 69% male with a median age of 65 (IQR: 57, 73). 73% of patients were to undergo first-line therapy at time of sample collection, with 72% of patients experiencing a progression, 41% having a time recorded at which an additional treatment regimen was initiated, and 56% having a recorded death. Median time to progression for this cohort was 5.5 months (95% CI: 3.0, 9.9), while median time to death was over three years, at 40.1 months (95% CI: 27.3, 59.0) (Figure 15A). 63% of patients had cutaneous melanoma and 17% had melanoma of unknown primary, while the remainder were either characterized as mucosal, uveal, or acral subtype. At the start of treatment, 73% of the cohort was staged as either Mlc or Mid, 60% of patients were wild type BRAF, 44% had lactate dehydrogenase (LDH, units / L) value that exceeded the upper limit of normal (ULN), and 40% had an ECOG performance status above 0 (Table 7A). As expected, patients with non-cutaneous melanoma, higher LDH, higher ECOG performance status, or are BRAF mutants exhibit shorter median time to death (Figures 18A-18D). The ECOG Performance Status Scale is a standard criteria that describes a patient’s level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). A higher ECOG value corresponds to a patient having a more limited daily living ability whereas a lower ECOG value (e.g., 0) corresponds to a more active patient able to carry on daily activities with fewer or no restriction.
[0273] The independent validation cohort used for additional confirmation of the predictor is composed of 70% male with a median age of 71 (IQR: 66, 81) as shown in Table 9. 85% of patients were to undergo pembrolizumab monotherapy, with 37% of patients experiencing a progression and 33% having a recorded death. Best overall response was determined, with 38% of the cohort having at least a partial response to therapy. Median time to progression for this cohort was not reached (95% CI: 9.9, NR) while median time to death was 18.6 months (95% CI: 15.8, NR) (Table 9). While this cohort has less follow-up than the discovery cohort, the distributions are comparable (Figure 15B).
[0274] Table 9. Demographic and clinical covariates in the independent validation cohort. Counts are followed by the appropriate column-wise percentage, while continuous variables are summarized by medians and either IQRs or, for time to event variables, 95% confidence limits (NR = not reached).
[0275] The identification of glycopeptide biomarkers associated with overall survival and early failure was described. Peptides and glycopeptides derived from 75 plasma proteins were quantified and univariate age- and sex-adjusted Cox regression were applied to identify biomarkers associated with OS. The label “early failure” (EF) was assigned to patients who progressed and died within 6 months of starting ICI treatment (n=40), “sustained control” (SC) was assigned to patients who neither progressed nor died in the first three years after ICI treatment start (n=56), and “other” was assigned otherwise (n=106) (Figures 19A-19B). When representing 143 differentially expressed biomarkers between the EF and SC groups at FDR<0.05 in a hierarchically-clustered heatmap, drastic differences were observed in their glycoproteomic profile.
[0276] The generation of a classifier to predict ICI benefit was described. A LASSO- regularized Cox-based classifier for prediction of individuals likely to benefit from ICI therapy was generated: from 64 biomarker features associated with OS (FDR<0.05), 14 were retained (13 glycopeptides and one non-glycosylated peptide), and achieved an unadjusted HR=5.1 (P=7.6>< 10'11) in the full discovery cohort, HR=10.3 (P=4.5>< 10'9) in the training set, HR=3.9 (P=0.012) in the validation set, and HR=2.7 (P=0.026) in the test set (Table 10, Figure 16A- 16D). In the full discovery cohort, 92 of the 179 patients classified as likely to benefit from ICI therapy died (51%), whereas 21 of 23 patients classified as unlikely to benefit died (91%), suggesting the classifier has a high sensitivity to detect likely non-responders. In the independent test set, the proportions shift to 58% and 86%, respectively.
[0277] Table 10. Performance of repeated five-fold cross-validated LASSO-regularizedCox regression-based classifier using 14 concentration-normalized features
[0278] The statistical significance was estimated in univariate Cox regression analyses of all demographic and clinical variables with and without adjustment. This was then used for variable selection and adjustment in the multivariable Cox regression analysis. Age, BRAF status, categorical LDH group, ECOG performance status, M stage, melanoma subtype, and line of therapy all achieved P<0.15 in both analyses (Table 12). Multivariable Cox regression analysis was then performed using the classifier prediction group as the primary independent variable and adjusting for the previously listed variables (Table 11). When applied to the full cohort, this model predicted that the risk of death for a patient that is classified as unlikely to benefit from ICI therapy based on their glycoproteomic risk score is about 3.4 times higher than if they were classified as likely to benefit, adjusting for the demographic and clinical variables (95% CI: 1.9, 6.1). Interestingly, variables such as age, categorical LDH group, ECOG performance status, subtype, and line of therapy generated models that were significant (P<0.05) without the inclusion of the classifier prediction variable. However, when the classifier prediction variable was included, the only predictors that remain statistically significant were classifier prediction (P=6.3* 10'5), melanoma subtype (P=5.1 >< 10'4), and lineof therapy (P=5.9>< 10'3) (Table 11). Using a likelihood ratio test to compare these two multivariable Cox models, there is sufficient evidence that the model that includes the classifier prediction provides a significantly better fit than the model without it (P=2.0x 1 O'4).
[0279] Table 11. Performance of Cox regression-based classifier in the discovery cohort
[0280] Table 12. Univariate Cox regression with respect to OS without and with adjustment for classifier prediction (likely / unlikely to benefit) in full discovery cohort; variables significant at P<0.15 in both frameworks (marked with an asterisk) are included in multivariable modeling shown in Table 10. Global p-values for categorical variables take missing values into account.
[0281] Next, the Cox-based classifier was applied based on 14 markers to an independent cohort of 27 patient samples. Remarkably, the model achieved comparable separability between the likely and unlikely to benefit classification groups relative to the discovery cohort (HR=5.6; P=0.027) (Figure 16E; Table 10). Notably, all four patients classified as unlikely to benefit from ICI therapy recorded progressive disease as best overall response, and three died (75%) (Table 13). Of the 23 patients who were classified as likely to benefit, 6 died (26%). Although the cohort was small in sample size, these data indicate that the classifier demonstrates high sensitivity to detect non-responders (Table 10).
[0282] Table 13. Demographic and clinical covariates in the external validation cohort stratified by classifier prediction. Counts are followed by the appropriate column-wise percentage, while continuous variables are summarized by medians and either IQRs or, for time to event variables, 95% confidence limits (NR = not reached).78(0283] The fucosylation of N-glycopeptide biomarkers that are associated with reduced clinical benefit of ICI therapy was described. Biomarkers showing statistically significant differences in relative abundance in respect to OS (P<0.05) were selected for further structural analysis. Among the 114 markers, 91 were N-glycopeptides, all carrying complex-type glycans. Strikingly, when looking at fucose content, these markers separated in two distributions that reflected the benefit of treatment (Figure 17A1), with fucosylated glycopeptides prevalent in patients with disease progression. Increased fucosylation has been described at the tumor site and has been linked to increased metastatic potential, modulation of TGF-beta signaling that is known to impact the distribution of T cells in the tumor, as well as PD-1 stability at the cell surface. Next, the sialic acid content in the same markers was analyzed, as alterations in sialic acid density in tumor cells have been extensively described in connection with inhibition of immune cell function. However, there was no correlation between the number of sialic acid units and benefit of ICI treatment (Figure 17A2). Other mechanisms, including expression of the asialoglycoprotein receptor, might contribute to maintaining a homogeneous level of sialylation in circulating glycoproteins. Instead, a correlation was observed between the number of sialic units in O-linked glycopeptides and the reduced benefit of treatment (Figure 17B); however, only a small number of O-glycopeptides were included in the panel. These species most likely correspond to disialylated core-1 ( -glycan tetrasaccharides that contribute to binding of the immune-suppressive receptor Siglec-7 found on natural killer cells. Access to non-glycosylated forms of the peptides allowed us to also evaluate the relevance of site occupancy: as N-glycans are involved in protein folding and can prevent interactions with other proteins, changes in site occupancy may dramatically changeprotein activity. Interestingly, alphal -antitrypsin (A1AT) and hemopexin exhibited opposite association with response to treatment in respect to site occupancy (Figure 17C). Glycosylation of Al AT was described to affect binding to IL-8 and neutrophil activation.
[0284] To test the validity of this observation, site-specific glycosylation features that represent the average number of specific monosaccharides at a given site, weighted by glycopeptide occupancy. Of 51 fucose-dependent features across our full research assay, 11 were strongly associated with benefit from ICI therapy based on univariate age- and sex- adjusted Cox regression analysis (Figure 17D). All 11 features were ultimately retained in a repeated cross-validated LASSO-regularized Cox regression model on a training set consisting of 40% of the cohort, yielding a hazard ratio of 2.9 (P=0.016) (Figure 17E2). A validation set consisting of 30% of the cohort was used to tune model hyperparameters (Figure 17E3). When applied to the remaining 30% of the cohort, this tuned model resulted in a HR of 3.5 (P=6.6* 10"3) (Figure 17E4). Altogether, these data support the notion that the fucosylation status of circulating glycoproteins is a critical parameter that stratifies patients based on the response to ICI therapy.
[0285] The group of site monomers in Table 14A include site monomers that have been determined relevant to distinguishing at least between immunotherapy responsive melanoma and immunotherapy nonresponsive melanoma. For example, the group of site monomers may be used to predict the probability of having immunotherapy responsive melanoma for use in informing treatment decisions. In one or more embodiments, the at least 1 site monomer includes at least 1, at least 2, at least 3, at least 4, at least 5, or more of the site monomers listed in Table 14A. It should be noted that the specific monomer in the set of peptide structures listed in Table 14A at the linking site is fucose.
[0286] Table 14A: Markers (Site Monomers) Associated with the Classification of Likely to Benefit or Not Likely to Benefit from Immunotherapy for Melanoma
[0287] Table 14B: Peptide Structures Corresponding to the Markers (Site Monomers) ofTable 14A.
[0288] Table 14B includes the peptide structure name (PS-NAME, e.g., Al AT_70_5402), which is a reference code for the protein name (e.g., Al AT), followed by the glycan linking site position in the protein (e.g., the number 70 that is preceded by an underscore and represents a sequential amino acid position in protein Al AT), and followed by the glycan structure GL number (e.g., the number 5402 that is preceded by an underscore and represents a glycan composition Hex(5)HexNAc(4)Fuc(0)NeuAc(2)). The Peptide Structure Name of Table 14B contains a prefix that represents an abbreviation (that may include a combination of letters and numbers) for a protein abbreviation that corresponds to the Protein Abbreviation of Table 14E. The term Linking Site Pos. within Protein Sequence is a number that refers to the sequential position of an amino acid of the corresponding protein in which a glycan is attached. For the Linking Site Pos. within Protein Sequence, the amino acid position of the peptide sequence is defined by the sequentially numbered order of amino acids based on the Uniprot ID of the corresponding protein for the peptide sequence. The term Linking Site Pos. within Peptide Sequence is a number that refers to the sequential position of an amino acid of the corresponding peptide in which a glycan is attached. For the Linking Site Pos. within peptide Sequence, the amino acid position of the peptide sequence is defined by the sequentially numbered order of amino acids for the peptide sequence. The term Glycan Structure GL No. is a number that corresponds to a symbol structure and a composition of the glycan as indicated in Table 14D. The term “Fucose position” refers to the attachment position of the fucose residue to the glycan, and can be “core”, “antennary”, both (“mixed”) or not applicable when a fucose residue is not found in the structure (“NA”).
[0289] In Table 14B, if the first number subsequent to the first underscore in the Peptide Structure (PS) NAME is inconsistent with the Glycan Linking Site Pos. in Protein Sequence column, then the Glycan Linking Site Pos. in Protein Sequence column should be used for identification of the peptide. In Table 14B, if the second number subsequent to the second underscore in the Peptide Structure (PS) NAME is inconsistent with the Glycan Structure GL NO column, then the Glycan Structure GL NO column should be used for identification of the glycan portion of the glycopeptide. If the Peptide Structure (PS) NAME does not contain any numbers, then the peptide is non-glycosylated. In some instances of the Peptide Structure (PS) NAME, subsequent to the prefix, there is a number noted with the notation MC that indicates that there was a missed cleavage at position in the peptide sequence as noted by the number. In some instances of the Peptide Structure (PS) NAME, there is a suffix NH3LOSS to indicate a loss of a NH3 group.
[0290] Table 14C: LC-MRM-MS parameters for peptide structures associated with Patients Having Melanoma that are Unlikely or Likely to Benefit with Immunotherapy in accordance with Table 14B.| 121 | 5521,174696 | 33,2 | 27 | 1105,6 | 5 | N / A _ N / A 366,1 | 1359,6 |
[0001] Table 14C shows various parameters associated with the identification of the peptide and glycopeptides using LC and MRM-MS. The retention time (RT) represents the amount of time in minutes for the peptide elute from the chromatography column. The collision energy represents the energy applied to the peptide for creating fragments (i.e., product ions) such as, for example, in the 2ndquadrupole of the triple quadrupole MS. The first precursor m / z represents a ratio value associated with an ionized form having a first precursor charge for the peptide or glycopeptide. Similarly, the second precursor m / z represents a ratio value associated with an ionized form having a second precursor charge for the peptide or glycopeptide. The first precursor ion is associated with a first product ion having a m / z ratio that was formed from a collision and the second precursor ion is associated with a second product ion having a m / z ratio that was formed from a collision. Under certain circumstances, the first precursor and the second precursor may be the same, but the associated first and second product m / z ratios are different.[02911 Table 14D: Glycan symbol structure and glycan composition of N-glycans that corresponds to the glycan structure GL NO in Table 14B.Legend for Table 14D
[0292] Table 14D illustrates the symbol structure and composition of detected glycan moieties that correspond to glycopeptides of Table 14B based on the Glycan GL NO. The term Symbol Structure illustrates a geometric linking structure of the carbohydrates where the bottommost carbohydrate such as N-acetylglucosamine is bound to the designated amino acid for an N-linked glycan and the rightmost carbohydrate such as N-acetylgalactosamine is bound to the designated amino acid for an O-linked glycan. It should be noted that N-linked glycans are in Table 14D. For reference, N-linked glycans have a glycan attached to the amino acid asparagine and O-linked glycans have a glycan attached to either a serine or a threonine. When composition is known and no structural information is available, the glycan structure is labeled as “not defined” term in the Glycan Structure Symbol column.
[0293] The identity of the various monosaccharides is illustrated by the Legend section located at the end of Table 14D. The abbreviations of the Legend are Glc that represents glucose and is indicated by a dark circle, Gal that represents galactose and is indicated by an open circle, Man that represents mannose and is indicated by a circle with intermediate grey shading, Fuc that represents fucose and is indicated by a dark triangle, Neu5 Ac that represents N-acetylneuraminic acid and is indicated by a dark diamond, GlcNAc that represents N- acetylglucosamine and is indicated by a dark square, GalNAc that represents N-acetylgalactosamine and is indicated by an open square, and ManNAc that represents N- acetylmannosamine and is indicated by a square with intermediate grey shading.
[0294] The term Composition refers to the number of various classes of carbohydrates that make up the glycan. The quantity for each class of carbohydrate is depicted as a number in parenthesis to the right of an abbreviation that corresponds to the class of the carbohydrate. The abbreviations for these classes are Hex, HexNAc, Fuc, and NeuAc that respectively correspond to hexose, N-acetylhexosamine, fucose, and N-acetylneuraminic acid. It should be noted that hexose sugars include glucose, galactose, and mannose; and N-acetylhexosamine sugars includes N-acetylglucosamine, N-acetylgalactosamine, and N-acetylmannosamine. In various embodiments, the terms Neu5Ac, NeuAc, and N-acetylneuraminic acid may be referred to as sialic acid.
[0295] Referring back to Table 14D, for some entries, there are two symbol structures provided for one Glycan Structure GL NO such as, for example, Glycan Structure GL NO 5400. Thus, the identify of a peptide that references a Glycan Structure GL NO that has two symbol structures could be either of the two possibilities based on the MRM of the LC-MS analysis. In some instances, a bracket symbol is used as part of the Symbol Structure to indicate that the precise bonding linkage is not exactly known, but that the linking line segment is attached to one of the plurality of adjacent carbohydrates immediately adjacent to the bracket.|0296] Table 14E: Protein and Protein Sequences associated with the Peptide Structures of Table 14B and Table 8A.[02971 Using the coefficients of Table 14A and calculated monomer weight scores based on the corresponding peptide structures of Table 14B, a probability can be determined by summing together the product of the monomer weight scores of each site monomer in the sample and the respective coefficient (of one column) and then adding the summation and the intercept to yield the logit of a probability score. For example, the logit of the probability, to which the inverse logit function can be applied, is equal to:
[0298] With respect to the above equations and Table 14A, the term “i” represents an integer corresponding to the respective site monomer. 02991 Table 15. Performance of monomer weight model using 11 fucose-specific features derived from N-glycopeptides that achieved FDR<0.05 in age- and sex-adjusted Cox regression analysis
[0300] Although ICI therapies have revolutionized treatment of metastatic melanoma, only a subset of patients achieve a durable response. Therefore, it is important to develop assays that accurately identify patients unlikely to benefit from ICI therapy. Such efforts might alsoprovide insight into specific factors that limit the efficacy of anti-PD-1, anti-PD-Ll, and anti- CTLA-4 antibodies, and might inform selection of different or combination therapies. Here, pre-treatment liquid biopsy samples were analyzed using a novel platform and signatures were identified to predict response of metastatic melanoma. The data indicated that blood glycoprotein biomarker profiles accurately predict the likelihood of a beneficial or not beneficial response in melanoma patients.
[0301] Glycosylation is the most abundant and complex form of post-translational modification of proteins and it profoundly affects their structure, conformation, and function. The elucidation of the relevance of differential protein glycosylation as a novel class of biomarkers has so far been limited by the technical challenges of generating and interpreting this information at scale. Our platform helped uncover a specific fucosylation signature in plasma N-glycoproteins that tracks with the lack of response to ICI therapy. Fucosyltransferases, the enzymes responsible for addition of fucose to glycans, are overexpressed in malignant melanoma. Presence of fucose in the N-glycan of IgGl significantly reduces its binding to FcgR. Core fucose has been shown to increase in metastatic melanoma cells and to affect cell invasion through the modulation of the stability of the adhesin L1CAM. Fucosylation can also alter TGF-0 signaling and may therefore drive immune- excluded tumor phenotypes. Moreover, fucosylation has been directly linked to the stability of receptors such as cell surface PD-1. It is interesting that a similar fucosylation signature is observed both in the tumor microenvironment and in the periphery.
[0302] The role of A1AT glycosylation in binding to IL-8 and neutrophil activation has previously been described. Moreover, our functional analysis shows association of Al AT and AACT with platelet activation and thus a likely predisposition to hypercoagulable state, a process previously described to be associated with complications of advanced melanoma. Network analysis of cancer-causing genes relates the B2M gene product to melanoma. Beta2- microglobulin is found in association with the MHC class I alpha chain and is involved in antigen presentation. Beta2-microglobulin unbalance may promote tumor escape from recognition by CD8+ T cells, and may have a role in neutrophil degranulation. LRG1 has been described to modulate the tumor microenvironment on neutrophil activation. We propose that cells at the tumor site produce factors that are released in the periphery and modulate expression and glycosylation of protein in the liver and blood cells. The complex glycoproteomic response may in turn impact disease progression and response to treatment.
[0303] When key clinical variables are stratified by the classifier prediction in the discovery cohort, a few patterns become clear. For patients with higher LDH values at treatment start, the median OS decreases, irrespective of the classification as likely or unlikely to respond to ICI therapy. In other words, while belonging to a higher LDH category is associated with increased risk of death, samples classified as likely to benefit exhibit increased median OS compared to the group categorized as unlikely to benefit, regardless of the LDH category of a patient. The same pattern is observed with respect to BRAF mutation status: while being a BRAF mutant is perhaps slightly associated with increased risk of death, being classified as likely to benefit increases median OS relative to being classified as unlikely to benefit regardless of BRAF status. Somewhat in contrast, patients who have ECOG performance status above 1 demonstrate short median overall survival regardless of classification. However, samples classified as unlikely to benefit have comparable median overall survival regardless of ECOG performance status. This phenomenon is additional evidence that the glycoproteomic classifier provides significant utility in identifying patients who are unlikely to respond to ICI therapy, regardless of other physiological characteristics.XI. Examples
[0304] The following example is included to demonstrate various embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the example that follows represent techniques discovered by the inventors to function well in the practice of the disclosure, and thus can be considered to constitute particular modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of methods and compositions of the disclosure.EXAMPLE 1SERUM GLYCOPEPTIDE SIGNATURES ASSOCIATED WITH REDUCED CLINICAL BENEFIT OF IMMUNECHECKPOINT INHIBITOR THERAPY ARE INDUCED BY CYTOKINES THAT MODULATE EXPRESSIONOF GLYCOSYLATION-RELATED GENES IN THE LIVER
[0305] The remarkable success of immune-checkpoint inhibition (ICI) in metastatic melanoma treatment has underscored the value of strategies that enhance the response of the immune system against cancer. However, as the prolonged benefits are observed in only approximately half of the patients and are often accompanied by significant adverse events, there is a need for predictive biomarkers and patient stratification strategies. While increasedPD-L1 expression and tumor mutational burden have shown some correlation with response to ICI treatment in certain cancers, these markers have limited predictive capability in metastatic melanoma.
[0306] By employing the encompassed glycoproteomics platform on pre-treatment plasma samples collected from 202 metastatic melanoma patients who were administered anti-PD-1 monotherapy or anti-PD-l / anti-CTLA-4 combination therapy, the inventors identified biomarkers that distinguish individuals likely to experience extended survival from those less likely to benefit from therapy and discovered a fucosylation signature in N-linked glycoproteins of patients with reduced overall survival. In-depth analysis of the fucosylated markers using bottom -up glycoproteomics revealed that the majority were core fucosylated, while a few presented with an outer-arm fucose modification. As the majority of the identified fucosylated serum markers are liver-derived glycoproteins, it was considered that inflammatory mediators produced by cells in the tumor microenvironment and released in blood circulation may act as drivers of fucosylation changes in the liver, in certain embodiments. Cytokines in the serum of the melanoma patients were measured and a set of molecules including TGF-pi, IL-ip, IL-6, IFN-P and TNFu were differentially expressed in patients classified based on a glycopeptide-based classifier. Treatment of human hepatocytes in vitro with these cytokines increased cell surface fucosylation, which could be prevented by antibodies that blocked the interaction of the cytokines to their receptors. Interestingly, gene expression analysis revealed that while TNF-a upregulated the expression of the GDP -Fucose transporter Slc35cl, TGF-pi induced FUT8 expression and IL-ip upregulated both Slc35cl and FUT3 in vitro.
[0307] Taken together, these results indicate that elevated levels of inflammatory markers in the serum of melanoma patients not benefiting from ICI therapy can function as molecular drivers for the synthesis of fucosylated proteins by inducing the expression of fucosylation- related genes in hepatocytes. In various embodiments, upregulation of fucosylation is a result of a hepatic reprogramming mechanism induced by cancer.EXAMPLE 2DEVELOPMENT OF ANION EXCHANGE-MEDIATED GLYCOPEPTIDE ENRICHMENT METHODS REVEALS INTEGRINS AS ENRICHED IN POLYLACNAC EXTENDED N-GLYCOPEPTIDES IN MALIGNANT MELANOMA CELLSOverview
[0308] Glycosylation is a key modulator of the functional state of proteins. Recent developments in large scale analysis of intact glycopeptides have enabled the identification of numerous glycan structures that are relevant in pathophysiological processes. However, one of such motifs found in N-glycans, poly-N-acetyllactosamine (polyLacNAc), still poses a substantial analytical challenge to mass spectrometry-based glycoproteomic analysis due to its relatively low abundance and large size. In this example, approaches for the systematic mapping of polyLacNAc-elongated N-glycans in cells were developed. The inventors first evaluated five anion exchange-based matrices for enriching intact glycopeptides and confirmed that the experimental system was able to broadly monitor chemical inhibition of fucosylation and enzymatic removal of sialylation. Lastly, optimal enrichment solutions were applied to discover polyLacNAc-containing motifs in cells engineered to modulate the expression of beta- 1,3-N-acetylglucosaminyltransferase 2 (B3GNT2), a key enzyme involved in polyLcNAc synthesis. Remarkably, integrins are substantially modified with polyLacNAc motifs in melanoma cells. This example demonstrates the feasibility of glycoproteomic approaches for identification of cell surface receptors modified with specific sugar motifs within remarkably large glycans.Examples of MethodsCell culture and reagents
[0309] The malignant melanoma cell line A375 was purchased from Ubigene (Brooklyn, NY). B3GNT2 knockout and B3GNT2 overexpression cell lines were generated by Ubigene by CRISPR-based mutation and lentivirus-based integration, respectively. Cells were cultured in Dulbecco's Modified Eagle's Medium (Thermo Scientific) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. Cells were maintained in a humidified incubator at 37°C with 5% CO2. For inhibition of fucosylation, cells were cultured in medium supplemented with 300 uM 2-fluoro-peracetyl-fucose (Cayman Chemicals) for 3 days.Sample preparation for MS analysis
[0310] Cell pellet was dissolved in 600 pL of lysis buffer (6 M urea, 100 mM Tris pH 8.5, 1% Triton, 5 mM tris(2-carboxyethyl)phosphine (TCEP), 20 mM Chloroacetamide (CAA) all bought from Sigma- Aldrich, 1 tablet of Complete mini EDTA free (Roche) and 1% Benzonase (Merck Millipore). Cells were disrupted by sonication for 30 cycles (10 sec on, 15 sec off) using a Bioruptor Plus (Diagenode). Cellular debris was removed by centrifugation at 20 000 g for Ih at 4 °C and the supernatant was subjected to methanol / chloroform precipitation. ImLof supernatant was mixed with 4 mL of methanol and 1 mL of chloroform (both from Sigma Aldrich) with 3 mL of ultrapure water. The mixture was spun for 20 min at 4000 g at room temperature (RT). The upper layer was discarded, and 3 mL of methanol was added, followed by 10 minute centrifugation at 4000 g at RT. Following centrifugation, the solvent was removed and the pellet was left to air dry for 10 min and resuspended in digestion buffer containing 100 mM Tris-HCl pH 8.5, 5 mM TCEP, 20 mM CAA and 0.5% RapiGest (Waters) to a concentration on 2 pg / uL and digested with Trypsin / Lys-C mix (Promega) in a 1 :50 ratio (w / w) overnight at 37 °C. The following day Rapigest was precipitated by acidification with trifluoroacetic acid (TFA) and the peptides were cleaned by Sep-Pak C18cc vac cartridge. Eluted peptides were directly subjected to glycopeptide enrichment. For sialidase treatment, glycopeptide enriched samples were treated with 0.01 U of Arthrobacter ureafaciens sialidase (Roche) in PBS for 2 hours, desalted and dried in a SpeedVac.
[0311] For fractionation experiments to obtain plasma and crude membrane fractions, 15 million cells per experiment were processed with a Minute Plasma Membrane Protein Isolation and Cell Fractionation kit (Invent biotechnologies, Minnesota, USA) according to the manufacturer instructions. The purified crude membrane and membrane fractions pellets were resuspended in digestion buffer (same as the whole cell approach above), and the peptides were desalted with Pierce Peptide desalting spin columns (Thermo Fisher). The eluates were directly used for glycopeptide enrichment.Glycopeptide enrichment
[0312] Oasis MAX (Waters), SOLA SAX (Thermo Fisher), HyperSep Retain AX (Thermo Fisher), HyperSep SAX (Thermo Fisher), and AttractSPE SAX (Affinisep USA) lee cartridges were equilibrated with 1 mL of Acetonitrile (ACN), followed by ImL of 100 mM tri ethylammonium acetate, 3x1 mL deionized water, and 1 mL 95% ACN 1% trifluoroacetic acid (TFA). The columns were then filled with 900 pL of 95%ACN 1%TFA and topped up with 150 pL (150 pg of peptides) of eluted peptides from desalting step (eluted in 50% ACN 0.1% FA). Columns were then washed three times with ImL of 95% ACN 1% TFA. Samples were eluted with 600 pL of 50% ACN 0.1% TFA and dried. Samples were stored dry in -80 oC until MS analysis.
[0313] For HILIC enrichment the iSPE-HILIC cartridge (Hilicon) 1 cc cartridge was washed with 3x1 mL 1% TFA, followed by 3xlmL 80% ACN 1% TFA. Approximately 1 mgof peptides was loaded in 80% ACN 1% TFA with flow through collected and passed through the cartridge again. Samples were further washed with 3x1 mL of 80% ACN 1% TFA, eluted with 500 pL 0.1% TFA dried and stored at -80 oC until MS analysis.MS analysis 0314] The dried samples were dissolved in 0.1% formic acid (FA) and analyzed on an Orbitrap Exploris 480 Mass Spectrometer (Thermo Fisher Scientific) coupled with an Ultimate 3000 RSLC nano System LC instrument (Dionex). The binary solvent system was composed of solvent A (99.9% water, 0.1% formic acid) and Solvent B (99.9% Acetonitrile, 0.1% formic acid). Samples were separated on a 75 pm * 50 cm column (Cl 8, 2 pm, 100 A; Acclaim PepMap, Thermo) under a 180 min linear gradient at a flow rate of 400 nL / min. The solvent gradient started at 1% B for 5 minutes, and separation was achieved using the following linear gradient steps: I) to 35% B over 134 minutes; II) to 90% B over 11 minutes; III) hold at 90% B for 5 minutes; and IV) to 1% B over 6 minutes; V) to 90% B over 4 minutes; VI) hold at 90% B for 2 minutes; VII) to 1% B over 2 minutes; VIII) to 90% B over 3 minutes and hold at 90% for 2 minutes. The column was then re-equilibrated by a 1 -minute gradient back to 1% B and held for 10 minutes.
[0315] The MS instrument was operated in data dependent mode and samples were ionized with a Nanospray Flex Ion Source at a spray voltage of 2800V. The MSI scans (m / z 400-2400) were acquired in the Orbitrap (120k resolution, 300% normalized AGC target) followed by HCD MS / MS acquisition of the top 20 precursors with the highest charge states in order of intensity and detection in the Orbitrap. The Stepped HCD mode triggered on oxonium containing MS / MS scans and was set with the stepped collision energies of 27%, 35%, and 43% (15k resolution, 300% normalized AGC target).Glycopeptide data analysis
[0316] All the raw files were analyzed by Glyco-Decipher. Default settings were used, enzyme was set as trypsin allowing for up to three missed cleavages. Cysteine carbamidomethylation and methionine oxidation were set as variable modifications. Spectrum expansion was enabled and the built-in GlyTouCan database was used to match glycan masses. Only glycopeptide spectrum matches with FDR <0.01 and a minimum of three matched core fragment ions (Peptide+HexNAc, Peptide+HexNAc2. . .) were kept for glycopeptide identification. Quantification was performed with a quantification module in Glyco-Decipherbased on summed peak areas of MSI elution profiles. Full technical details behind the search engine can be found in earlier studiesf 18, 19] . Data analysis and visualization was performed with Graph Pad Prism 9. Gene ontology and pathway analyses were performed with Shiny GO [20-22],
[0317] Exemplary Results
[0318] To map expression of polyLacNAc on surface glycoproteins of malignant melanoma cells, the A375 cell line and variants were utilized that either lacked or overexpressed the B3GNT2 enzyme, which is implicated in the synthesis of polyLacNAc
[0011] , Next, the most effective methods for glycopeptide enrichment were sought. It was considered that the most commonly used approaches are based on hydrophilic interaction chromatography (HILIC) and anion exchange-based enrichment methods. HILIC-based enrichment is reported to suffer from a low recovery rate (~1% yield of starting material), whereas anion exchange approaches provide -10% yield
[0023] , However, it was observed that the term "anion exchange" encompassed multiple commercially available solutions used in the literature [23-25], Among the more frequently encountered options, the following were identified: 1) mix-mode anion exchange (MAX); 2) strong anion exchange SOLA (SOLA); 3) HyperSep retain anion exchange (RAX); 4) HyperSep anion exchange (hySAX); and 5) Affinisep strong anion exchange (afSAX). It was first investigated if there were any differences in enrichment efficiency among these cartridges (Figure 21).
[0319] There was enrichment of 300 ug of peptides derived from A375 malignant melanoma cell line overexpressing the B3GNT2 enzyme and analysis of the resulting glycoproteome. As a first pass, the enrichment efficiency was evaluated of each cartridge as a number of MS2 oxonium ions containing scans, which are indicative of glycopeptides, divided by a total number of MS2 scans. Each of the five enrichment approaches yielded an enrichment efficiency of over 80% (82-89% range) (Table 16).Table 16. Overview of enrichment efficiency from whole cell lysates of B3GNT2 overexpressing A375 cell line.Enrichment MS2 Scan MS2 Oxonium Scans Enrichment efficiencySOLA 153979 135124 87.75% afSAX 153190 128515 83.89% hySAX 149855 122807 81.95%MAX 151015 126176 83.55%RAX 153359 136401 88.94%10320 [ Next, glycopeptide composition was analyzed in each sample, and SOLA and RAX cartridges provided the highest number of unique glycopeptides (-2000 each), followed by afSAX, MAX and hySAX (Figure 22A). Next, to investigate whether the increased number of glycopeptides represents similar increase in unique glycoprotein identifications, or more detailed characterization of same glycoproteins, the numbers were compared of unique glycoprotein identifications amongst the enrichment approaches (Figure 22B). SOLA and RAX provided a higher number of unique glycoproteins, albeit the differences were less pronounced compared to unique glycopeptide identification, indicating that the main benefit of SOLA and RAX as opposed to other tested enrichment methods is a more comprehensive coverage of peptide glycoforms.
[0321] Next, potential global biases were evaluated in types of glycosylation introduced by the enrichment methods. Each of the approaches resulted in comparable profiles of high mannose, complex, truncated and modified glycan types (Figure 23A). In agreement with the literature
[0026] , the A375 cell line predominantly expressed high mannose type N-glycans, possibly as a result of culture conditions
[0027] , As SOLA and RAX cartridges resulted in a higher number of glycopeptide identifications, further analyses were restricted to these two methods. Of note, the time required for the samples to pass through the columns by gravity flow varied based on the material: it took -90 minutes for Affinisep SAX, -60 minutes for SOLA and MAX, and -20 minutes for RAX and Hypersep SAX. This aspect represents an important consideration when designing large scale experiments, which might require applying positive or negative pressure through a vacuum manifold.
[0322] Validation of glycoproteomic search results
[0323] Because one aspect was to identify polyLacNAc-containing N-glycopeptides, which are categorized as complex type N-glycans, membrane fractionation approaches were tested to increase the proportion of these N-glycans and exclude the contributions of endoplasmic reticulum and Golgi compartments, which are hubs of glycoprotein synthesis and a main source of high mannose N-glycans[l], Lysates were tested from 15 million cells to plasma membrane enrichment and both the crude membrane and the plasma membrane fractions were purified. Based on oxonium ion analysis, there was about 95% enrichment efficiency (Table 17), likely due to removal of cytosolic proteins that could interfere withenrichment. Intriguingly, plasma membrane fractionation yielded about 40 ug total peptides amount, which was still sufficient to obtain -2000 glycopeptides identifications with SOLA SAX, and about 20% lower identifications by RAX.
[0324] Table 17. Comparison of enrichment efficiencies of 2-Fluoro-Fucose treated cells and membrane fractionation approaches.Sample* Enrichment MS2 MS2 Oxonium EnrichmentScan containing efficiency scan153974 129783 84 9%B3GNT2 KO WC RAX 154858 128279 82.84%B3GNT2 OE FFWC RAX 148822 118144 79.39%B3GNT2 OE WC RAX 156633 131859 84.18%B3GNT2 KO_FFWC SOLA 153398 115986 75.61%B3GNT2 KO WC SOLA 156051 131296 84.14% 155203 135482 8729%157202 134208 8537%B3GNT2 OE CM RAX 163265 150640 92.27%B3GNT2 OE PM RAX 163116 153429 94.06%B3GNT2 OE CM SOLA 159848 150374 94.07%B3GNT2 OE PM SOLA 161385 154587 95.79%B3GNT2 OE CM FF SOLA 159766 154263 96.56%B3GNT2 OE PM FF SOLA 154809 147420 95.23%*OE-Overexpressed, KO-Knock Out, WC-Whole Cell, CM- Crude Membrane,PM- Plasma Membrane, FF- 2-Fluoro-Fucose treated
[0325] There was an overall increase in the proportion of complex type glycans by 1.6-fold when compared with whole cell lysates (Figure 23B), indicating that membrane fractionation increases the enrichment efficiency of complex type N-glycans, albeit at a cost of significant increase in the amount of material required.
[0326] Next, to evaluate the quality of the glycopeptide identification workflow, samples were analyzed from cells grown in presence of the fucose inhibitor 2-fluoro-peracetyl-fucose (2-FF) or samples treated with sialidase. Glycopeptide enrichment by SOLA from untreated samples resulted in complex type N-glycans being 72% fucosylated and 95% sialylated, while the RAX-based method produced complex type N-glycans that were 52% fucosylated and 92% sialylated (Figures 23C-23D). 2-FF treatment drastically decreased the proportion of complex N-glycans carrying fucose: the proportion of species with fucose went from 72% to 14% in the SOLA-based experiment, and from 52% to 3% in RAX-based experiment (Figure 23C). Comparable results were obtained with SOLA-enriched crude and plasma membrane fractions (Figure 26). 2-FF did not completely abolish fucosylation in the conditions tested, in agreement with what was previously reported
[0028] , Finally, sialic acids were enzymatically removed with a pan-sialidase. SOLA-enriched glycopeptides were desialylated and analyzed revealing virtually no presence of sialylated glycopeptides (Figure 23D). Taken together, these data indicate that SOLA- and RAX-based enrichment methods are effective strategies for capturing changes in glycosylation in large scale glycoproteomic experiments.Detection of glycoproteins containing polyLacNAc
[0327] Next, the platform was applied to gain insight into the proteins modified with the polyLacNAc motif. PolyLacNAc can be challenging to distinguish from an increase in N- glycan branching: for example, triantennary N-glycans with a single polyLacNAc repeat have identical composition and mass to a tetra-antennary N-glycan. As mentioned, to facilitate polyLacNAc detection, a melanoma cell line was engineered to remove or overexpress B3GNT2. Surprisingly, there were no differences in N-glycosylation landscape between the B3GNT2 knockout and the overexpressing cell line, suggesting that in A375 cells either B3GNT2 is not the main driver of polyLacNAc elongation or the lack of B3GNT2 might be compensated for by other members of B3GNTX family, such as B3GNT3.
[0328] PolyLacNAc-modified glycopeptides were searched for, and a number of glycoproteins were identified, including the DR alpha chain of HLA class II histocompatibility antigen (HLA-DRA) (Figure 24A). The signature oxonium ion at m / z 731 corresponding to a (HexNAcHex)2 repeat was indicative of a tetra-antennary glycan with a polyLacNAc. A detailed look into other HLA-DRA glycopeptide spectrum matches revealed a species containing 7 hexoses, 6 N-acetylhexosamine, 3 N-acetylneuraminic acid and one fucose. Whereas this would usually be attributed to a tetra-antennary N-glycan, the presence of a m / z731 signal led to the conclusion that it was a polyLacNAc-elongated tri-antennary glycan (Figure 24B). Sialidase treatment enabled the detection of additional polyLacNAc compositions associated with HLA-DRA (Figure 27A-27C), as removal of sialic acid reduced the glycoform heterogeneity and increased ionization efficiency of glycopeptides, leading to increased MS sensitivity
[0029] , A simpler but stringent filter was utilized, and there was focus on compositions containing 7 or more N-acetylhexosamine residues for follow up analyses.
[0329] To characterize the roles of polyLacNAc-bearing glycoproteins in A375 cells, a subset of proteins were analyzed that contained 7 or more N-acetylhexosamine units using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Interestingly, when contrasted with pathway analysis of the entire glycoproteome, there was a strong enrichment of polyLacNAc-modified glycoproteins in the “Extracellular matrix (ECM)-receptor interaction” pathway, followed by the “Other glycan degradation” and the “Lysosome” pathways (Figure 24C-24D) The latter was particularly noteworthy as the lysosomal membrane proteins 1 and 2 (LAMP1 and LAMP2) are prominent examples of polyLacNAc-modified proteins
[0013] , providing further validation of our analytical approach. To gain deeper insights into the ECM- receptor interactions pathway, the glycoproteins involved in this pathway were examined (as shown in Figure 28). The analysis revealed the presence of polyLacNAc on Integrins alpha 1, 3, 5, and V, as well as Integrins beta 1 and 6, along with their respective ligands such as Vitronectin, Tenascin, CD44, and Thrombospondin 1. As integrins serve as crucial adhesion receptors capable of bidirectional signaling across the plasma membrane and there is evidence of the impact of integrin glycosylation on their function [30-32], the findings represent an intriguing avenue for further studies
[0033] ,Modeling polyLacNAc-modified N-glycans of TSPAN13 reveals possible functional implications
[0330] After demonstrating the feasibility of detecting polyLacNAc elongated N-glycans, one objective was to characterize the potential physical or functional implications of such modification. Tetraspanin- 13 (TSPAN13) was a focus, as it was detected with extensive polyLacNAc modifications in A375 cells (Figure 29, Figure 25B) , and the relatively small size of the protein renders it tractable for structural investigation. The tetraspanin family consists of 33 transmembrane proteins. No natural ligands have been identified; instead, their function relies on lateral protein-protein interactions on the cell membrane, with integrins being one of their key interactors
[0034] , To gain insights into the polyLacNAc-elongated N-glycan onTSPAN13, Alpha fold-based structure prediction was combined with GLYCAM-based glycan modeling (Figure 25A). The N-glycan appeared to protrude from the extracellular loop of TSPAN13. Considering the highly dynamic nature of glycans, in some embodiments changes in glycosylation in this region are likely to exert functional consequences, and the other members of the TSP AN family appear to all share heavily glycosylated extracellular domains (Figure 25). Remarkably, a recent interactome analysis of galectin-3, a lectin that binds to lactose or LacNAc repeats, has revealed interactions with multiple integrins and tetraspanins
[0035] , This evidence, combined with the data presented here, provides further support to the existence of an integrin / tetraspanin / galectin interaction axis and highlights the contribution of the glycan structure in engaging galectin-3 to modulate the integrin-tetraspanin interplay.Considerations
[0331] In this example, different anion exchange enrichment methods produce overlapping but not identical results in glycopeptide enrichment. The findings highlight the superior performance of SOLA SAX and HyperSep Retain AX cartridges. However, it is worth noting that the model malignant melanoma cell line exhibited a high proportion of high mannose N- glycans, which may have influenced the enrichment efficiency across different cartridges. These results emphasize the importance of selecting the appropriate enrichment method based on the specific glycan characteristics and sample. Moreover, the results obtained from the GlycoDecipher search engine were validated through chemical inhibition of fucosylation and enzymatic removal of sialylation. Finally, the investigation into malignant melanoma cell lines has identified integrins as proteins enriched in polyLacNAc-elongated N-glycans, providing a useful direction for functional exploration and therapeutic exploitation of aberrant glycosylation.EXAMPLE 3ASSIGNMENT OF THE POSITION OF FUCOSE IN MARKERS ASSOCIATED WITH BENEFIT OFTREATMENT
[0332] Tryptic glycopeptides of commonly abundant plasma glycoproteins were identified using high resolution mass spectrometry and analyzing collision induced fragmentation. The oxonium ion mass spectra from the fragmentation of glycopeptides were analyzed to determine the fucose orientation. Based on the mass of the various breakdown fragments of the glycopeptide-derived glycans, a determination was made if the fucose was a “core” fucose, “antennary” fucose (also referred to as an outer-arm fucose), “mixed” (i.e. containing a mixture of both “core” and “antennary” fucose), or “not-identified”.I l l[0333) Figure 31 is a representative figure of a mass spectra with m / z represented on the X-axis and intensity (and therefore abundance) represented on the Y-axis. Arrows indicate the breakdown products indicating the fucose is on the outer-arm (purple diamond - sialic acid, yellow circle - galactose, blue square - N-acetylglucosamine, red triangle - fucose, green circle - mannose). It is worth noting that there is a 4 glycan breakdown fragment composed of sialic acid, galactose, N-acetylglucosamine, and fucose (m / z value of 803.294). In the 4 glycan breakdown fragment, the sialic acid is connected to galactose, galactose is connected to N- acetylglucosamine, and N-acetylglucosamine is connected to fucose. The 4 glycan breakdown fragment represents a single antennary branch having a fucose in an outer arm fucose position where the aggregate glycan was cleaved at a linkage between a mannose and a N- acetylglucosamine.
[0334] Referring back to Figure 31, there is another breakdown fragment that has 3 glycans that is the child of the 4 glycan breakdown fragments with a sialic acid removed. The 3 glycan breakdown fragments include galactose, N-acetylglucosamine, and fucose (m / z value of 512.198). In the 3 glycan breakdown fragment, the galactose is connected to N- acetylglucosamine, and N-acetylglucosamine is connected to fucose. The presence of the 4 glycan breakdown fragment and the 3 glycan breakdown fragment as shown in Figure 31 indicates the presence of outer arm fucosylation. In addition, it should also be noted that no fragments consistent with a core fucose orientation were measured.Analysis of factors leading to the generation of fucosylated glycoproteins1) Cell surface fucosylation of hepatocytes exposed to different cytokinesExamples of Methods:
[0335] HEPG2 and HEP3B were seeded onto 12-well plates in the incubator at 37°C with 5% CO2 overnight. Recombinant human cytokines IFN-P were purchased from StemCell (Vancouver, BC), and recombinant human TNF-a, IL-10, IL-8, IL-6, TGF-pi, IL-ip were purchased from Biolegend (San Diego, CA). The cytokines were diluted to concentrations of 0 ng / mL, 1 ng / mL, 10 ng / mL, and 100 ng / mL in phosphate-buff ered saline (PBS). The prepared mixture of cytokines was added directly to the wells in triplicate and incubated for 48 hours. After incubation, cells were harvested and stained with Aleuria aurantia lectin (AAL) and Lens culinaris lectin (LCA) for 30 minutes on ice. Following staining, cells were washedwith the cell staining buffer (Biolegend), and data acquisition was carried out using a flow cytometer and analyzed using FlowJo software. 0336| Human hepatocyte cell lines HEPG2 (Figure 32) and HEP3B (Figure 33) were stimulated with increasing concentrations of the cytokines for 48h and the binding of AAL or LCA (specific for core fucosylation) lectins to the cell surface was analyzed by flow cytometry. HEPG2 and HEP3B cell lines responded similarly to all cytokines tested, with TGFP-1, IFNP, TNFa and IL-ip inducing the higher fold changes in cell surface fucosylation in a dose dependent manner. Interestingly, IL- 10, IL-8 and IL- 18 played a more dualistic role, inducing either upregulation or down regulation of cell surface fucosylation depending on the cell line and concentration tested.2) Cell surface fucosylation of hepatocytes exposed to different cytokines in presence or absence of cytokine-blocking antibodiesExamples of Methods:
[0337] Human recombinant IFN-P, TNF-a, IL-6, TGF-pi, IL- ip were diluted to 100 ng / ml in PBS. Additionally, human IL-ip Neutralizing Antibody (clone 4H5), Human IFN-P Neutralizing Antibody (clone 10B 10), human IL-6 Neutralizing Antibody (clone 3H3), Human TNF-a (adalimumab) antibody, and Human anti-TGF-P (BioXCell cat# BE0057 / lmg) were used at concentrations of 0.1 pg / mL, 1 pg / mL, and 10 pg / mL. The cytokines and the neutralizing antibodies were mixed and incubated at RT for 30 minutes before adding to the cells. Then the mixture was added directly to the wells in triplicate and incubated for 48 hours. The staining procedures were done as described in the previous section.(0338) In order to confirm that TGFP-1, IFNP, TNFa and IL-ip-induced upregulation of fucosylation depends on binding to its receptor, the cytokines were pre-incubated with their respective blocking antibodies at increasing concentrations. Induction of fucosylation by TGFP-1, IFNP, TNFa and IL-ip were blocked by antibodies (Figure 34). ) Gene expression analysis in hepatocytes exposed to different cytokinesExamples of Methods:[03391 RNA were isolated and purified from the cytokine-treated cells using Monarch total RNA miniprep kit (New England Biolabs, Ipswich, WA) according to the manufacturer’s recommendation. RNA concentrations were calculated using NanoDrop. RNA were reverse-transcribed into cDNA by the addition of a mixture of 10 mM DTT, oligo d(T), SuperScript IV First-Strand Synthesis System (Thermo Fisher), 0.5 mM dNTPs. The reactions were performed using Taqman (Thermo Fisher Scientific) with the single tube primers selective for FUT8, SLC38C1, FUT6 and FUT3 (Thermo Fisher). Applications were performed using Real- Time Sequence Detection System (Applied Biosystems, CA) Dissociation curves were checked for each reaction, and results are reported as the relative expression normalized to the P-actin housekeeping gene (Thermo Fisher). To create graphical representations, the foldvariation was calculated using the 2A-(AACt) method and the relative quantification value was calculated based on the fold change difference.
[0340] To understand the mechanisms by which the cytokines upregulate protein fucosylation, the expression of fucosylation-related genes was evaluated in hepatocytes treated with the cytokines. TGFP-1, IFNP, TNFa and IL-ip modulated the expression of the GDP- Fucose transporter (Slc35cl) and fucosyltransferases (FUT3, FUT6 and FUT8) (Figure 35).4) Quantification of inflammatory cytokines in the serum of metastatic melanoma patients
[0341] The levels of cytokines and chemokines in serum samples from both the Massachusetts General Hospital (Table 18) and University of Southern Australia (Table 19) cohorts were measured using the LEGENDplex technology (Biolegend) according to the manufacturer's instructions.
[0342] Table 18. Z scores were calculated for a set of patients of the Massachusetts General Hospital classified as “less likely” or “more likely” to benefit from therapy, based on a glycopeptide-based classifierTable 19. Z scores were calculated for the patients of the University of Southern Australia classified as “less likely” or “more likely” to benefit from therapy, based on a glycopeptide-based classifier* * * *ReferencesAll publications mentioned in the specification are indicative of the level of those skilled in the art to which the invention pertains. All publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.[1] Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol 2020 2112 2020;21 :729-49. https: / / doi.org / 10.1038 / s41580-020-00294-x.[2] Varki A. Biological roles of glycans. Glycobiology 2017;27:3-49. https: / / doi.org / 10.1093 / GLYCOB / CWW086.[3] Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer 2015 159 2015;15:540-55. https: / / doi.org / 10.1038 / nrc3982.[4] Mereiter S, Balmana M, Campos D, Gomes J, Reis CA. Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading? Cancer Cell 2019;36:6-16. https: / / doi.Org / 10.1016 / J.CCELL.2019.06.006.[5] Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: A promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer 2021; 1875: 188464. https: / / doi.org / 10.1016 / TBBCAN.2020.188464.[6] Chandrasekar D, Guerrier C, Alisson-Silva F, Dhar C, Caval T, Schwarz F, et al. Warning signs from the crypt: Aberrant protein glycosylation marks opportunities for early colorectal cancer detection. Clin Transl Gastroenterol 2023;Publish Ahead of Print. https: / / doi.org / 10.14309 / ctg.0000000000000592.[7] Pickering C, Aiyetan P, Xu G, Mitchell A, Rice R, Najjar YG, et al. Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy. Front Immunol 2023;14:l 187332. https: / / doi.Org / 10.3389 / fimmu.2023. l 187332.[8] Caval T, Alisson-Silva F, Schwarz F. Roles of glycosylation at the cancer cell surface: opportunities for large scale glycoproteomics. Theranostics 2023;13:2605-15. https: / / doi.org / 10.7150 / thno.81760.[9] Takahashi M, Hasegawa Y, Gao C, Kuroki Y, Taniguchi N. N-glycans of growth factor receptors: their role in receptor function and disease implications. Clin Sci Lond Engl 1979 2016;130: 1781-92. https: / / doi.org / 10.1042 / CS20160273.
[0010] Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of TripleNegative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell 2018;33: 187- 201. elO. https: / / doi.Org / 10.1016 / J.CCELL.2018.01.009.
[0011] Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, et al. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nat Commun 2022; 13: 1606. https: / / doi.org / 10.1038 / s41467-022- 29205-8.
[0012] Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J 1999;18: 1516-25. https: / / doi.Org / 10.1093 / emboj / 18.6.1516.
[0013] Saitoh O, Wang WC, Lotan R, Fukuda M. Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 1992;267:5700-11. https: / / doi.org / 10.1016 / s0021-9258(18)42823-2.
[0014] Cummingss RD, Kornfeld S. The Distribution of Repeating [Gal@l,4GlcNAc@l,3] Sequences in Asparagine-linked Oligosaccharides of the Mouse Lymphoma Cell Lines BW5147 and PHAR 2.1. vol. 259. 1984.
[0015] Van Den Eijnden DH, Koenderman AH, Schiphorst WE. Biosynthesis of blood group i-active polylactosaminoglycans. Partial purification and properties of an UDP-GlcNAc:N- acetyllactosaminide beta 1 — 3-N-acetylglucosaminyltransferase from Novikoff tumor cell ascites fluid. J Biol Chem 1988;263: 12461-71. https: / / doi.org / 10.1016 / S0021- 9258(18)37777-9.
[0016] Bagdonaite I, Malaker SA, Polasky DA, Riley NM, Schjoldager K, Vakhrushev SY, et al. Glycoproteomics. Nat Rev Methods Primer 2022 21 2022;2: 1-29. https: / / doi.org / 10.1038 / s43586-022-00128-4.
[0017] Riley NM, Bertozzi CR, Pitteri SJ. A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry-Based Glycoproteomics. Mol Cell Proteomics 2021;20:100029. https: / / doi.org / 10.1074 / MCP.R120.002277.
[0018] Fang Z, Qin H, Mao J, Wang Z, Zhang N, Wang Y, et al. Glyco-Decipher enables glycan database-independent peptide matching and in-depth characterization of site-specific N-glycosylation. Nat Commun 2022;13. https: / / doi.org / 10.1038 / s41467-022-29530-y.
[0019] Wang Z, Fang Z, Liu L, Zhu H, Wang Y, Zhao C, et al. Development of an Integrated Platform for the Simultaneous Enrichment and Characterization of N- and O-Linked Intact Glycopeptides. Anal Chem 2023;95:7448-57. https: / / doi.org / 10.1021 / acs.analchem.2c04305.
[0020] Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics 2020;36:2628-9. https: / / doi.org / 10.1093 / bioinformatics / btz931.
[0021] Luo W, Brouwer C. Pathview: an R / Bioconductor package for pathway -based data integration and visualization. Bioinformatics 2013;29: 1830-1. https: / / doi.org / 10.1093 / bioinformatics / btt285.
[0022] Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res 2021;49:D545-51. https: / / doi.org / 10.1093 / nar / gkaa970.
[0023] Yang W, Shah P, Hu Y, Toghi Eshghi S, Sun S, Liu Y, et al. Comparison of Enrichment Methods for Intact N- and O-Linked Glycopeptides Using Strong Anion Exchange and Hydrophilic Interaction Liquid Chromatography. Anal Chem 2017;89: 11193— 7. https: / / doi.org / 10.1021 / acs.analchem.7b03641.
[0024] Totten SM, Feasley CL, Bermudez A, Pitteri SJ. Parallel Comparison of N-Linked Glycopeptide Enrichment Techniques Reveals Extensive Glycoproteomic Analysis of Plasma Enabled by SAX-ERLIC. J Proteome Res 2017;16: 1249-60. https: / / doi.org / 10.1021 / acs.jproteome.6b00849.
[0025] Bradberry MM, Peters-Clarke TM, Shishkova E, Chapman ER, Coon JJ. N- glycoproteomics of brain synapses and synaptic vesicles. Cell Rep 2023;42: 112368. https: / / doi.Org / 10.1016 / j.celrep.2023.112368.
[0026] Chen M, Assis DM, Benet M, McClung CM, Gordon EA, Ghose S, et al.Comparative site-specific N-glycoproteome analysis reveals aberrant N-glycosylation and gives insights into mannose-6-phosphate pathway in cancer. Commun Biol 2023;6:48. https: / / doi.org / 10.1038 / s42003-023-04439-4.
[0027] Tharp KM, Park S, Timblin GA, Richards AL, Berg JA, Twells NM, et al. The microenvironment dictates glycocalyx construction and immune surveillance. BioRxiv 2023. https: / / doi.org / 10.1101 / 2023.06.23.546317.
[0028] Zhou Y, Fukuda T, Hang Q, Hou S, Isaji T, Kameyama A, et al. Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation. S ci Rep 2017;7: 11563. https: / / doi.org / 10.1038 / s41598- 017-11911-9.
[0029] Caval T, Buettner A, Haberger M, Reusch D, Heck AJR. Discrepancies between High-Resolution Native and Glycopeptide-Centric Mass Spectrometric Approaches: A Case Study into the Glycosylation of Erythropoietin Variants. J Am Soc Mass Spectrom 2021;32:2099-104. https: / / doi.org / 10.1021 / jasms.lc00060.
[0030] Janik ME, Przybylo M, Pochec E, Pokrywka M, Litynska A. Effect of a3[31 and av[33 integrin glycosylation on interaction of melanoma cells with vitronectin 2010;57.
[0031] Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J 2004;21 :9-15.
[0032] Li C, Yang Z, Du Y, Tang H, Chen J, Hu D, et al. BCMabl, A Monoclonal Antibody against Aberrantly Glycosylated Integrin a3[31, Has Potent Antitumor Activity of Bladder Cancer In Vivo. Clin Cancer Res 2014;20:4001-13. https: / / doi.org / 10.1158 / 1078-0432.CCR- 13-3397.
[0033] Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther 2023;8: l. https: / / doi.org / 10.1038 / s41392-022-01259-6.
[0034] Stipp CS. Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 2010;12:e3. https: / / doi.org / 10.1017 / S1462399409001355.
[0035] Joeh E, O’Leary T, Li W, Hawkins R, Hung JR, Parker CG, et al. Mapping glycan- mediated galectin-3 interactions by live cell proximity labeling. Proc Natl Acad Sci U S A 2020;117:27329-38. https: / / doi.Org / 10.1073 / PNAS.2009206117 / SUPPL_FILE / PNAS.2009206117.SD03.XLSX.
[0343] Additional Aspects
[0344] Aspect 1. A method of classifying a biological sample with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing one or more monomer weight scores of a set of peptide structures from a biological sample from the subject using a machine learning model to generate a disease indicator; andB) generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing the responsiveness to immune checkpoint inhibitory therapy, wherein the one or more monomer weight scores correspond to at least one site monomer identified in Table 14A.
[0345] Aspect 2. A method of classifying a biological sample with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing one or more monomer weight scores of a set of peptide structures from a biological sample from the subject using a machine learning model to generate a disease indicator;B) generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing the responsiveness to immune checkpoint inhibitory therapy, wherein the one or more monomer weight scores correspond to at least one site monomer identified in Table 14A; andC) administering to the subject a therapeutically effective amount of immunotherapy.
[0346] In view of Aspect 1 or 2 and Figure 9, exemplary values of monomer weight scores are 5.62, 4.62, 0, and 1.89 for the site monomers AGPl_33_hex, AGPl_33_hexnac, AGPl_33_fuco, AGPl_33_sial, respectively.
[0347] Aspect 3. The method of Aspects 1 or 2, wherein the analyzing of the one or more monomer weight scores of the set of peptide structures from the biological sample from the subject comprises: i) calculating a site occupancy score, for a given peptide structure at a linking site, as a function of an adjusted-raw abundance value for the given peptide structure and a sum of a set of adjusted-raw abundance values of the set of peptide structures; and ii) calculating a monomer weight score for a site monomer as a sum of glycopeptide structure monomer weight scores of a corresponding set of peptide structures at the linking site.
[0348] In view of Aspect 3, Figure 9 shows exemplary values for adjusted-raw abundance values such as 2712.326, 1164.745, 1552.056, 66.69198, 452.7419 that correspond to the given peptide structures AGP1_33_54O2, AGPl_33_6501, AGP1_33_65O2, AGPl_33_6503, AGP1 33 7603, respectively. Figure 9 also shows an exemplary value for the sum of a set of adjusted-raw abundance values of the set of peptide structures that is 5948.5609 (labeled as the denominator). Figure 9 shows exemplary values for the site occupancy scores such as 0.4559634, 0.1958028, 0.2609128, 0.01121145, and 0.07610949 that correspond to the given peptide structures AGP1_33_54O2, AGPl_33_6501, AGP1_33_65O2, AGPl_33_6503, AGP1 33 7603, respectively. The site occupancy scores is a quotient where one of the adjusted-raw abundance values is the numerator and the sum of a set of adjusted-raw abundance values is the denominator.
[0349] Aspect 4. The method of Aspect 3, further comprising, prior to i), receiving a set of raw abundance values of the set of peptide structures and normalizing the set of raw abundance values to a corresponding reference run to generate the set of adjusted-raw abundance values.
[0350] Aspect 5. The method of Aspects 3 or 4, further comprising, prior to ii), calculating the glycopeptide structure monomer weight score as a function of the site occupancy score and the number of a specific monomer for the given peptide structure. In view of Aspect 5, Figure 9 shows exemplary calculations for determining the glycopeptide structure monomer weight scores such as 0.456 * 5 for the peptide structure AGP1 33 5402 with the specific monomer of hexose at the linking site 33.
[0351] Aspect 6. The method of any one of Aspects 3-5, wherein the set of peptide structures is from a biological sample from a subject. 03521 Aspect 7. The method of Aspect 6, wherein the biological sample comprises serum or plasma samples.[035 j Aspect 8. The method of Aspect 7, wherein the reference run comprises serum or plasma samples.
[0354] Aspect 9. The method of any one of Aspects 3-8, further comprising: calculating a site occupancy score, for a given peptide structure at the linking site, as the quotient of the adjusted-raw abundance value for the given peptide structure over the sum of the set of adjusted-raw abundance values.
[0355] Aspect 10. The method of Aspect 5, further comprising: calculating a peptide structure monomer weight score as a product of the site occupancy score and the number of specific monomers for the given peptide structure.
[0356] Aspect 11. The method of Aspect 10, further comprising: calculating a monomer weight score for the subject as a sum of the glycopeptide structure monomer weight scores for each peptide structure at the linking site.
[0357] Aspect 12. The method of any one of Aspects 3-11, wherein the set of raw abundance values is generated using multiple reaction monitoring mass spectrometry (MRM- MS).
[0358] Aspect 13. The method of any one of Aspects 1-12, wherein the immune checkpoint inhibitor therapy comprises ipilimumab, nivolumab, and / or pembrolizumab.
[0359] Aspect 14. The method of any one of Aspects 1-13, wherein generating the diagnosis output comprises: generating a report identifying that the biological sample evidences the responsiveness to immune checkpoint inhibitory therapy.
[0360] Aspect 15. The method of any one of Aspects 5-14, wherein the specific monomer is fucose.
[0361] Aspect 16. The method of any one of Aspects 3-18, further comprising: calculating a second monomer weight score for another site monomer as another sum of glycopeptide structure monomer weight scores of a corresponding set of peptide structures at a linking site, wherein the another site monomer is different than the site monomer.
[0362] Aspect 17. The method of any one of Aspects 3-16, further comprising: calculating a plurality of additional monomer weight scores as functions of the site occupancy score and aplurality of multipliers, wherein the multipliers is a number of a specific monomer in the set of peptide structures at a linking site. 03631 Aspect 18. The method of any one of Aspects 1-17, wherein the linking site for a set of peptide structures for the site monomer corresponds to a common linking site having a same amino acid residue of a peptide of the site monomer.(0364] Aspect 19. The method of any one of Aspects 1-18, wherein the site monomers of Table 14A comprise the peptide structures of Table 14B. For example, the site monomer ICl_253_fuco comprises the peptide structures corresponding to SEQ ID NO: 109-112 having a common linker number of 253.(0365] Aspect 20. The method of any one of Aspects 5-19, wherein the specific monomer is fucose, wherein the generating the diagnosis output comprises: further classifying the biological sample from the subject as being likely to benefit from immune checkpoint inhibitory therapy and having an “inflamed tumor” immune phenotype.
[0366] Aspect 21. The method of Aspect 20, wherein the inflamed tumor immune phenotype comprises cells selected from the group consisting of B cells, regulatory T cells, exhausted T cells, myeloid suppressor cells, tumor cells, cancer associated fibroblast cells, and combinations thereof
[0367] Aspect 22. The method of any one of Aspects 5-19, wherein the specific monomer is fucose, wherein the generating the diagnosis output comprises: further classifying the biological sample as being unlikely to benefit from immune checkpoint inhibitory therapy and having either an immune-excluded tumor or immune desert tumor.
[0368] Aspect 23. The method of Aspect 22, wherein the immune-excluded tumor includes stromal interactions.
[0369] Aspect 24. The method of Aspect 22, wherein the immune desert tumor includes a condition selected from the group consisting of no priming, tolerance, and immunologic ignorance.
[0370] Aspect 25. A method of classifying a biological sample with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing an amount for each peptide structure in a set of peptide structures from a biological sample from the subject, wherein each peptide structure comprises a fucosylated glycan or an afucosylated glycan; andB) generating a diagnosis output based on the amount of fucosylated glycans that classifies the biological sample as evidencing that the subject is unlikely to benefit fromimmune checkpoint inhibitory therapy and having either an immune-excluded tumor or an immune desert tumor.[03711 Aspect 26. The method of Aspect 25, wherein the immune-excluded tumor includes stromal interactions.
[0372] Aspect 27. The method of Aspect 25, wherein the immune desert tumor includes a condition selected from the group consisting of no priming, tolerance, and immunologic ignorance.
[0373] Aspect 28. A method of classifying a biological sample with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing an amount for each peptide structure in a set of peptide structures from a biological sample from the subject, wherein each peptide structure comprises a fucosylated glycan or an afucosylated glycan; andB) generating a diagnosis output based on the amount of afucosylated glycans that classifies the biological sample as evidencing that the subject is likely to benefit from immune checkpoint inhibitory therapy and having an inflamed tumor immune phenotype.
[0374] Aspect 29. The method of Aspect 28, wherein the inflamed tumor immune phenotype comprises cells selected from the group consisting of B cells, regulatory T cells, exhausted T cells, myeloid suppressor cells, tumor cells, cancer associated fibroblast cells, and combinations thereof(0375] Aspect 30. A method for managing a treatment for a subject diagnosed with a melanoma, the method comprising: receiving peptide structure data corresponding to a set of glycoproteins in a biological sample obtained from the subject; computing a treatment score using quantification data identified from the peptide structure data for a set of peptide structures, wherein the set of peptide structures includes at least one peptide structure identified from a plurality of peptide structures listed in Table 8A; generating a treatment output that indicates a predicted response to the treatment for the subject using the treatment score.
[0376] Aspect 31. The method of Aspect 30, wherein the at least one peptide structure of Table 8A includes a glycan symbol structure or a glycan composition in accordance with Table8C[0377) Aspect 32. The method of Aspects 1 or 2, wherein the analyzing of the one or more monomer weight scores of the set of peptide structures from the biological sample from the subject comprises: i) calculating a site occupancy score, for a given peptide structure at a linking site, as a function of an adjusted-raw abundance value for the given peptide structure and a sum of a set of adjusted-raw abundance values of the set of peptide structures; and ii) calculating a monomer weight score as a sum of a product of the site occupancy score and a multiplier for each peptide structure of the set having the linking site, wherein the multiplier is the number of a specific monomer in the set of peptide structures at the linking site.
[0378] Aspect 33. A method of treating a subject suffering from an inflamed tumor immune phenotype, the method comprising: administering to the subject an immune checkpoint inhibitor therapy, wherein the subject has been determined to be responsive to the immune checkpoint inhibitor therapy via a trained machine learning classifier that distinguishes between responsive and non-responsive subjects who have received the immune checkpoint inhibitor therapy, based at least in part on analyzing levels in the subject of one or more monomer weight scores corresponding to at least one site monomer identified in Table 14A
[0379] Aspect 34. The method of Aspect 33, wherein the inflamed tumor immune phenotype comprises cells selected from the group consisting of B cells, regulatory T cells, exhausted T cells, myeloid suppressor cells, tumor cells, cancer associated fibroblast cells, and combinations thereof.
[0380] Aspect 35. A method of classifying a biological sample from a subject, comprising: enriching the sample with anion exchange matrix, analyzing the enriched sample with a mass spectrometer, analyzing the glycopeptide composition, and determining the functional consequences of the glycosylation patterns of proteins in the sample.
[0381] Aspect 36. A method of mapping polyLacNAc in cells of a subject, comprising: enriching the sample with anion exchange matrix, analyzing enriched sample with a mass spectrometer; and analyzing the glycopeptide composition.
[0382] Aspect 37. The method of Aspect 36, wherein the polyLacNAc comprises an elongated N-glycan.
[0383] Aspect 38. The method of Aspect 35 or Aspect 36, wherein the anion exchange matrix comprises one or more of: mix-mode anion exchange (MAX); strong anion exchange SOLA (SOLA); HyperSep retain anion exchange (RAX); HyperSep anion exchange (hySAX); or Affinisep strong anion exchange (afSAX).
[0384] Aspect 39. The method of Aspect 35 or Aspect 36, wherein the enrichment efficiency of the anion exchange matrix is about 80%.
[0385] Aspect 40. The method of Aspect 36, wherein the enrichment efficiency of and anion exchange matrix is from about 82% to about 89%.
[0386] Aspect 41. The method of Aspect 36, wherein the sample takes from about 20 minutes to about 90 minutes to flow through the anion exchange matrix by gravity flow.
[0387] Aspect 42. The method of Aspect 36, also includes membrane fractionation prior to anion exchange enriching.
[0388] Aspect 43. The method of Aspect 42, wherein the membrane fractionation comprises the crude membrane and the plasma membrane fractions.
[0389] Aspect 44. The method of Aspect 42, wherein cyctolic proteins were removed prior to anion exchange enrichment.Additional Considerations
[0390] Any headers and / or subheaders between sections and subsections of this document are included solely for the purpose of improving readability and do not imply that features cannot be combined across sections and subsection. Accordingly, sections and subsections do not describe separate embodiments.[03911 While the present teachings are described in conjunction with various embodiments, it is not intended that the present teachings be limited to such embodiments. On the contrary, the present teachings encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art. The present description provides preferred exemplary embodiments, and is not intended to limit the scope, applicability, or configuration of the disclosure. Rather, the present description of the preferred exemplary embodiments will provide those skilled in the art with an enabling description for implementing various embodiments.
[0392] It is understood that various changes may be made in the function and arrangement of elements without departing from the spirit and scope as set forth in the appended claims. Thus, such modifications and variations are considered to be within the scope set forth in the appended claims. Further, the terms and expressions which have been employed are used asterms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed.
[0393] In describing the various embodiments, the specification may have presented a method and / or process as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the various embodiments.
[0394] Some embodiments of the present disclosure include a system including one or more data processors. In some embodiments, the system includes a non-transitory computer readable storage medium containing instructions which, when executed on the one or more data processors, cause the one or more data processors to perform part or all of one or more methods and / or part or all of one or more processes disclosed herein. Some embodiments of the present disclosure include a computer-program product tangibly embodied in a non-transitory machine-readable storage medium, including instructions configured to cause one or more data processors to perform part or all of one or more methods and / or part or all of one or more processes disclosed herein.
[0395] Specific details are given in the present description to provide an understanding of the embodiments. However, it is understood that the embodiments may be practiced without these specific details. For example, circuits, systems, networks, processes, and other components may be shown as components in block diagram form in order not to obscure the embodiments in unnecessary detail. In other instances, well-known circuits, processes, algorithms, structures, and techniques may be shown without unnecessary detail in order to avoid obscuring the embodiments.
Claims
CLAIMSWhat is claimed:
1. A method of classifying a biological sample from a subject with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing one or more monomer weight scores of a set of peptide structures from a biological sample from the subject using a machine learning model to generate a disease indicator; andB) generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing the responsiveness to immune checkpoint inhibitory therapy, wherein the one or more monomer weight scores correspond to at least one site monomer identified in Table 14A.
2. A method of classifying a biological sample from a subject with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing one or more monomer weight scores of a set of peptide structures from a biological sample from the subject using a machine learning model to generate a disease indicator;B) generating a diagnosis output based on the disease indicator that classifies the biological sample as evidencing the responsiveness to immune checkpoint inhibitory therapy, wherein the one or more monomer weight scores correspond to at least one site monomer identified in Table 14A; andC) administering to the subject a therapeutically effective amount of immunotherapy.
3. The method of claim 1, wherein the analyzing of the one or more monomer weight scores of the set of peptide structures from the biological sample from the subject comprises: i) calculating a site occupancy score, for a given peptide structure at a linking site, as a function of an adjusted-raw abundance value for the given peptide structure and a sum of a set of adjusted-raw abundance values of the set of peptide structures; andii) calculating a monomer weight score for a site monomer as a sum of glycopeptide structure monomer weight scores of a corresponding set of peptide structures at the linking site.
4. The method of claim 3, further comprising, prior to i), receiving a set of raw abundance values of the set of peptide structures and normalizing the set of raw abundance values to a corresponding reference run to generate the set of adjusted-raw abundance values.
5. The method of claims 3, further comprising, prior to ii), calculating the glycopeptide structure monomer weight score as a function of the site occupancy score and the number of a specific monomer for the given peptide structure.
6. The method of claim 3, wherein the set of peptide structures is from a biological sample from a subject.
7. The method of claim 6, wherein the biological sample comprises serum or plasma samples.
8. The method of claim 7, wherein the reference run comprises serum or plasma samples.
9. The method of claim 3, further comprising: calculating a site occupancy score, for a given peptide structure at the linking site, as the quotient of the adjusted-raw abundance value for the given peptide structure over the sum of the set of adjusted-raw abundance values.
10. The method of claim 5, further comprising: calculating a peptide structure monomer weight score as a product of the site occupancy score and the number of specific monomers for the given peptide structure.
11. The method of claim 10, further comprising: calculating a monomer weight score for the subject as a sum of the glycopeptide structure monomer weight scores for each peptide structure at the linking site.
12. The method of claim 3, wherein the set of raw abundance values is generated using multiple reaction monitoring mass spectrometry (MRM-MS).
13. The method of claim 1, wherein the immune checkpoint inhibitor therapy comprises ipilimumab, nivolumab, and / or pembrolizumab.
14. The method of claim 1, wherein generating the diagnosis output comprises: generating a report identifying that the biological sample evidences the responsiveness to immune checkpoint inhibitory therapy.
15. The method of claim 5, wherein the specific monomer is fucose.
16. The method of claim 3, further comprising: calculating a second monomer weight score for another site monomer as another sum of glycopeptide structure monomer weight scores of a corresponding set of peptide structures at a linking site, wherein the another site monomer is different than the site monomer.
17. The method of claim 3, further comprising: calculating a plurality of additional monomer weight scores as functions of the site occupancy score and a plurality of multipliers, wherein the multipliers is a number of a specific monomer in the set of peptide structures at a linking site.
18. The method of claim 1, wherein the linking site for a set of peptide structures for the site monomer corresponds to a common linking site having a same amino acid residue of a peptide of the site monomer.
19. The method of claim 1, wherein the site monomers of Table 14A comprise the peptide structures of Table 14B20. The method of claim 5, wherein the specific monomer is fucose, wherein the generating the diagnosis output comprises: further classifying the biological sample from the subject as being likely to benefit from immune checkpoint inhibitory therapy and having an inflamed tumor immune phenotype.
21. The method of claim 20, wherein the inflamed tumor immune phenotype comprises cells selected from the group consisting of B cells, regulatory T cells, exhausted T cells, myeloid suppressor cells, tumor cells, cancer associated fibroblast cells, and combinations thereof22. The method of claim 5, wherein the specific monomer is fucose, wherein the generating the diagnosis output comprises: further classifying the biological sample as being unlikely to benefit from immune checkpoint inhibitory therapy and having either an immune-excluded tumor or immune desert tumor.
23. The method of claim 22, wherein the immune-excluded tumor includes stromal interactions.
24. The method of claim 22, wherein the immune desert tumor includes a condition selected from the group consisting of no priming, tolerance, and immunologic ignorance.
25. A method of classifying a biological sample from a subject with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing an amount for each peptide structure in a set of peptide structures from a biological sample from the subject, wherein each peptide structure comprises a fucosylated glycan or an afucosylated glycan; andB) generating a diagnosis output based on the amount of fucosylated glycans that classifies the biological sample as evidencing that the subject is unlikely to benefit from immune checkpoint inhibitory therapy and having either an immune-excluded tumor or an immune desert tumor.
26. The method of claim 25, wherein the immune-excluded tumor includes stromal interactions.
27. The method of claim 25, wherein the immune desert tumor includes a condition selected from the group consisting of no priming, tolerance, and immunologic ignorance.
28. A method of classifying a biological sample from a subject with respect to a responsiveness to immune checkpoint inhibitor therapy, the method comprising:A) analyzing an amount for each peptide structure in a set of peptide structures from a biological sample from the subject, wherein each peptide structure comprises a fucosylated glycan or an afucosylated glycan; andB) generating a diagnosis output based on the amount of afucosylated glycans that classifies the biological sample as evidencing that the subject is likely to benefit from immune checkpoint inhibitory therapy and having an inflamed tumor immune phenotype.
29. The method of claim 28, wherein the inflamed tumor immune phenotype comprises cells selected from the group consisting of B cells, regulatory T cells, exhausted T cells, myeloid suppressor cells, tumor cells, cancer associated fibroblast cells, and combinations thereof.
30. A method for managing a treatment for a subject diagnosed with a melanoma, the method comprising: receiving peptide structure data corresponding to a set of glycoproteins in a biological sample obtained from the subject; computing a treatment score using quantification data identified from the peptide structure data for a set of peptide structures, wherein the set of peptide structures includes at least one peptide structure identified from a plurality of peptide structures listed in Table 8A; generating a treatment output that indicates a predicted response to the treatment for the subject using the treatment score.
31. The method of claim 30, wherein the at least one peptide structure of Table 8A includes a glycan symbol structure or a glycan composition in accordance with Table 8C.
32. A method of treating a subject suffering from an inflamed tumor immune phenotype, the method comprising: administering to the subject an immune checkpoint inhibitor therapy, wherein the subject has been determined to be responsive to the immune checkpoint inhibitor therapy via a trained machine learning classifier that distinguishes between responsive and non-responsive subjects who have received the immune checkpoint inhibitortherapy, based at least in part on analyzing levels in the subject of one or more monomer weight scores corresponding to at least one site monomer identified inTable 14A33. The method of claim 32, wherein the inflamed tumor immune phenotype comprises cells selected from the group consisting of B cells, regulatory T cells, exhausted T cells, myeloid suppressor cells, tumor cells, cancer associated fibroblast cells, and combinations thereof.
34. A method of classifying a biological sample from a subject, comprising: enriching the sample with anion exchange matrix, analyzing the enriched sample with a mass spectrometer, analyzing the glycopeptide composition, and determining the functional consequences of the glycosylation patterns of proteins in the sample.
35. A method of mapping polyLacNAc in cells of a subject, comprising: enriching the sample with anion exchange matrix, analyzing enriched sample with a mass spectrometer; and analyzing the glycopeptide composition.
36. The method of claim 35, wherein the polyLacNAc comprises an elongated N-glycan.
37. The method of claim 34 or 35, wherein the anion exchange matrix comprises one or more of: mix-mode anion exchange (MAX); strong anion exchange SOLA (SOLA); HyperSep retain anion exchange (RAX); HyperSep anion exchange (hySAX); or Affinisep strong anion exchange (afSAX).
38. The method of claims 34 or 35, wherein the enrichment efficiency of the anion exchange matrix is about 80%.
39. The method of claim 35, wherein the enrichment efficiency of and anion exchange matrix is from about 82% to about 89%.
40. The method of claim 35, wherein the sample takes from about 20 minutes to about 90 minutes to flow through the anion exchange matrix by gravity flow.
41. The method of claim 35, also includes membrane fractionation prior to anion exchange enriching.
42. The method of claim 41, wherein the membrane fractionation comprises the crude membrane and the plasma membrane fractions.
43. The method of claim 42, wherein cyctolic proteins were removed prior to anion exchange enrichment.
Citation Information
Patent Citations
Synergistic combination of immunologic inhibitors for the treatment of cancer
US10034939B2
Systems and methods for generating, visualizing and classifying molecular functional profiles
US10311967B2
Biomarkers for determining an immuno-onocology response
US20220310230A1
Biomarkers for diagnosing ovarian cancer
US20230055572A1
Sample preparation for glycoproteomic analysis that includes diagnosis of disease
WO2023164672A2
